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Abstract 
Background: Children with severe neurodisability (ND) commonly suffer with 
respiratory disease and this is the leading cause of premature death. The nature 
of this respiratory disease is however, poorly understood. The underlying 
aetiology is often multifactorial, but aspiration (direct or reflux) is likely to play 
a key role. Unfortunately, diagnostic tests for reflux or direct aspiration are 
limited. There is a clinical need for high quality research on children with severe 
ND to define underlying mechanisms of respiratory disease and guide 
management. 
Aims: In this study, the aims were to (i) characterise respiratory symptoms and 
their relationship with lower airway inflammation in children with severe ND, (ii) 
explore available bronchial lavage (BAL) biomarkers of reflux aspiration, 
assessing their validity and their relationship to clinical and airway inflammatory 
data, (iii) develop a novel assay for the accurate detection/quantification of 
pepsin in BAL, (iv) investigate the validity of an -amylase assay in paediatric 
BAL and explore the relationship of -amylase levels with lower airway 
inflammation and clinical symptoms, and (v) investigate the effects of pH 
alteration and pepsin exposure on airway epithelial cells (AEC). 
Methods: Clinical data and BAL samples were collected from children with 
severe ND at times of stability and respiratory deterioration and also from 
healthy controls. BAL differential cell counts and cytokine measurements (ELISA) 
were performed. Lower airway microbial colonisation/infection was assessed. 
BAL pepsin measurement was attempted using a number of methods, and the 
feasibility of inhibitor affinity enrichment and LC-MRM-MS techniques to identify 
and quantify BAL pepsin was explored using SDS PAGE gel and mass spectrometry 
analysis. BAL alpha-amylase activity was measured using an ethylidene-pNP-G7 
based assay. BEAS-2B cells were cultured in monolayer and the 
cytotoxic/inflammatory effects of pH alteration and pepsin exposure were 
explored through trypan blue staining and cytokine assays. 
Results: Children with severe ND have burdensome chronic respiratory symptoms 
that impact on their quality of life and that of their families’. Symptoms may 
relate to lower airway inflammatory levels. A trend for greater airway 
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neutrophilia and respiratory symptoms was seen in those with lower airway 
microbial positivity. Available ‘in house’ pepsin ELISA assays were not robust but 
Western Blot results indicated a higher frequency of BAL pepsin positivity in ND 
patients with acute respiratory deterioration. Notably, positivity was also found 
in some healthy controls, highlighting the need for a quantitative assay. The use 
of an immobilized inhibitor (pepstatin agarose) to recover pepsin from paediatric 
BAL samples was shown to be feasible. Subsequent digestion of pepsin and 
detection by LC-MSMS with selective ion monitoring was demonstrated. 
Significantly increased BAL alpha-amylase levels were seen in Elective-ND 
patients compared to healthy controls and furthermore, significant correlations 
were observed with BAL lower airway inflammatory markers. BEAS-2B cells were 
sensitive to mild acidification, with up-regulation of TGF-1, IL-6 and IL-8 mRNA 
expression. A corresponding rise in protein secretion was not necessarily seen 
and in some cases, was significantly down-regulated. No significant cytotoxicity 
or decrease in cell viability was observed in any condition.  
Conclusions: In children with severe ND, chronic respiratory symptoms may be 
directly related to lower airway inflammation and bacterial colonization. 
Measurement and quantification of pepsin in BAL (as a marker of reflux 
aspiration) is difficult. However, an inhibitor affinity enhanced mass 
spectrometry based technique has potential as a ‘gold-standard’ method for 
identification and quantification of pepsin in BAL. BAL alpha-amylase activity 
shows promise as a biomarker of direct aspiration. Mild alterations in airway pH 
may directly contribute to the pathophysiology of inflammatory airway disease 
and specifically, reflux-aspiration related lung disease in this group. This 
requires further study as a potential novel therapeutic target.  
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Ab    antibody 
AEC    airway epithelial cell 
AmBic    ammonium bicarbonate 
BAL    non-bronchoscopic broncho-alveolar lavage 
BEGM    Bronchial Epithelial Cell Growth Media 
BSA    bovine serum albumin 
cDNA    complementary deoxyribonucleic acid 
CF    cystic fibrosis 
CO2     carbon dioxide 
CP    cerebral palsy 
CT    cycle threshold 
Cu    copper 
CV    coefficient of variation 
dH20    distilled water 
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ERS    European Respiratory Society 
ESI    electrospray ionisation 
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eV    electronvolt 
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g    grams 
Glu-fib   glu-1-fibrinopeptide B 
GMFCS   Gross Motor Function Classification System 
GORD    gastro-oesophageal reflux disease 
HCl    hydrochloric acid 
HDU    High Dependancy Unit 
HEPES    4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid  
IAN    iodoacetamide 
IL    Interleukin 
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IL-6    Interleukin 6 
IL-8    Interleukin 8 
IQR    inter-quartile range 
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L    litres 
LC-MSMS   liquid chromatography-tandem mass spectrometry 
LDH    lactate dehydrogenase 
LLM    lipid laden macrophages 
LLMI    lipid laden macrophage index 
LPS    lipopolysaccharide 
LRSQ    Liverpool Respiratory Symptom Questionnaire 
LRSQ-Neuro   Liverpool Respiratory Symptom Questionnaire (Neuro version) 
m/z     mass to charge ratio 
MALDI-TOF   Matrix-assisted laser desorption ionisation-time of flight 
mins    minutes 
ml    millilitres 
mm    millimoles 
mmHg    millimetres of mercury 
MRM    multiple reaction monitoring 
mRNA    messenger ribonucleic acid 
MS    mass spectrometry 
MSMS    tandem mass spectrometry 
NaOH    sodium hydroxide 
ND    neurodisability 
ng    nanograms 
nm    nanometres 
nM    nanomoles 
ºC    degrees centigrade 
PBS    phosphate buffered saline 
PBS-T    phosphate buffered saline and tween 20 
pg    picograms 
pH-MII    combined pH and impedance testing 
PICU    Paediatric Intensive Care Unit 
pmol    picomole 
qPCR    quantitative polymerase chain reaction 
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rpm    revolutions per minute 
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SDS    sodium dodecyl sulphate 
secs    seconds 
TBS    tris buffered saline 
TBS-T    tris buffered saline and tween 20 
TCA    trichloroacetic acid 
TGFβ-1   Transforming Growth Factor Beta-1 
U    units 
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  Chapter 1 – Introduction 
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1.1  Respiratory disease is a major cause of morbidity and 
mortality in neurodisabled children 
1.1.1 Definition, classification and incidence of neurodisability 
‘Neurodisability’ is a term used to describe conditions where there is functional 
compromise as a result of central or peripheral nervous system impairment. 
There are hundreds of causes of paediatric neurodisability (ND) including 
structural, genetic and metabolic defects (Nelson Textbook of Pediatrics, 2011). 
Cerebral palsy (CP) is the commonest cause of paediatric ND, affecting 2-
2.5/1000 live births in the United Kingdom (UK), with 20-43% of this group having 
quadriplegic CP (Odding, Roebroeck, & Stam, 2006). There are various causes of 
CP, including intra-cerebral haemorrhage, infection and intra-partum asphyxia 
(Gupta & Appleton, 2001). CP is essentially an ‘umbrella term’ used to describe 
the resulting clinical presentation. It is described by Rosenbaum et al as ‘a group 
of permanent disorders of the development of movement and posture, causing 
activity limitations that are attributed to non-progressive disturbances that 
occurred in the developing foetal or infant brain. The motor disorders of 
cerebral palsy are often accompanied by disturbances of sensation, perception, 
cognition, communication and behaviour, by epilepsy and by secondary 
musculoskeletal problems’ (P. Rosenbaum et al., 2007).  
There are a number of different classifications of CP (depending on the type, 
area and extent of brain injury and resulting clinical signs) and it is important to 
be aware that there is considerable variability in the extent of disability and 
accompanying co-morbidities. Consequently, there is a degree of unavoidable 
inter-subject heterogeneity which must be considered when studying children 
with CP, and even more so when studying a wider group of children with 
‘paediatric ND’. Therefore, this thesis focuses only on children with central 
causes of ND (not disorders of the peripheral nervous system) and severe 
physical impairment (not independently mobile).  
1.1.2  Gross Motor Function Classification and correlation of 
degree of impairment with morbidity and mortality 
A commonly used method of classifying physical impairment in children with CP 
is the Gross Motor Function Classification system (GMFCS). This internationally 
recognised system was devised by Palisano and colleagues in 1997 and has been 
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widely used within the literature (R. Palisano et al., 1997; R. J. Palisano, 
Rosenbaum, Bartlett, & Livingston, 2008). Similar systems are required for use in 
other areas of ND (non-CP). However, these are not available to date, likely due 
to the inherent challenges of developing such systems in children with ND, as 
discussed by Rosenbaum et al.  (P. L. Rosenbaum, Palisano, Bartlett, Galuppi, & 
Russell, 2008).   
Studies have shown that GMFCS level is often highly correlated with other 
aspects of disability (such as fine motor function, learning disability and 
epilepsy) (Beckung & Hagberg, 2002). Severity of motor impairment is also 
closely linked to co-morbidities such as gastro-intestinal problems, feeding 
difficulties and respiratory complications (Erkin, Culha, Ozel, & Kirbiyik, 2010; 
Liptak et al., 2001). It is perhaps unsurprising therefore, that degree of motor 
impairment is a strong predictor of overall survival (Reid, Carlin, & Reddihough, 
2012; Westbom, Bergstrand, Wagner, & Nordmark, 2011). In their study of 
outcomes in CP, Hutton and colleagues considered four distinct areas of 
disability; ambulation, manual dexterity, cognitive ability and visual disability 
(Jane L. Hutton, 2008). They used internationally agreed definitions for severe 
impairment in all four areas. Figure 1.1 shows survival statistics in a UK cohort 
of 596 people with CP, presented according to severity of impairment in each of 
the four areas of disability (Jane L. Hutton, 2008; J. L. Hutton, Colver, Mackie, 
& Rosenbloom, 2000). Within each of these disability groups, mortality was 
increased in those with severe impairment. Respiratory conditions were the 
commonest cause of premature mortality in those who died under the age of 
forty. This is in agreement with other studies, an Australian population study  
specifically identifying aspiration pneumonia as a significant cause of death 
(Jane L. Hutton, 2008; Reid et al., 2012). Therefore, the severely impaired are a 
particularly pertinent group to study when investigating aspiration lung disease 
in children with ND.   
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Figure 1.1 Survival of a UK cohort of 596 people with CP. 
Graphs show that survival is reduced in those with severe disability in all four disability categories 
studied. Hutton JL et al. Outcome in cerebral palsy: life-expectancy. Paediatrics and Child Health 
Volume 18, Issue 9 2008 419 – 422 
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1.1.3 Burden of respiratory disease in children with ND 
The exact burden of respiratory disease in children with ND has been poorly 
documented, with the majority of published literature being based on 
hospitalisation and mortality data rather than daily burden of symptoms and the 
associated effects on quality of life.   
Children with ND make up a significant proportion of those children seen in the 
emergency department (Massin, Montesanti, Gérard, & Lepage, 2006). Reviews 
of admission data have concluded that respiratory tract infection and increased 
seizure activity are the commonest reasons for hospital admission in this group, 
who are at high risk of prolonged admissions and high readmission rates (Mahon 
& Kibirige, 2004; Young et al., 2011). Berry et al conducted a retrospective 
cohort analysis of >300,000 patients and documented a high incidence of ND in 
the sub-group of patients who required four or more admissions per year (Berry 
Jg & et al., 2011).  
A local retrospective audit at Alder Hey Children’s Hospital (UK) included data 
on 132 patients with severe ND treated at the hospital over a thirteen year 
period (courtesy of Dr C. Halfhide and Dr A. Curran, unpublished data). The 
audit indicated an increased frequency of admission compared to the general 
population (40 times), markedly increased mean length of stay (0.9 vs. 22 days) 
and also high PICU and HDU admission rates. These data also indicated that 
admission for respiratory deterioration seemed to increase with age (Figure 
1.2), suggesting deterioration in respiratory status over time. National PICU 
audit data obtained from PICANET suggests that following admission to PICU with 
a respiratory deterioration, the number of ventilated days and mortality rate are 
approximately double that of other admission groups. These data imply that 
prophylactic and early community based acute interventions may be central to 
improving quality of life for patients and families and saving healthcare 
resources in this group.  
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Figure 1.2 The percentage of total admissions which are due to primary respiratory causes 
in children with ND increase with age 
Line graph to show admission data from 132 patients with severe ND treated at Alder Hey 
Children’s Hospital over a thirteen year period. This indicates that the proportion of total admissions 
that are due to primary respiratory causes increase with age. Graph provided by Dr Clare Halfhide 
(Consultant Respiratory Paediatrician, Alder Hey). 
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Authors have highlighted the importance of child and family quality of life as the 
priority outcome in both clinical management and research in this area (Marks, 
2008) (Baxter, 2007). It is surprising therefore, that there are no high quality 
data available on the frequency and type of respiratory symptoms in this patient 
group and the effects on the child and family. Also, the limited interventional 
studies that have been conducted often do not prioritise quality of life and daily 
symptomatology as an outcome measure, more commonly focusing on objective 
medical measures, which may hold less importance to the family and child 
(Mahant, Pastor, DeOliveira, Nicholas, & Langer, 2011; Samson-Fang, Butler, & 
O'Donnell, 2003). This may partly be due to the challenges of objective 
assessment in this group and the lack of validated outcome measures.  
1.1.4 Respiratory care of children with ND has considerable 
healthcare cost implications 
The impact of recurrent and prolonged hospital admissions for children with ND 
on health service expenditure is significant. A review of US paediatric hospital 
admissions in 2006 documented that 29% of US children’s hospital expenditure 
was on inpatient care of children with ND and at least 10% of these admissions 
were for respiratory tract infection (Berry et al., 2012). The cost of recurrent 
hospital admission should not be underestimated; the afore mentioned (Section 
1.1.3) 2011 retrospective cohort study documenting that those with recurrent 
admissions (>4 times/year) accounted for 23% of the total inpatient charges for 
the study follow up period (39% of this group being children with neurological 
disorders) (Berry Jg & et al., 2011).  
It has been suggested that early, community co-ordinated care may reduce 
admission rates and consequent expenditure in children with ND (Berry Jg & et 
al., 2011; Berry et al., 2012). A recent pilot study at Alder Hey Children’s 
Hospital (UK) demonstrated substantial financial benefits through employment 
and formalisation of this approach, using early, co-ordinated community 
physiotherapy in children with complex ND (Jackson S, 2012). Positive effects of 
adjuvant therapy (such as nebulised hypertonic saline and antibiotics) on 
symptoms were discussed within this study. However, these therapies have not 
been formally assessed in randomised controlled trials for this group of patients. 
Again, this highlights the need for improved evidence based care, ultimately 
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leading to standardisation of respiratory management for children with severe 
ND.  
1.1.5 Mortality 
Various international groups have explored survival rates in children with either 
non-specific neurological diagnoses or  specifically CP, following the 
establishment of several population based databases. The life expectancy of 
children with severe disability is undoubtedly shorter than the general 
population (Thomas & Barnes, 2010). Estimates of survival at twenty years of age 
in children with severe CP range from 40-60% and studies agree that severity of 
impairment is the strongest predictor of survival, those with mild impairment 
having a 99% chance of survival at 20 years (J. L. Hutton, 2006; Jane L. Hutton, 
2008; Westbom et al., 2011). Both CP specific studies and studies of children 
with non-specific neurological diagnoses are in agreement that level of 
immobility and the need for feeding assistance are strong predictors of survival 
and that generally, the more functional disability a child has, the higher the 
mortality risk (A. Cohen, Asor, & Tirosh, 2008; Eyman, Grossman, Chaney, & 
Call, 1990; Jane L. Hutton, 2008; Katz, 2009; Strauss, Eyman, & Grossman, 1996; 
Strauss, Kastner, Ashwal, & White, 1997; Thomas & Barnes, 2010).  Clearly, 
functional disability itself places the child at increased risk of complications 
such as respiratory compromise secondary to immobility, but importantly, also 
reflects the level of neurological disability. Finally, all these studies are in 
agreement that respiratory causes are the leading cause of death in this group. 
Conclusions differ regarding change in survival statistics over recent decades. 
Reid et al cited no improvement since the 1970’s in their Australian study which 
spanned 1970-2004 (Reid et al., 2012). However, Strauss and colleagues found a 
3.4% fall in mortality rate per year in severely disabled children in a Californian 
population study (1983-2002) (Strauss, Shavelle, Reynolds, Rosenbloom, & Day, 
2007). The latter group highlight methodological weaknesses in the Australian 
paper (Strauss, Rosenbloom, Shavelle, & Brooks, 2012). They advocate a 
‘person-year’ approach, taking account of motor function, factors such as 
gastrostomy usage and age when calculating any change in the probability of 
death in a given calendar year over the study period. This approach was not 
taken by Reid et al and was a fundamental weakness in their study; increases in 
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survival of preterm infants and accompanying influences on the severity of 
impairment in this population may well have influenced survival statistics.  
The limitations of studies in this area have been extensively discussed in the 
literature (J. L. Hutton, 2006; Jane L. Hutton, 2008; Thomas & Barnes, 2010). 
Multiple factors potentially influence the findings of epidemiological studies and 
the complex task of predicting life expectancy. These include clarity of disorder 
definition, use of crude classification of functionality, length of follow up 
period, numbers of subjects included, appropriate range of subject disability and 
age at which life expectancy is calculated in the developing child. Thomas and 
colleagues concluded that no prospective, large cohort studies to date can be 
relied on to predict life expectancy and that a pragmatic clinical approach 
should be undertaken (Thomas & Barnes, 2010). 
1.1.6 Aetiology and patho-physiology of respiratory disease in ND 
Children with ND pose a unique set of challenges to respiratory healthcare 
professionals. They are complex to assess and manage clinically due to the 
multi-factorial aetiology of their respiratory disease which includes poor cough, 
muscle weakness, scoliosis, poor nutrition, sleep apnoea, gastro-oesophageal 
reflux and direct (salivary) or indirect (reflux) aspiration, all of which can 
ultimately lead to chronic lower airway inflammation and bacterial colonisation 
(Figure 1.3) (Seddon & Khan, 2003). 
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Figure 1.3 Aetiology of respiratory disease in children with ND 
Diagram to highlight the complex multifactorial aetiology of respiratory disease in children with ND 
(created using Microsoft Office Powerpoint) 
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Children with ND commonly present to hospital with respiratory symptoms and a 
recent systematic review highlighted the severe consequences of lower 
respiratory tract infection in this group. The authors discussed the impact of 
prolonged recovery on a child's quality of life and the increased risk of further 
hospital acquired infections with recurrent, prolonged admissions (Kirk, 2008).  
It is difficult to define the relative contribution of the various co-morbid factors 
to respiratory outcomes in this complex group of patients. Consequently, 
outcomes of respiratory interventions are difficult to assess and the evidence 
base for clinical management is extremely limited. Berry et al refer to ‘crisis 
driven care’ when discussing respiratory management and they highlight that a 
reactionary approach to care potentially contributes to high admission rates, 
long hospital stays and a high re-admission rate (Berry et al., 2012). The paucity 
of high quality clinical studies can partly be explained by the difficulty in 
undertaking an objective respiratory assessment of children with ND and the 
consequent challenges in designing study outcome measures (Rajendu Srivastava 
et al., 2009). However, the potential to reduce the burden of respiratory 
disease, thus improving patient and family quality of life and the saving of 
healthcare resources, makes investment in this field a priority (R. Srivastava & 
Stone, 2011).  
Much of the literature on respiratory disease in children with ND is based on 
clinical experience rather than scientific knowledge. Over the following sub-
sections, some important areas for consideration in the respiratory management 
of this patient group are discussed. Gastro-oesophageal reflux disease (GORD), 
swallowing dysfunction and pulmonary aspiration are all major considerations in 
the pathogenesis of respiratory disease in this group and are the main focus of 
this thesis. They are discussed in increased detail in Section 1.2.   
Further understanding of the relative contribution of each of these aetiological 
factors to respiratory symptomatology would aid our understanding of the patho-
physiology of respiratory disease and guide the best approach to clinical 
management. A multi-disciplinary approach to clinical care has been shown to 
be effective, but is currently variable by region (Waespi, Seddon, & Khan, 2000). 
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1.1.6.1 Poor cough and muscle weakness 
Cough efficiency is often impaired in children with ND (Seddon & Khan, 2003). 
An effective cough is important for airway protection against aspiration and 
clearance of airway secretions, both in health and importantly, at times of 
airway infection. The physiological mechanism of cough generation is complex. 
It requires adequate coordination and function of inspiratory, expiratory and 
bulbar muscles in order to produce a forceful contraction and propel airway 
secretions to the top of the airway (Healy & Panitch, 2010; Seddon & Khan, 
2003). Muscular control and co-ordination may be particularly impaired in 
children with central ND. Additionally, immobility and chest wall deformity 
(secondary, for example, to scoliosis) will ultimately contribute to muscle 
weakness. 
Afferent airway receptor sensitivity is central to the initiation of cough. There 
are many potential reasons for this to be reduced in children with severe ND, 
including the high incidence of gastro-oesophageal reflux leading to laryngo-
pharyngeal sensory deficits (Aviv, Liu, Parides, Kaplan, & Close, 2000). This has 
been observed in videofluoroscopy studies, which have demonstrated a high 
incidence of ‘silent’ aspiration in this patient group (K. A. Weir, McMahon, 
Taylor, & Chang, 2011).  
Ultimately, poor cough and muscle weakness lead to pooling of airway 
secretions, recurrent infection and likely chronic inflammation. Chest 
physiotherapy and airway clearance devices are used in the management of 
these common problems, although with a limited evidence base (Marks, 2008).  
1.1.6.2 Kyphoscoliosis 
Kyphoscoliosis affects many children with ND (Healy & Panitch, 2010; Persson-
Bunke, Hägglund, Lauge-Pedersen, Ma, & Westbom, 2012). It develops primarily 
as a result of unequal muscle tone and gravity in children with central ND. From 
a respiratory perspective, this results in decreased tidal volumes (with 
subsequent effects on airway clearance and expansion) due to changes in chest 
wall compliance and decreased efficiency of respiratory muscle function. The 
effects on airway expansion can be asymmetrical and can lead to problems with 
ventilation perfusion mismatch (Tsiligiannis & Grivas, 2012). Ultimately, as 
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scoliosis progresses it leads to increased work of breathing and respiratory 
failure, as well as other undesirable effects such as further reduced mobility, 
gastro-intestinal problems and pain (McCarthy, D'Andrea, Betz, & Clements, 
2006). Spinal braces and specialist seating are often unsuccessful in halting 
progression of scoliosis in this group (Koop, 2009). Scoliosis should be carefully 
monitored and in progressive cases, spinal fusion surgery may be considered 
(following careful multidisciplinary assessment) with the aim of stabilising 
posture and lung function.  
1.1.6.3 Poor nutrition 
Good nutrition is known to be important in the management of any chronic 
respiratory disease and there is evidence to support an influence on overall 
prognosis in some respiratory diseases, for example, cystic fibrosis (Nogay, 2012; 
Shepherd et al., 1986; Steinkamp & Wiedemann, 2002). Malnutrition directly 
influences the condition of respiratory muscles (through catabolism), leading 
directly to increased muscle weakness. It also has potential detrimental effects 
on various aspects of immune function, including cell-mediated immunity, 
phagocyte function, complement system function and antibody production 
(Chandra & Kumari, 1994). Finally, malnutrition has potential effects on other 
important aspects of health such as brain growth, developmental progress and 
bone mineral density (Andrew & Sullivan, 2010).  
There are numerous potential causes of malnutrition in the neuro-disabled child 
including feeding difficulties (dysphagia or food aversion), poor positioning, 
effects of medication on feeding (such as constipation or sedation), decreased 
appetite, GORD and difficulties with communication (Andrew, Parr, & Sullivan, 
2012; Seddon & Khan, 2003). Ideally, a multi-disciplinary approach to assessment 
and management should be undertaken. Peter Sullivan, a  gastroenterologist 
with expertise in this area, stated that nutritional supplementation in this group 
should aim ‘to achieve the child's genetic growth potential within the limits of 
their neurological condition whilst maintaining good nutrition’ (Andrew & 
Sullivan, 2010). 
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1.1.6.4 Sleep apnoea 
There is an increased incidence of sleep disordered breathing in children with ND 
compared to healthy children (Zucconi & Bruni, 2001). Sleep disordered 
breathing can be due to problems with central respiratory drive or due to 
obstructive sleep apnoea.  
Obstructive sleep apnoea is common in children with CP (Shintani et al., 1998). 
Contributory factors can be enlarged tonsillar/adenoid tissue or poor pharyngeal 
muscle control (Shintani et al., 1998). This leads to increased upper airway 
resistance in rapid eye movement sleep, leading to hypoxaemia and hypercarbia 
which in turn can lead to increased seizure activity, daytime sleepiness, 
headaches, behavioural problems and ultimately, pulmonary hypertension 
(Marks, 2008; White, 2005). Over time, central chemoreceptors become more 
tolerant to hypercarbia, allowing longer periods of hypoxia during REM sleep, 
thereby increasing risk to the patient (White, 2005).  
Alternatively, any neurological condition affecting central respiratory drive 
centres in the brainstem can lead to central sleep apnoea, particularly 
degenerative central neurological conditions such as chiari malformation and 
unrecognised hydrocephalus (Marks, 2008; White, 2005).  
Management includes ear, nose and throat or neuro-surgical intervention, where 
indicated. The use of non-invasive ventilation (continuous positive airways 
pressure or biphasic support) is becoming more widespread and there is evidence 
that this can improve the quality of life (Hsiao & Nixon, 2008; Kitazumi, 1998). A 
final alternative for management of obstructive sleep apnoea, untreatable by 
other means, is tracheostomy placement.  
1.1.6.5 Other factors 
The potential for underlying primary respiratory disease, such as asthma or 
chronic lung disease of prematurity should always be considered in the 
respiratory management of the patient with central ND. 
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1.2 Recurrent aspiration is a likely key contributory 
factor in respiratory disease in children with ND 
1.2.1 Gastro-oesophageal reflux disease is common in children 
with ND 
Gastro-oesophageal reflux refers to the retrograde passage of stomach contents 
into the oesophagus. This physiological phenomenon can occur normally in 
healthy children and adults at any time, particularly after eating. In health, it 
lasts for short periods of time only and is asymptomatic (Vandenplas et al., 
2009). This becomes a disease process when it causes recurrent symptoms or 
complications (Vandenplas et al., 2009).  
The high incidence of GORD in children with ND is well recognised. Up to 75% of 
those with severe CP have GORD, with contributory factors including decreased 
lower oesophageal sphincter tone, delayed gastric emptying, impaired 
oesophageal motility, scoliosis, seizures, medications, and poor positioning 
(Gustafsson & Tibbling, 1994; Mazzoleni et al., 1991; Peter B. Sullivan, 2008). 
Somerville and colleagues found evidence of chronic oesophagitis on upper 
airway endoscopy in 57% of 182 children with severe developmental disability 
(Somerville et al., 2008). Respiratory symptoms and complications of GORD may 
include cough, wheeze, shortness of breath and recurrent pneumonia (Boesch et 
al., 2006). However, it is important to consider that although these sequelae 
may be a direct result of GORD through recurrent micro-aspiration or direct 
stimulation of the distal oesophagus, they may also be unrelated. It can be 
difficult to establish a causal relationship (Mansfield & Stein, 1978). The risk of 
micro-aspiration with GORD is potentially increased due to impaired laryngeal 
sensation, known to be associated with recurrent gastro-oesophageal reflux (Aviv 
et al., 2000). Equally, respiratory symptoms themselves can cause/increase 
GORD. This ‘chicken and egg’ scenario results in limitation of our understanding 
of the effects of GORD on the airway and has been discussed at length in the 
literature (Shields, Bateman, McCallion, van Wijk, & Wenzl, 2011). 
GORD can be particularly difficult to diagnose in children with ND, due to 
difficulties in communication and interpretation of behaviour. Clinical 
investigations including upper gastro-intestinal contrast studies, upper 
gastrointestinal endoscopy, pH studies and newer modalities such as impedance 
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monitoring are all used by gastroenterologists to aid diagnosis (Vandenplas et 
al., 2009) (Peter B. Sullivan, 2008).  
1.2.2 Swallowing dysfunction is common in children with 
neurodisability 
Dysfunctional swallowing (from oral and pharyngeal motor impairment) is also 
common in children with ND (Andrew et al., 2012). This can present with a wide 
range of symptoms, from subtle feeding difficulties and nutritional deficiencies 
to overt symptoms of aspiration and recurrent lower respiratory tract infection. 
A ‘safe swallow’ requires a level of oral motor skill to ensure adequate oral food 
preparation, formation of a bolus and a co-ordination of oral, pharyngeal and 
oesophageal muscles, enabling safe passage of the bolus into the stomach with 
accompanying airway protection from aspiration. Estimations of swallowing 
dysfunction frequency (as assessed by videofluoroscopy) in children with severe 
ND can be up to 70%, depending on the population studied (Andrew et al., 2012; 
Arvedson, Rogers, Buck, Smart, & Msall, 1994; Mirrett, Riski, Glascott, & 
Johnson, 1994; Somerville et al., 2008; K. Weir, McMahon, Barry, Masters, & 
Chang, 2009; K. A. Weir et al., 2011). An important observation from 
videofluoroscopy studies is the high frequency of silent, symptomless aspiration 
in this group, leading many authors to conclude that any child with neurological 
dysfunction who presents with feeding difficulties should undergo a 
videofluoroscopic assessment (Andrew et al., 2012; K. A. Weir et al., 2011). 
1.2.3 Differentiation of direct and reflux aspiration 
Pulmonary aspiration is the abnormal passage of the contents of the upper 
airway into the lower airway. The clinical consequences of recurrent aspiration 
can range from recurrent cough and wheeze and recurrent lower respiratory 
tract infection to acute life threatening events and catastrophic pulmonary 
injury and death in cases of large volume aspiration (Boesch et al., 2006). The 
commoner clinical scenario of repeated small-volume aspiration can potentially 
lead to chronic pulmonary disease, as discussed in Section 1.5.  
The high incidence of GORD and swallowing dysfunction in children with severe 
ND places them at higher risk of recurrent aspiration than the general 
population. Aspiration can be direct (aspiration of oral contents such as food or 
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saliva into the lungs), reflux-aspiration (aspiration of refluxed stomach contents 
into the lungs) or a combination of both. It is important to be able to 
differentiate direct and indirect aspiration as the clinical management is 
distinct, as detailed in Sections 1.2.4 and 1.2.5. In a research setting, we are 
unable to fully assess the outcomes of intervention without being able to assess 
the relative contributions of the different types of aspiration to clinical 
symptoms.  
1.2.4 Clinical management of direct aspiration 
Direct aspiration can include aspiration of solid food, liquid or saliva. Diagnosis 
of direct aspiration is discussed in Section 1.3. Following diagnosis, interventions 
such as alteration of food consistency and optimal positioning of the child for 
feeding can be useful. Ideally, feeding interventions should be undertaken 
following multi-disciplinary assessment, as discussed in Section 1.1.6.3.  
In patients where oral feeding cannot be maintained (due to risk of direct 
aspiration or inadequate nutritional intake) percutaneous gastrostomy feeding 
may be considered. This intervention potentially eliminates the risk of direct 
aspiration of food. However, it does not alter the frequency of salivary 
aspiration. There is little documented about the frequency of salivary aspiration 
and its direct clinical consequences in the literature, due to limitations in 
diagnostic abilities, as discussed in Section 1.3. However, salivary aspiration is 
potentially an important contributory factor in aspiration lung disease in 
children with ND, particularly due to the potential for instillation of pathogenic 
bacteria from the oral cavity into the lungs in a group who may have poor oral 
and dental hygiene, increasing the incidence of anaerobic pneumonia (Wallis & 
Ryan, 2012).  
There are various medical and surgical options for management of salivary 
aspiration. Anti-cholinergic medications (such as glycopyrrolate), which interact 
with peripheral muscarinic receptors, are commonly used in the management of 
sialorrhoea (Eiland, 2012). The side effect profile of these medications, which 
includes anti-cholinergic symptoms and mucous plugging, and the limited 
evidence base for their use are discussed in Chapter 3.  Most of the literature 
concerning their use has focussed on control of sialorrhoea rather than improving 
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respiratory outcomes, perhaps again because of the difficulties in diagnosing 
salivary aspiration and limited data regarding the role of salivary aspiration in 
causality of respiratory symptoms (Eiland, 2012; Zeller, Davidson, Lee, & 
Cavanaugh, 2012; Zeller, Lee, Cavanaugh, & Davidson, 2012).  
Surgical management options include sub-mandibular and parotid gland 
botulinum toxin or removal of sub-mandibular glands and ligation of parotid 
glands (Ellies et al., 2002; Walshe, Smith, & Pennington, 2012; Wilken, Aslami, & 
Backes, 2008). The evidence base for these interventions is similarly limited and 
they are used with variable success, particularly from a respiratory symptom 
perspective (as discussed in Section 3.5 of this thesis).   
1.2.5 Clinical management of reflux aspiration 
The aim of reflux aspiration management is ideally to stop the reflux of gastric 
contents into the oesophagus. However, a secondary aim may be to minimise 
symptoms caused by the refluxate by neutralising the acidity of the stomach 
contents. Management options include lifestyle, pharmacological and surgical 
approaches. Simple measures aimed at reducing the frequency of reflux events 
include changing the feed volume and frequency, altering the child’s position for 
feeding, and thickening feeds (Vandenplas et al., 2009). 
Where these simple measures fail, there are various pharmacological options. 
Pro-kinetic agents, such as domperidone and erythromycin, are commonly used 
with the aim of encouraging prompt gastric emptying. However, the evidence for 
their efficacy in children is limited  (as discussed in Section 3.5) (Pritchard, 
Baber, & Stephenson, 2005; Vandenplas et al., 2009). Proton pump inhibitors are 
often used for reflux symptom control and treatment of oesophagitis, limiting 
the acidity of the refluxate by blocking the proton pump (H+/K+ ATPase) of the 
gastric parietal cells. There is some evidence that these are effective when used 
for the purposes of gastroenterological reflux symptom control (Hassall, 2005).  
However, their role in the management of reflux aspiration is questionable 
because in the context of chronic, small-volume reflux-aspiration the refluxate 
is likely to be mildly acidic or neutral pH on reaching the lower airway (as 
discussed in Chapter 7). Indeed, some studies suggest that there may be an 
increased risk of lower respiratory tract infection in those on proton pump 
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inhibitors, possibly due to gastric bacterial overgrowth (Fohl & Regal, 2011; 
Theisen et al., 2000). 
Where medical management fails, patients are referred for surgical assessment 
for anti-reflux procedures. Fundoplication is the commonest anti-reflux 
procedure. In the United States, children with ND represent approximately 40% 
of the paediatric population undergoing fundoplication (Lasser, Liao, & Burd, 
2006).  This technique involves wrapping the upper part of the stomach (the 
fundus) around the lower end of the oesophagus, creating a muscular tunnel, 
aiding the lower oesophageal sphincter in preventing reflux of stomach contents 
into the oesophagus (Shields et al., 2011).  However, surgery associated 
morbidity and mortality rates are higher in children with ND and primary failure 
and ‘re-do’ fundoplication rates are increased (Hassall, 2005; Lasser et al., 2006; 
Pearl et al., 1990; C. D. Smith et al., 1992; Subramaniam & Dickson, 2000; 
Wockenforth, Gillespie, & Jaffray, 2011). Results from studies on respiratory 
outcomes, gastrointestinal outcomes, and quality of life after fundoplication 
have been contradictory and some surgical centres are now advocating increased 
scrutiny in selecting children who may benefit from fundoplication (Fonkalsrud 
et al., 1998; Goldin, Sawin, Seidel, & Flum, 2006; Martinez, Ginnpease, Caniano, 
Vinocur, & Golladay, 1992; Shields et al., 2011; C. D. Smith et al., 1992; Rajendu 
Srivastava et al., 2009). Other options used in the surgical management of GORD 
include jejunal feeding and gastro-oesophageal dissociation (Verey & Cusick, 
2008; Wales et al., 2002; Wockenforth et al., 2011). High quality prospective 
trials are needed to assess the outcomes of these interventions in children with 
ND, with careful attention being paid to patient group specific outcome 
measures (Vernon-Roberts & Sullivan, 2007).  
1.3 Existing diagnostic tests for aspiration are limited 
1.3.1 Clinical assessment 
Clinical assessment of feeding, swallowing and risk of aspiration is made by a 
speech and language therapist, with multi-disciplinary input into any subsequent 
management. Clinical assessment is known to have limited sensitivity in 
identifying aspiration in many patient groups, but particularly in those with ND, 
due to the high incidence of ‘silent’ aspiration. Therefore, most authors 
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recommend a videofluoroscopy assessment in any child with ND who presents 
with feeding difficulties (Andrew et al., 2012; K. A. Weir et al., 2011). 
1.3.2 Videofluoroscopy 
Videofluoroscopy has long been considered the ‘gold standard’ for assessment of 
swallowing. This radiographic technique, in which real-time fluoroscopic images 
of a swallow of a radio-opaque food or liquid bolus are obtained, provides 
dynamic information on all phases of swallowing, from oral management of a 
food bolus to the pharyngeal and oesophageal phases. In paediatric practice, it 
is undertaken following a thorough clinical assessment by a speech and language 
therapist; it is used as a complementary tool to bedside assessment (Hiorns & 
Ryan, 2006). Bedside assessment alone has repeatedly been shown to have a 
lower sensitivity in aspiration diagnosis compared to videofluoroscopy, 
particularly with aspiration of solids and at times when ‘silent’ aspiration occurs 
(a common scenario in the neuro-disabled children)(K. Weir et al., 2009; K. A. 
Weir et al., 2011). A speech and language therapist should be present at the 
time of the procedure, during which recommendations about food consistency 
and positioning of the child for feeding can be made. 
There are several important limitations to videofluoroscopy and consequently 
some authors have questioned whether it should be regarded as a true ‘gold 
standard’. Studies comparing videofluoroscopy with direct endoscopic 
visualisation of the airway (FEES) in adults have found discrepancies between 
the two techniques (Chih-Hsiu, Tzu-Yu, Jiann-Chyuan, Yeun-Chung, & Shiann-
Yann, 1997). There have also been concerns about the interpretation of 
videofluoroscopy in cases where frank aspiration was not observed; inter and 
intra- assessor variability has been demonstrated in reporting on adequacy of 
swallow (Kuhlemeier, Yates, & Palmer, 1998; Ott, 1998; Stoeckli, Huisman, 
Seifert, & Martin-Harris, 2003). In view of aspiration being an intermittent event 
and videofluoroscopy providing a ‘one off’ examination of a swallow, aspiration 
cannot be totally ruled out within the limits of this test. Furthermore, micro-
aspiration may be below the level of sensitivity of the investigation. Radiation 
exposure precludes the possibility of multiple repeat examinations and 
therefore, fatiguability cannot be tested using this technique. Finally, 
videofluoroscopy requires the child to be able to feed by mouth and if the child 
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only takes small quantities, the evaluation is limited (Boesch et al., 2006). 
Therefore, a videofluoroscopy examination would generally not be conducted on 
days when children with ND may be at most at risk of aspiration for example, 
when they have received supplementary anti-seizure medication. Finally, and 
importantly in the context of this thesis, videofluoroscopy does not directly 
differentiate direct and reflux aspiration.  
1.3.3 Lipid laden macrophages 
Lipid laden macrophages (LLMs) (alveolar macrophages with ingested lipid within 
their cytoplasm) can be seen after Oil-Red-O staining on microscopic 
examination of BAL cells (Reid-Nicholson, Kulkarni, Adeagbo, Looney, & Crosby, 
2010). Their detection has been reported to be of value in diagnosing aspiration 
for decades (Pinkerton, 1928). In 1985, the LLM index (LLMI), which grades the 
amount of lipid in the cytoplasm of 100 macrophages (grade 0-4, giving an index 
of 0-400), was first described (Corwin & Irwin, 1985). Two years later, Colombo 
and Hallberg assessed this technique in BAL samples from children with and 
without suspected aspiration (Colombo, Hallberg, & Sammut, 1992). They 
concluded that LLMs were a non-specific finding, but a quantitative index with a 
diagnostic ‘cut-off’ might be useful. Animal studies have shown rapid 
macrophage uptake of exogenous lipid after intra-tracheal milk instillation, 
which lasts for 2 to 4 days after a single instillation and longer with recurrent 
instillations (Colombo & Hallberg, 2000).  
Subsequently, many studies have reported LLMI as a useful clinical marker of 
gastric aspiration in children (Ahrens et al., 1999; Collins et al., 1995; Yang, 
Steele, Anbar, Sinacori, & Powers, 2001). More recently, Borrelli et al showed 
correlation of proximal non-acid reflux episodes (detected with the newer 
modality of pH and multichannel intraluminal impedance monitoring, or pH-MII) 
with LLMI, although interestingly this contrasted with the findings of Rosen et al 
(Borrelli et al., 2010; Rosen, Fritz, Nurkoa, Simon, & Nurko, 2008).  
The role of LLMI as a criterion standard for diagnosing reflux aspiration is widely 
disputed. Studies have reported significant variation in the sensitivity and 
specificity of the LLMI (57%-100% and 57%-89%, respectively) (Ahrens et al., 
1999; Colombo & Hallberg, 1987; Corwin & Irwin, 1985; Ding et al., 2002; Yang 
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et al., 2001). Ahrens et al examined BAL from children in 3 groups: with chest 
disease and GORD, with recurrent pneumonia but no evidence of GORD, and 
healthy controls. They found LLMs to be present in all samples, raising questions 
about whether the source of the lipid was always exogenous (Ahrens et al., 
1999). Known alternative endogenous sources of lipid include parenteral 
nutrition, tissue/cell membrane breakdown, and airway surfactant 
phospholipids. These last two sources of lipid alter in respiratory infection and 
inflammation (Ahrens et al., 1999; Colombo & Hallberg, 1987; Knauer-Fischer & 
Ratjen, 1999; Ratjen, Rehn, & Costabel, 1996). Thus, LLMI is elevated 
independent of reflux aspiration in other pulmonary diseases such as cystic 
fibrosis, allergic alveolitis, and bronchiolitis obliterans (Knauer-Fischer & Ratjen, 
1999).  
The idea of establishing an LLMI cut-off value or range has been proposed; this 
would take into account time since the last aspiration event and the potential 
for subclinical aspiration in otherwise healthy children. However, the range 
suggested is particularly broad (Ahrens et al., 1999; Colombo & Hallberg, 1987). 
Also, previous studies have reported poor inter-rater reliability in LLMI scoring 
and, worryingly, intra-rater reliability between blinded, experienced 
cytopathologists (Camoretti-Mercado & Solway, 2005; Reid-Nicholson et al., 
2010; Yang et al., 2001). These discrepancies would directly preclude the 
possibility of having a reliable LLMI ‘cut-off’ range.  
In summary, it would seem that LLM lack the required specificity to be used as a 
diagnostic test for reflux-aspiration. Their current role may be in providing 
supportive evidence (in patients with highly positive results) for a diagnosis of 
aspiration but they should be interpreted with caution and within the context of 
the clinical assessment and other investigation results.  
1.3.4 Other tests 
Multiple other tests for reflux and direct aspiration have been used in clinical 
practice and are discussed within the literature. These include gastric 
scintigraphy, radionucleotide salivograms and dye studies in patients with a 
tracheostomy. However, none of these tests have been shown to have the 
required sensitivity to be used as a diagnostic test for aspiration in routine 
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clinical practice (Boesch et al., 2006; Peruzzi, Logemann, Currie, & Moen, 2001). 
Finally, Boesch et al, in their review of chronic pulmonary aspiration in children, 
discuss ‘difficult cases’ where all investigations are negative but clinical 
suspicion of aspiration is high. In some cases, a trial of stopping oral feeding has 
improved respiratory symptoms (Boesch et al., 2006). These clinical observations 
reinforce the limitations of the currently available diagnostic tests for 
aspiration.  
1.4 Novel tests for aspiration 
Several novel bronchial lavage (BAL) or sputum sample based tests of direct and 
reflux aspiration have been discussed within the research literature but 
interestingly, these have not previously been investigated in children with ND, a 
group at particularly high risk of aspiration. The available evidence regarding 
these novel tests is discussed below. 
1.4.1 Pepsin 
Pepsin (an acidic protease) is the primary proteolytic enzyme of the digestive 
system. It is produced by the chief cells of the stomach lining as pepsinogen and 
cleaved to pepsin in an acidic environment. Pepsin is not known to be produced 
by extra-oesophageal tissues and is therefore, first, a measure of reflux if found 
in the upper airway, and second, reflux aspiration if found in the lungs. 
Importantly, it is potentially a causative agent in extra-oesophageal injury. 
Animal studies have shown that BAL pepsin is a highly sensitive and specific 
marker of aspiration after forced gastric juice aspiration, with raised pepsin 
levels being detected up to 48 hours post aspiration event (Badellino et al., 
1996; N. A. Metheny et al., 2004; H. B. Zhang, Van Hook, Fan, Mallory, & 
Elidemir, 2005). Various methods of pepsin measurement are discussed within 
the literature. 
1.4.1.1 Enzymatic pepsin assays 
The enzymatic activity of human pepsin 3b is pH dependent, having maximum 
activity at pH 2 becoming inactive at pH 6.5. It remains stable up to pH 7 but 
becomes irreversibly damaged at pH 8 (Nikki Johnston, Dettmar, Bishwokarma, 
Lively, & Koufman, 2007). Enzymatic assays include a sample re-acidification 
step (to re-activate any pH deactivated pepsin) followed by a quantification of 
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substrate digestion measured by protein digestion, spectroscopy, or other 
methods. Sample pepsin concentration is determined relative to a standard 
curve of substrate digestion activity for known pepsin concentrations, and then 
normalized to total sample protein. In samples up to pH 7, pepsin retains 
approximately 79% of its enzymatic activity on re-acidification (Nikki Johnston et 
al., 2007). Previous studies have shown correlative relationships between airway 
sample pepsin measurements and other clinical parameters of reflux or disease 
using the enzymatic assay (Sabeena Farhath et al., 2006; S. Farhath et al., 2008; 
U. Krishnan, Mitchell, Messina, Day, & Bohane, 2002; Potluri et al., 2003).  
However, this type of assay has a number of limitations. In addition to the 
stomach, pepsinogen is also produced in the lung (pepsinogen C) and is found in 
serum (pepsinogen A and C) (Foster, Aktar, Kopf, Zhang, & Guttentag, 2004). 
Thus, activation of pepsin by acidification could also potentially cleave 
pepsinogen to pepsin, leading to false positive results. Other potential problems 
include interference from other proteases (such as cathepsins), freeze/thawing 
of samples affecting activity and highly proteinaceous samples inhibiting pepsin 
activity (Badellino et al., 1996; He et al., 2007; U. Krishnan et al., 2002)). Most 
importantly, if the sample pH is above pH 7, enzymatic activity may be reduced 
to a variable degree between samples upon reactivation, leading to potential 
false-negative results and difficulties in quantitative comparisons between 
samples (Nikki Johnston et al., 2007). 
1.4.1.2 Immunologic pepsin assays 
Enzyme Linked Immunosorbent Assays (ELISAs) and Western blotting techniques 
can be used to assess pepsin concentrations, but both are dependent on the 
quality and specificity of the pepsin antibody, many of which are known to cross-
react with pepsinogen. More specific antibodies to human pepsin have been 
developed, and these have been shown to have a high specificity through gel 
electrophoresis and mass spectrometry studies (Crapko, Kerschner, Syring, & 
Johnston, 2007; Knight, Lively, Johnston, Dettmar, & Koufman, 2005). Both 
sandwich and indirect pepsin ELISA methods have been published. These 
techniques are cheap, more sensitive (0.2 ng/ml) than published enzymatic 
methods, and they allow multiple sample analysis. Sandwich ELISAs are probably 
less liable to non-specific antibody capture as initial antigen “capture” with a 
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primary antibody increases the ratio of antigen to non-specific protein bound to 
the platform. There is only one commercially available assay (USCN Life 
Science). However, assay documentation suggests that it is not fully validated 
across multiple respiratory sample types, and on inquiry, the antibody used has 
significant cross-reactivity with pepsinogen. Much pepsin research is therefore 
still dependent on ‘in-house’ kits.  
Western blot analysis (WB) provides the advantage of being able to differentiate 
positive signal due to pepsin, pepsinogen, or other interfering proteins because 
proteins are separated by molecular weight. A further advantage is that, unlike 
enzymatic assays, it measures protein levels, and thus clinical samples above pH 
7 should not test ‘false negative’ by WB analysis. WBs for pepsin analysis have 
been reported, including in the analysis of laryngeal and sub-glottic biopsies 
(Kim, Lee, Yeo, Kim, & Cho, 2008; Knight et al., 2005; N. A. Metheny et al., 
2004). The Wisconsin group have now validated this method for analysis of BAL, 
with a pepsin lower limit of sensitivity of 0.05 ng (Johnston et al, unpublished 
data). The main disadvantage of WB is that it is semi-quantitative at best and in 
bronchial lavage samples, there is no reliable and validated protein which can be 
used for normalisation. 
1.4.1.3 Human studies  
Pepsin has been proposed as a useful biomarker of reflux aspiration in adults and 
in paediatric studies. Krishnan et al. detected pepsin enzymatic activity in 31 of 
37 tracheal aspirates from children with GORD compared with 0 of 26 healthy 
controls (A. Krishnan et al., 2007). Significantly raised BAL pepsin levels have 
also been found in children with chronic cough and proximal reflux (Farrell, 
McMaster, Gibson, Shields, & McCallion, 2006). Similarly, Starosta et al. showed 
raised BAL pepsin levels in 96 children with chronic lung disease, with and 
without GORD (Starosta et al., 2007). However, specificity was low, and there 
was extensive group overlap. Pepsin has also been used as a marker of aspiration 
in children ventilated on intensive care. However, results vary widely with 
reported pepsin positivity in tracheal aspirate ranging from 13.5% to 70% 
(Gopalareddy et al., 2008; Kathleen L. Meert, Daphtary, & Metheny, 2002), 
possibly due to differences in assay sensitivity. Interestingly, recent studies using 
very sensitive assays have found low pepsin levels in healthy paediatric control 
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patients (McNally et al., 2011). The authors acknowledge that reflux of gastric 
contents into the pharynx occurs frequently in normal, asymptomatic children, 
and healthy adults have been shown to aspirate nasopharyngeal secretions 
during sleep. Therefore, this finding is perhaps unsurprising (Gleeson, Eggli, & 
Maxwell, 1997; Ramaiah, Stevenson, & McCallion, 2005).  
Other groups have correlated pepsin levels with respiratory pathology. pH-MII 
studies in lung transplant recipients have shown that acid and alkaline reflux is 
common (Blondeau, Dupont, et al., 2008). Pepsin levels in BAL from lung 
transplant patients correlate with acute rejection, implying a contribution of 
pepsin to allograft injury (Stovold et al., 2007; Ward et al., 2005). Farhath et al 
found 92% pepsin positivity on analysis of tracheal aspirates from preterm 
ventilated neonates, and correlated pepsin levels with development of 
bronchopulmonary dysplasia (Sabeena Farhath et al., 2006; S. Farhath et al., 
2008). Finally, correlations between BAL pepsin levels and airway neutrophils or 
inflammatory cytokines have been reported in GORD, cystic fibrosis, and post 
lung transplant (Blondeau, Merters, et al., 2008; McNally et al., 2011; Starosta 
et al., 2007).  
Pepsin levels in more readily available samples such as sputum, saliva, and 
exhaled breath condensate have also been examined (A. Krishnan et al., 2007). 
Analysis of induced sputum from healthy children found pepsin was detectable in 
saliva from 17 of 19 children pre-sputum induction, and 19 of 19, post-sputum 
induction (median 14.7 ng/ml, range 8.3-25.6 ng/ml) (Ervine, McMaster, 
McCallion, & Shields, 2009). There is no evidence that pepsin is produced by the 
salivary glands; thus, these results are again consistent with the concept of 
normal physiological reflux in children (Ramaiah et al., 2005). In the adult 
literature, a variety of assays have been used to detect pepsin within sputum 
and saliva in patients with GERD and respiratory symptoms (Kim et al., 2008; 
Knight et al., 2005; Li et al., 2008; Potluri et al., 2003; Strugala, Dettmar, & 
Morice, 2009; Wang et al., 2010)). The variation in the frequency of pepsin 
detection in control subjects and the levels of pepsin reported in 
salivary/sputum samples is striking. In addition, pepsin levels detected in BAL 
studies appear to conflict with some of the sputum literature. Similar or lower 
levels have been reported in sputum/salivary studies compared with those 
reported in BAL studies, where samples are subject to significant dilution during 
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collection. When clinical specimens are analyzed by ELISA, antibody interference 
is always possible and particularly so when dealing with thick and proteinaceous 
samples, such as sputum. Therefore, rigorous assay validation is essential. 
Authors have called for assay standardization as a priority, so that normative 
values can be established for paediatric and adult age groups (Davis et al., 
2010).  
1.4.2 Bile acids 
Bile acids are present in gastric juice as a result of duodeno-gastric reflux. They 
are not present consistently and are therefore not as potentially useful as a 
biomarker of reflux-aspiration. However, it is  important to consider them in 
investigating aspiration lung injury, as they have been implicated in extra-
oesophageal injury in the oesophagus, larynx, ear, and lung (Blondeau, Dupont, 
et al., 2008; Blondeau, Merters, et al., 2008; D'Ovidio et al., 2005; Woodland & 
Sifrim, 2010; Wu et al., 2009). Pearson and Parikh measured bile acid levels in 
fasting gastric juice in adults and found median concentrations of 0 μmol/L 
(range 0-150 μmol/L) in normal subjects and 100 μmol/L (range 0-410 μmol/L) in 
patients with oesophagitis (Pearson & Parikh, 2011). Although gastric juice and 
airway bile acid concentrations have not been investigated in children with ND, 
one would hypothesise that they may be increased, given the high incidence of 
bowel dysmotility in this group (Peter B. Sullivan, 2008). Under normal 
circumstances, the majority of bile acids within gastric juice are conjugated 
(Vertzoni, Archontaki, & Reppas, 2008). However, many patients with ND take 
proton pump inhibitors, and this can result in bacterial overgrowth, causing de-
conjugation of bile acids (Theisen et al., 2000). Secondary bile acids are 
potentially more damaging to extraesophageal tissues due to increased lipid 
solubility (Pearson & Parikh, 2011). Therefore, bronchial lavage bile acid 
measurement, although limited in potential for use as a biomarker of reflux-
aspiration, is potentially useful in research of the pathogenesis of aspiration lung 
disease. 
1.4.3 Alpha-amylase 
Alpha-amylase is an enzyme which has various isoforms and is predominantly 
found in pancreatic juice or in saliva in humans (Ferey-Roux et al., 1998; Hirtz 
et al., 2005). It’s function in saliva is to start the digestive process through 
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hydrolysis of alpha bonds in large polysaccharides (such as starch and glycogen) 
(Ragunath, Manuel, Kasinathan, & Ramasubbu, 2008).  
When studying amylase as a biomarker of direct aspiration, it is important to 
acknowledge that a low level of amylase can be detectable in the normal lung, 
as demonstrated in Nandapalan’s study of tracheal aspirate amylase levels on 
laryngectomised patients (Nandapalan, McIlwain, & England, 1995). Similarly, 
the increased pulmonary production of amylase in certain pulmonary conditions, 
including malignancy and TB, should also be considered and this is further 
discussed in Section 5.5 of this thesis (Joseph et al., 1992; G. D. Lee et al., 
2003; Villena, Echave-Sustaeta, Lopez-Encuentra, & Navarro, 1995; Villena et 
al., 2002). However, amylase has the potential to be a useful biomarker of 
direct aspiration if clear differentiation can be demonstrated between those 
with clinical evidence of aspiration and healthy or disease controls. In a small 
study of 9 patients with clinical or radiological evidence of aspiration and 19 
controls undergoing diagnostic bronchoscopy or general anaesthetic, Smith et al 
concluded that there was a clear separation in amylase levels between the 
groups (D. D. Smith & McNamara, 1976). However, since that time, there have 
been few further studies of amylase as a biomarker of direct aspiration (Clarke, 
Bain, Davies, Levin, & Lambert, 1981; Nandapalan, McIlwain, & Hamilton, 1995). 
Interestingly, a clinical study by Nandapalan and colleagues suggested that high 
tracheo-bronchial amylase levels were predictive of subsequent respiratory 
deterioration in patients with tracheostomies in the Intensive Care setting 
(Nandapalan, McIlwain, & Hamilton, 1995). However, no other studies have 
subsequently made comparisons of lower airway alpha-amylase levels with lower 
airway inflammatory markers and respiratory symptoms.  
Consequently, the literature would suggest that alpha-amylase has shown 
promise as a biomarker of direct aspiration but has been inadequately 
investigated in the clinical research setting to date.  
1.4.4  Milk laden macrophages 
Some groups have attempted to improve the specificity of the lipid laden 
macrophage test by looking specifically for human and bovine milk proteins 
within the alveolar macrophages (α-lactalbumin and β-lactoglobulin, 
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respectively). This would aid differentiation of exogenous and endogenous lipid, 
a significant limitation of the lipid laden macrophage index (as discussed in 
Section 1.3.3). An initial study of single and repeated forced aspiration in a 
murine model suggested that testing for alveolar milk proteins in BAL was both 
specific and offered improved sensitivity when compared with lipid laden 
macrophage staining alone (Elidemir, Fan, & Colasurdo, 2000). Two further 
studies investigated alveolar macrophage milk protein in infants and young 
children, either ventilated on Intensive Care or undergoing bronchoscopy for 
respiratory symptoms. The Intensive Care based study by Miller et al, showed 
positivity in 12 patients who were being fed and had clinical or radiological 
evidence of aspiration (Miller et al., 2002). A later study found some correlation 
between positivity and incidence of gastro-oesophageal reflux and laryngo-
tracheal anatomical abnormality (De Baets et al., 2010). However, there were 
concerns about specificity of staining in both studies, some positivity being 
demonstrated in control groups. 
The proposed measurement of a more specific lipid in alveolar macrophages 
perhaps, still deserves further investigation. However, it could be argued that 
the measurement of milk proteins is limited because a) it would only be useful in 
infants, young children or potentially the gastrostomy fed with chronic disease, 
who take milk as a regular part of their diet throughout the day, b) it would not 
only be influenced by the frequency of aspiration events but also the frequency 
of feeding and c) it could potentially indicate reflux or direct aspiration in the 
orally fed child and would be unhelpful in differentiating the two. 
1.5 Clinical outcomes of recurrent aspiration  
Available clinical studies examining the pulmonary patho-physiological outcomes 
of recurrent direct and reflux aspiration are based solely on association rather 
than evidence of causation, due to the limitations of diagnostic testing, as 
discussed above. However, it is thought that recurrent aspiration can be 
associated with recurrent lower respiratory tract infections, potentially leading 
to chronic inflammatory changes, which subsequently can result in longer term 
airway damage, such as bronchiectasis or lung parenchymal damage (Seddon & 
Khan, 2003). Animal studies of forced aspiration provide supportive evidence of 
this disease process, although the physiological relevance of forced instillation 
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of hydrochloric acid directly into the lungs (as often performed in a number of 
these studies) is questionable (Amigoni et al., 2008; Chang et al., 2012; Ishizuka 
et al., 2001; Maniatis et al., 2012; Westphalen, Monma, Islam, & Bhattacharya, 
2012). Indeed, animal studies of forced instillation of both acidic and pH neutral 
gastric juice have suggested that other components of the gastric juice (such as 
enzymatic or microbial elements) may also be damaging to the airway 
epithelium, independent of pH (Mertens et al., 2010; Tang et al., 2012). The 
airway epithelium is the first to encounter inhaled substances following 
aspiration and therefore, the direct immunological response of airway epithelial 
cells to elements of the refluxate is relevant in furthering our patho-
physiological understanding of aspiration lung disease. The evidence regarding 
airway epithelial cell response following exposure to potentially injurious 
elements of the aspirate is discussed further in Chapter 7 of this thesis.   
Two recent clinical studies have added further interesting evidence to this 
proposed patho-physiological process in children with severe ND. Somerville et 
al studied 294 paediatric patients with severe developmental disability in the 
clinic setting. Within this group, 92% had symptoms of dysphagia, 67% had 
symptoms (or had previously had symptoms) of GORD and 65% had recurrent 
lower respiratory tract infections (Somerville et al., 2008). On investigation 53% 
had evidence of GORD related damage on upper airway endoscopy (182 patients 
examined), 41% showed evidence of aspiration on videofluoroscopy (174 patients 
examined) and 68% showed evidence of bronchiectasis on CT scan of the thorax 
(62 patients examined). A more recent retrospective study of 100 paediatric 
patients who had established videofluoroscopy or airway endoscopy diagnoses of 
aspiration and had undergone CT scan of the thorax, found that 66% had 
evidence of bronchiectasis, alarmingly including 51% of those less than two years 
of age (Piccione, McPhail, Fenchel, Brody, & Boesch, 2012). They found that 
severe neurological impairment and history of GORD were significant predictors 
of bronchiectasis, but notably clinical history/examination and respiratory 
symptoms were not. Sixteen patients underwent repeat CT scan following 
instigation of clinical management including feed modification, airway clearance 
therapy, fundoplication and salivary secretion management. In 81% the changes 
were stable or improving (44%). The authors did not specify whether these 
children had ND but the results would imply that pulmonary outcomes associated 
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with direct or reflux aspiration may be modifiable with appropriate 
management.  
Both of these studies are significantly limited as they are solely based on clinical 
associations, with no evidence of direct causation. The children with ND 
included in these studies were likely to have had other factors contributing to 
their respiratory disease, independent of aspiration. More detailed prospective 
observational and interventional studies are needed in order to tease out the 
relative contributions of these factors.  
1.6 Closing remarks and aims and objectives of this 
thesis 
Children with severe ND often suffer with burdensome respiratory disease and 
respiratory complications are the leading cause of premature death in this 
group. Respiratory complications often result in repeated, prolonged hospital 
admissions which are costly and are likely to impinge on child and family quality 
of life. The aetiology of this respiratory disease is undoubtedly multi-factorial.  
However, aspiration (whether reflux-associated or direct) is likely to play a 
significant role. Due to the challenges of research in this area and limitations in 
diagnostic testing, the evidence base for clinical management and outcomes of 
interventions is limited. With improved understanding of the burden of 
respiratory disease and relative contribution of reflux and direct aspiration in 
this group, there is potential to work towards optimisation and standardisation 
of clinical care.  
The original objectives of this study were firstly, to characterise the burden of 
respiratory symptoms in children with ND and explore the relationship of 
respiratory symptoms with co-morbidities and lower airway inflammatory 
markers. Secondly, to explore both established and novel bronchial lavage 
biomarkers of reflux aspiration in this group, assessing their validity and the 
relationship of any results generated to clinical and inflammatory data. Finally, 
to conduct an investigation into the effects of mild pH alteration and pepsin on 
the airway epithelial cell.  
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As the study progressed, further objectives were generated. Development of a 
novel test for accurate detection and quantification of pepsin in bronchial lavage 
fluid became a key study objective. Also, investigation of the validity of alpha-
amylase as a biomarker of direct aspiration and the relationship of alpha-
amylase levels to lower airway inflammatory markers and clinical symptoms was 
explored.  
The study hypotheses were that ‘children with severe neurodisability have a high 
burden of chronic respiratory symptoms and concomitant high levels of lower 
airway inflammation. Both direct and reflux aspiration contribute to respiratory 
symptoms and lower airway inflammation through direct airway epithelial injury 
by elements of the aspirate.’ 
In order to address these hypotheses, a prospective observational cohort study 
was performed. Clinical data and non-bronchoscopic bronchial lavage samples 
were collected from children with ND both at a time of stability and a time of 
respiratory deterioration and also from a group of healthy control children. Using 
the clinical data, BAL samples and an airway epithelial cell culture model, it was 
possible to explore; 
1) Respiratory symptoms (as assessed by a respiratory symptom questionnaire) 
and their relationship to clinical characteristics and co-morbidities in children 
with ND. 
2) Lower airway inflammatory profile in children with ND both at a time of 
stability and respiratory deterioration compared to healthy controls, and the 
relationship to respiratory symptoms. 
3) Biomarkers of direct and reflux aspiration in BAL fluid, including validity of 
available laboratory techniques.  
4) Development of a novel assay for measurement of pepsin in BAL. 
5) The effects of pepsin and mild pH alteration on airway epithelial cells in a 
monolayer airway epithelial cell culture model. 
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A chapter on each of these areas is included within this thesis.  
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  Chapter 2 Materials and Methods 
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2.1 Patient recruitment, consent, data collection and 
ethics 
To realise the aims of this study, three groups of patients were recruited during 
their admission to Alder Hey Children’s Hospital, Liverpool. The first group 
consisted of children with ND, admitted to the paediatric intensive care unit 
(PICU) with a respiratory deterioration. It was anticipated that a number of 
these children may have experienced an acute aspiration event shortly prior to 
admission and therefore, BAL biomarkers of aspiration may be increased. A 
second group of children with ND was included, admitted electively for non-
urgent surgical procedures. Theoretically, this group should be stable from a 
respiratory perspective. They were an important group to include, in order to 
assess the influence of chronic aspiration and any relationship between chronic 
aspiration and background respiratory symptoms and lower airway inflammation. 
Finally, a group of healthy control children, admitted for elective surgical 
procedures were involved as a comparison group.  
It would have been ideal to include a non-ND PICU patient group however, 
because of competing studies on PICU, recruitment to such a group was not 
possible. It was also not possible to recruit every eligible patient during the 
study period due to researcher availability. Consequently, a convenience 
sequential approach was taken to recruitment.  
Unfortunately, there were no previous data on which to base a power 
calculation for study group sample sizes. Therefore, a pragmatic sample size 
target of thirty patients per study group was set.  
2.1.1  Paediatric intensive care neurodisability group (PICU-ND) 
Children were eligible for inclusion in the study if they were over two years of 
age, had a central ND (not neuromuscular disease), were non-ambulant (GMFCS 
IV-V) and were ventilated on the PICU for a respiratory deterioration (R. Palisano 
et al., 1997). Patients who had been ventilated for more than 48 hours were not 
eligible. Demographic details, past medical history, medication history, current 
clinical management (including time since intubation), previous respiratory 
management and respiratory sample microbiology results were recorded on a 
bespoke, standardised data collection form (Appendix 1). Results of 
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investigations for suspected GORD and videofluoroscopy assessments were 
recorded, as well as information about surgical feeding interventions or anti-
reflux procedures. 
2.1.2  Elective neurodisability group (Elective-ND) 
Children were eligible for inclusion in the study if they were over two years of 
age, had a central neurodisability (not neuromuscular disease), were non-
ambulant (GMFCS IV-V) and were being admitted for elective surgery, which 
would require a general anaesthetic and endo-tracheal intubation (as opposed to 
a laryngeal mask airway, which is commonly used for minor surgical procedures). 
Clinical information was collected and collated from all participants on a 
standardised data collection form (Appendix 1). 
2.1.3  Healthy control group 
Children over the age of two years were recruited at the time of admission for 
routine elective minor surgical procedures for which they would require a 
general anaesthetic and endo-tracheal intubation. Children were not eligible for 
inclusion if they had a chronic illness or were taking any regular medication. 
Following a period of recruitment, children who were admitted for grommet 
insertion or tonsillectomy were excluded from the study due to the possible 
associations of otitis media and adeno-tonsillar hypertrophy with GORD (Crapko 
et al., 2007; Stapleton & Brodsky, 2008; Tasker et al., 2002b). Demographic 
details, past medical history, medication history and reason for admission were 
recorded on a standardised data collection form (Appendix 1). 
2.1.4  Ethics and Consent 
This study was approved by the local research ethics committee (REC reference 
09/H1002/58). All patients and parents received written information about the 
study (Appendix 2 - patient/parent information leaflets). Written informed 
consent (and assent where appropriate) was taken from all parents (and 
patients) prior to collection of data or clinical samples using standard Alder Hey 
Trust consent forms. 
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2.2  Assessment of clinical symptoms 
2.2.1  Respiratory symptom questionnaire 
No validated respiratory symptom score exists within the literature for children 
with ND. In this study, parents of all recruits completed a modified version of 
the Liverpool Respiratory Symptom Questionnaire (LRSQ). Previously, the LRSQ 
has been partially validated in preschool children with wheeze and in children 
with cystic fibrosis (Powell, McNamara, Solis, & Shaw, 2002; Trinick, Southern, & 
McNamara, 2012). The questionnaire enquires about respiratory symptoms over 
the previous three months and is divided into eight domains; daytime, nocturnal, 
URTI, interval, activity, other respiratory symptoms and the effect of these 
symptoms on both child and family. For the purposes of this study, we removed 
the ‘activity symptoms’ domain and a question about effects of respiratory 
symptoms on physical activity from the ‘Effects of symptoms on the child’ 
domain as by definition, the ND study group were not independently mobile. 
Thus, we created a modified version of the questionnaire (Appendix 3 - LRSQ-
Neuro). This modification negates validation data gathered from previous studies 
using the LRSQ (Powell, McNamara, Solis, & Shaw, 2002; Trinick, Southern, & 
McNamara, 2012). However, the questionnaire scores would not have been 
comparable between control and ND groups without these changes and no 
alternative validated respiratory questionnaire exists for this patient group.  
There were 27 questions in total, spread across seven domains, with a maximum 
total score of 108. Parents/patients completed the questionnaire independently 
following recruitment to the study. 
2.2.2  GORD and pulmonary aspiration symptom assessment 
No prospectively validated gastro-oesophageal reflux symptom score exists 
within the literature for use in children over two years of age. A commonly used 
score, which has been partially validated in the paediatric population, is the 
Reflux Symptom Index (Belafsky, Postma, & Koufman, 2002; Simons et al., 
2008). It was anticipated that children recruited to the ND study groups may be 
fed via gastrostomy and may not communicate verbally, thus potentially limiting 
parental assessment of difficulty in swallowing and change in voice. The 
questions from the Reflux Symptom Index were adapted to create a set of five 
questions which were appropriate for use across the study population. The 
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questions enquired about cough, pain, choking, shortness of breath and vomiting 
with, or shortly following, feeds (whether they were oral, nasogastric or via 
gastrostomy). Questions were answered on a Likert scale from ‘not at all’ (score 
0) to ‘every day’ (score 4). Some of the questions within the LRSQ-Neuro and 
GORD symptom questionnaires also address commonly encountered symptoms of 
pulmonary aspiration. The GORD symptom questionnaire is included in Appendix 
4. 
2.3 Broncho-alveolar lavage samples 
2.3.1 Sampling, equipment and technique 
Non-bronchoscopic bronchoalveolar lavage (BAL) samples were collected either 
following induction of anaesthetic for elective surgery in the anaesthetic room 
or when the child was muscle relaxed on PICU. The European Respiratory Society 
(ERS) guidelines on collection of BAL in children were followed (de Blic et al., 
2000).The equipment required for BAL sampling included a sterile 10G suction 
catheter (Pennine Healthcare), a three-way tap (Codan Steritex), a tracheal 
suction set (Unomedical), two 10ml sterile syringes, sterile 0.9% saline solution 
and a suction machine (Figure 2.1). A suction catheter was passed down the 
endo-tracheal tube until resistance was felt. Two 1 ml/kg aliquots of normal 
saline were instilled separately (maximum aliquot volume 20ml). BAL fluid was 
recovered with constant suction pressure of <100mmHg and collected into a 
tracheal suction set (mucus trap). Oximetry monitoring was performed 
throughout the procedure. 
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Figure 2.1 Equipment required for non-bronchoscopic broncho-alveolar lavage sample 
collection 
The equipment required for non-bronchoscopic broncho-alveolar lavage sample collection includes 
a sterile 10G suction catheter (Pennine Healthcare), a three-way tap (Codan Steritex), a tracheal 
suction set (Unomedical) and a 10ml syringe with sterile 0.9% saline. 
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2.3.2  BAL sample processing 
Following collection, BAL samples were processed immediately in the laboratory. 
The ERS guidelines on the processing of BAL in children were followed (de Blic et 
al., 2000). 
2.3.2.1 Cell counting 
Total volume of BAL sample returned was recorded and percentage recovery was 
calculated. The sample was gently mixed using a vortex, following which three 
10µl aliquots were removed for cell counting. An equal volume (10µl) of trypan 
blue stain (Sigma Aldrich, Dorset, UK, diluted 1:2) was added to each aliquot. 
Following mixing, 10µl was pipetted under the positioned cover-slip of a 
Neubauer haemocytometer. Using a light microscope (Vickers 20/0.5 objective 
lens), the cell number in four 1x1mm squares (each holding 100 nanolitres) was 
counted. To calculate the number of cells per millilitre (ml), the following 
equation was used; (count x 2)/4 x 10,000). This figure was multiplied by the 
sample volume recovered (ml) to give the total cell count. Non-viable cells 
(which take up trypan blue stain differentially) were not included in the cell 
count. Bronchial epithelial cells (the number of which was low in adequate 
samples) were also excluded from the count. Samples with a cell count of less 
than 500,000 were immediately excluded from further analysis. Sample 
adequacy was assessed, based on volume returned and numbers of bronchial 
epithelial cells. Total counts were performed on three separate aliquots and the 
mean value was recorded. 
2.3.2.2 Processing and storage 
BAL pH measurement was made within fifteen minutes (mins) of collection using 
a pH meter (Philips PW 9418), which was calibrated and cleaned prior to each 
reading. An aliquot of whole BAL, sufficient (from the total cell count) to 
provide adequate cell numbers to produce four cytospin slides, was set aside 
(50,000 cells/slide). The remaining sample was centrifuged at 2656g for 5 mins. 
The BAL supernatant was aliquoted into 1.5ml Eppendorf tubes and stored at 
minus 80 ºC until further analysis, with a minimum of 200µl in each tube. The 
cell pellet was divided for protein (2 million cells) and/or mRNA (1 million cells) 
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analysis. Protein pellets were stored dry. Cell pellets for mRNA analysis were 
stored in 350µl RLT lysis buffer (1ml RLT buffer (Qiagen Ltd, Crawley, UK) and 
10µl Beta-mercaptoethanol (Sigma Aldrich, UK)) 
2.3.2.3 Cytospin slide preparation, modified Wright-Giemsa 
staining (Diff-quick) and differential cell counting 
Cytospin slides were prepared from a volume of whole BAL, calculated (from the 
total cell count) to contain approximately 50,000 cells. In samples of high 
cellularity, the total sample volume was made up to 100µl with sterile 
phosphate buffered saline (PBS). The samples were applied to cyto-chambers 
which were secured in slide carriers containing Xtra-adhesive slides (Surgipath® 
Consumables) and centrifuged at 500 xg for 5 mins in a Rotofix 32A. 
‘Diff-quick’ stain is a modified Wright-Giemsa stain. Following brief air drying, 
slides were fixed with Diff Quick fixative (100% methanol, Reastain CE) by 
dipping five times and allowing excess to drip off the slide. Slides were then 
dipped five times in the eosinophilic staining ‘Solution 1’ followed by five dips in 
the basic ‘Solution 2’ (eosin Y and azur blue respectively, Reastain CE). Slides 
were rinsed in dH20 before being allowed to air-dry. They were then briefly 
dipped in xylene before a cover slip was applied, using DPX mounting media. 
A differential cell count was made using a light microscope with an oil emersion 
lens (Figure 2.2). Three hundred cells were counted and any bronchial epithelial 
cells or unidentifiable cells were not included in the count. Cell types were 
expressed as a percentage of the total cell count. A mean value was calculated 
from three cell counts. 
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Figure 2.2 Examples of cell types observed in BAL fluid from study recruits 
Diff-Quick staining (Reastain CE) was performed on BAL cytospin slides. Cells were visualised 
using a light microscope with an oil emersion lens.  
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2.3.2.4 Oil Red-O staining and lipid laden macrophage 
assessment 
Stock Oil Red-O stain was prepared by adding 1 gram (g) of Oil Red-O (Sigma 
Aldrich, UK) to 100ml of 60% triethyl phosphate (Sigma Aldrich, UK). This was 
incubated at 60ºC for 2-3 hours, stirring occasionally. The mixture was filtered 
through fluted filter paper whilst still hot. 
Cytospin slides were prepared as previously described. Following centrifugation, 
the slides were rapidly air dried using low flow cold air, followed by rinsing in 
60% triethyl phosphate for 30 seconds (secs). Oil Red O stain was applied for 15 
mins. Differentiation was achieved by washing off excess dye with 60% triethyl 
phosphate. Slides were then rinsed in dH20 for 15 secs. Counterstaining was 
performed using haematoxylin (Gill III Surgipath®, Leica Microsystems) for 15 secs 
followed by a further dH20 rinse for 15 secs. Scott’s tap water substitute was used 
to blue the haematoxylin for 15 secs. Following further rinsing in dH20, a cover-slip 
was applied using glycerol gelatine aqueous mountant (Sigma Aldrich, UK). 
Slides were assessed for lipid staining of the alveolar macrophages using a light 
microscope with an oil emersion lens. The limitations of lipid laden macrophage 
index reporting are discussed in Chapter 1. In cases where evidence of alveolar 
macrophage lipid staining was seen, slides were forwarded to the local 
cytopathologist for interpretation according to local guidelines (Figure 2.3). All 
slides were reported by the same cytopathologist (Professor Lesley Turnbull). Lipid 
laden macrophage index scores were not reported due to concerns regarding 
misinterpretation (as discussed in section 1.3.3). Any lipid laden macrophage 
positivity was assessed within the context of the inflammatory background of the 
sample and a positive or negative report was issued. It was agreed that any cases 
of a positive report would be discussed with the medical team in charge of the 
child’s care and that an appropriate course of clinical action would be discussed 
with the family. 
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Figure 2.3 Examples of a. negative and b. positive BAL alveolar macrophages for 
cytoplasmic lipid, tested using Oil Red O staining. 
Oil Red O staining was performed on cytospin slides of BAL samples and alveolar macrophages 
were visualised using a light microscope with an oil emersion lens. All samples with any positive 
staining were interpreted by a cytopathologist according to local policies. 
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2.3.2.5 Quantipro Bicinchoninic Acid Assay  
Measurement of BAL total protein content was performed using a Quantipro 
(Bicinchoninic acid) assay kit (Sigma Aldrich, UK). The Bicinchoninic acid assay is 
based on the principle of Cu2+-protein complex formation and reduction of Cu2+ 
to Cu1+ under alkaline conditions. This reduction is proportional to the amount of 
protein present in a linear relationship between 0.5-30 µg/ml. 
A bovine serum albumin (BSA) stock solution of 900 µg/ml was prepared to use as 
a standard. All samples and standards were processed in duplicate. PBS (150µl) 
was added to all standard wells, with the exception of the two top standard 
wells, on a 96 well plate (Corning, Costar). For each top standard well, 10µl of 
the BSA stock solution was added to 290µl of PBS, giving a concentration of 
30µg/ml. Serial 1:2 dilutions were then made to give a seven point standard 
curve. BAL supernatants were pre-diluted, as detailed below, and 150µl volume 
was added to sample wells, each sample being assayed in duplicate. The 
Quantipro working solution is a mixture of 25 parts ‘QA’ (sodium carbonate, 
sodium tartate, and sodium bicarbonate in 0.2 M NaOH, pH 11.25) with 25 parts 
‘QB’ (4% (w/v) bicinchoninic acid solution, pH 8.5). and 1 part ‘QC’ (4% (w/v) 
copper(II) sulfate, pentahydrate solution). The working solution was mixed with 
samples 1:1. A cover was applied and the plate was incubated on a plate 
agitator at 60ºC for 60 mins. The absorbance was measured at 560 nm using a 
microplate reader (Bio-tek) and results were recorded using KC Junior software 
(Bio-tek). The sample total protein concentration was calculated from the 
standard curve.  
For sample dilution optimisation, six samples (a range of elective and PICU 
samples) were run at dilutions (with PBS) ranging from 1:20 to 1:160. Optimal 
sample dilution was found to be 1:20 for healthy controls and 1:80-1:160 for 
PICU samples, allowing all samples to fall within the range of the standard 
curve. Linearity of dilution was checked and was found to be acceptable (Figure 
2.4). Mean intra-assay and inter-assay coefficients of variation were found to be 
4.04% (n=20) and 14.5% (n=4), respectively. 
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Figure 2.4 Good linearity of dilution was observed when assessing three BAL supernatant 
samples run at three dilutions using the Quantipro total protein assay (Sigma, UK) 
Scatter graph to show dilution corrected total protein measurements for three BAL supernatant 
samples, run at three dilutions. Good linearity of dilution was seen and therefore, there was little 
variation in total protein measurement by sample dilution. This provided validation for use of 
varying, optimised sample dilutions according to patient group. 
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2.3.2.6 Correction for epithelial lining fluid dilution 
BAL fluid collection provides a useful method of assessing the lower airway in 
both research and clinical settings. However, a widely recognised limitation of 
this technique is the variable dilution of the airway epithelial lining fluid within 
the returned sample. The possibility of using a dilutional marker to correct for 
this has been debated within the literature and various internal markers, such as 
albumin and urea, have been considered. However, all have potential significant 
limitations (Shields & Riedler, 2000; Ward, Fenwick, Booth, & Walters, 1997; 
Ward, Thien, Secombe, Gollant, & Walters, 2000). An ERS taskforce (2000) made 
recommendations that BAL data should not be corrected for dilution until a 
reliable method had been established. There has been no change to this 
recommendation to date (de Blic et al., 2000). 
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2.4 Enzyme linked immunosorbent assays (ELISA) and 
enzyme activity assays 
R&D systems Duo-Set ELISA Development kits were used for Interleukin-8 (IL-8), 
Interleukin-6 (IL-6) and Transforming Growth Factor-Beta1 (TGF-1) protein 
measurement in BAL samples and/or cell culture supernatants. Antibody (Ab) 
and protein standard concentrations used for the ELISAs are listed in Table 2.1. 
The manufacturer of these ELISAs had not validated their use in BAL 
supernatants. Standard steps of assay validation include calculation of intra- and 
inter-assay coefficients of variation and spike recovery experiments (Food and 
Drug Administration, 2001). These validation steps were performed using BAL at 
the dilutions stated in the individual IL-8 and TGF-1 ELISA methods (Sections 
1.4.2 and 1.4.4, respectively) and the results are documented in Table 2.1. 
Inter- and intra-plate coefficients of variation were calculated as detailed in 
Section 2.9. Spike recovery experiments were performed by spiking a known 
concentration of the protein of the interest into a BAL supernatant sample (also 
processing the same BAL supernatant alone with an equivalent volume dH20 
spike, in order to measure the baseline level of the protein of interest in the 
sample and thus, calculate the true spike retrieval). An identical protein spike 
was also performed in reagent diluent, on the same plate. Percentage spike 
retrieval was calculated by dividing the amount retrieved in sample matrix by 
the amount retrieved in reagent diluent and multiplying by 100. Acceptable 
spike recovery is considered to be 80-120% (Administration). 
Table 2-1 Table of commercial ELISA Ab concentrations and validation data for use of IL-8 
and TGF-1 duoset ELISA (R&D systems, UK) with BAL 
ELISA IL-8 IL-6 TGF-1   
Capture Ab (µg/ml) 4 2 2 
Detection.Ab (ng/ml) 20 50 300 
High standard (pg/ml) 2000 600 2000 
Low standard (pg/ml) 31.25 9.3 31.25 
Mean intra-assay CV (% n>20) 2.06 n/a 7.51 
Mean inter-assay CV (% n=3) 5.86 n/a 5.31 
Spike retrieval (% n=4) 94.5 n/a 101.5 
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2.4.1 Optimisation of sample dilution 
Optimal sample dilution was ascertained for each ELISA by running a range of 
samples (healthy control and PICU-ND) several times at various dilutions and 
identifying the dilution factor which would allow the majority of samples to fall 
within the linear portion of the standard curve and all samples to fall below the 
top standard. Corrections for dilution were made at the end of the analysis. 
2.4.2 Measurement of interleukin-8 in BAL and cell culture 
supernatants 
An aliquot of capture antibody (calculated to give the desired Ab concentration 
on dilution in 10ml volume) was diluted in 10ml PBS. All wells of a 96 well 
immuno-plate (MaxisorpTM, Nunc Brand) were coated with 100µl of capture 
antibody solution. The plate was sealed and incubated at room temperature (RT) 
overnight. Following aspiration of the capture antibody, an automatic plate 
washer was used to aspirate and fill the wells with 400µl wash buffer (0.05% 
Tween 20 in PBS, pH7.2-7.4) three times. The plate was then inverted and 
blotted. All wells were blocked with 300µl of block buffer (1% BSA in PBS) and 
the plate was incubated at RT for one hour. The three aspiration/wash cycles 
were then repeated. BAL samples were diluted 1:10 in reagent diluent (0.1% 
BSA, 0.05% Tween® 20 in Tris-buffered saline, pH7.2-7.4) and cell culture 
supernatants were processed neat. Samples (100µl/well) were loaded in 
duplicate. A seven point standard curve was run in duplicate, using two fold 
dilutions (in reagent diluent) from a high standard of 2000pg/ml. The plate was 
resealed and incubated at 37ºC for one hour. The aspiration/wash step was 
repeated. The detection antibody was diluted in 10ml reagent diluent, giving the 
required Ab concentration, and 100µl was added to each well. The plate was 
resealed and incubated at 37ºC for one hour. Following the aspiration/wash 
step, 100µl of Streptavidin-HRP (diluted 1:200 in reagent diluent) was added to 
each well. The plate was resealed and incubated at RT out of direct light for 20 
mins. The aspiration/wash step was repeated, then 100µl 3,3’,5,5’-
Tetramethylbenzidine (Sigma, UK) was added to each well. The plate was 
incubated for up to 20 mins in the dark until the lowest standard had developed 
colour, following which 50µl of ‘stop’ solution (2N H2SO4) was added to each 
well. The plate was read using a microplate reader (Bio-tek) at 450nm and the 
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standard curve was generated using KC Junior software (Bio-tek), from which 
sample IL-8 concentrations were calculated.  
2.4.3 Measurement of Interleukin–6 in cell culture supernatants 
The methods for measurement of IL-6 using the IL-6 Duoset ELISA (R&D systems, 
UK) were identical to the methods described above, except the reagent diluent 
used was 1% BSA in PBS (pH 7.2-7.4) and the standard curve high standard was 
600pg/ml. Cell culture supernatants were processed neat or at 1:2 dilution, 
depending on sample volumes available. 
2.4.4 Measurement of TGF-1 in BAL and cell culture 
supernatants 
Latent TGF-1 required activation before measurement by ELISA, using acid 
activation and neutralisation. For cell culture supernatants, 30µl 1N HCL was 
added to 150µl of sample, mixed and incubated at RT for 10 mins. Neutralisation 
was with 30µl 1.2N NaOH/0.5M HEPES. Following mixing, the sample was assayed 
in duplicate with no further dilution (100µl/well). For BAL, 50µl 1N HCL was 
added to 100µl sample, mixed and incubated at RT for 10 mins. Neutralisation 
was with 50 µl 1.2N NaOH/0.5M HEPES. Following mixing, the sample was 
assayed with no further dilution (total 100µl/well). 
The TGF-1 assay protocol was identical to the IL-8 protocol except the block 
buffer was 5% Tween® 20 in PBS and the reagent diluent was 1.4% Reagent 
Diluent Concentrate 1 (R&D systems) and 0.05% Tween® 20 in PBS. The high 
standard was 2000pg/ml. 
2.4.5 Measurement of pepsin in BAL 
2.4.5.1 ELISA 1 
This is the protocol of an ‘in house’ assay developed at the University of 
Newcastle (Tasker et al., 2002a). Primary and secondary Ab details are listed in 
Table 2.2. 
For the standard curve, ten standards of 0-10 ng/ml porcine pepsin A solution 
(100µl volume) were constructed in duplicate across the top of a 96 well 
immuno-plate (MaxisorpTM, Nunc Brand), using lyophilised porcine pepsin A 
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(Sigma Aldrich, UK) and reagent diluent (0.1% BSA, 0.05% Tween 20 in PBS). The 
rest of the plate was divided into two: the first half was for analysis of samples 
using the primary and secondary Abs and the second half was for analysis of 
samples using the secondary Ab only (to check and correct for any non-specific 
binding of the secondary Ab). BAL samples were loaded at a 1:5 dilution and 
analysed in duplicate on both halves of the plate. The plate was covered and 
incubated at RT overnight. All wells were then aspirated and washed three times 
with wash buffer (0.05% Tween 20 in PBS (pH7.2-7.4)). Following this, all wells 
were blocked with 300µl block buffer (1% BSA in PBS) and incubated for 1 hour at 
RT. The aspiration/wash step was then repeated. The primary Ab was then 
added to all wells (100µl, 5ug/ml). The plate was covered and incubated at RT 
for 1.5 hours. Following the aspiration/wash step, the secondary Ab was added 
to all wells (100µl, 1:10,000 dilution following reconstitution according to the 
manufacturer’s instructions). The plate was re-covered and incubated for a 
further 1.5 hours. Following the aspiration/wash step, 100µl 2,2’-Azino-bis(3-
ethylbenzothiazoline-6-sµlfonic acid) liquid substrate system (Sigma, UK) was 
added to each well (pre-warmed to RT). The plate was incubated in the dark for 
45 mins (optimised based on rate of standard curve colour development). To 
stop the reaction, 100µl 1% SDS was added to each well. The plate was read 
using a microplate reader (Bio-tek) at 405nm and the standard curve was 
generated using KC Junior software (Bio-tek). Any fluorescence emitted from 
samples due to non-specific binding of the secondary Ab was subtracted from the 
corresponding readings with the primary and secondary Ab. Pepsin levels were 
calculated from the standard curve and multiplied by two (the team who 
developed the ELISA have previously established that the porcine pepsin primary 
antibody is cross reactive with human pepsin with half the level of affinity for 
porcine pepsin). 
2.4.5.2 ELISA 2 
This is the protocol of an ‘in house’ assay developed at Queens University Belfast 
(Farrell et al., 2006). Primary and secondary Abs used in this method are listed 
in Table 2.2.  
All wells of a 96 well immuno-plate (MaxisorpTM, Nunc Brand) were coated with 
100µl of primary Ab (10ug/ml 0.05M carbonate-bicarbonate buffer, pH 9.6). The 
 68 
plate was sealed and incubated overnight at RT. All wells were aspirated and 
washed five times with 300μl wash buffer (0.05% Tween 20 / PBS wash buffer) 
following which the plate was blotted dry. All wells were blocked with 300µl 
block buffer (3% filtered Ovalbumin (Sigma, UK) in PBS) and the plate was 
incubated for two hours at RT. The 3% Ovalbumin / PBS was filtered through 
50μm nylon gauze. The aspiration/wash step was repeated. Porcine pepsin 
standards (lyophilised porcine pepsin A, Sigma Aldrich, UK) were prepared in 
0.1% BSA/PBS at concentrations of 1, 5, 7.5, 10, 50, 75, 100ng/ml and assayed in 
duplicate (100µl volume). BAL samples were assayed neat (100µl) in duplicate 
and 100μl of 0.1% BSA/PBS was added to blank wells. The plate was sealed and 
incubated at RT for 2 hours, following which the aspiration/wash step was 
repeated. Following blotting, all wells were coated with secondary Ab (2ug/ml in 
3% filtered Ovalbumin/PBS) and the plate was incubated for two hours at RT. 
Following a final aspiration/wash step, 100μl of 3,3’,5,5’-Tetramethylbenzidine 
substrate was added to all wells and the plate was incubated for 30 mins under 
subdued light. The reaction was stopped with 100μl 2M Sulphuric acid. The plate 
was read using a microplate reader (Bio-tek) at 450nm (with a wavelength 
correction at 540nm) and a four parameter logistic standard curve fit was 
generated using KC Junior software from which sample pepsin values were 
calculated. 
Table 2-2 Table of ‘in house’ pepsin ELISA Abs, suppliers and working concentrations 
Assay Ab Working 
concentration  
Host Supplier 
ELISA 1 
primary 
Purified polyclonal anti-
porcine pepsin A 
5ug/ml  Goat Biodesign, US 
(W59117G) 
ELISA 1 
secondary 
Monoclonal anti goat/sheep 
IgG-peroxidase 
1:10000 
dilution 
Mouse Sigma Aldrich, 
UK (A9452) 
ELISA 2 
primary 
Purified polyclonal anti-
porcine pepsin A 
10ug/ml Goat US Biological, 
US (P3270-06) 
ELISA 2 
secondary 
Purified polyclonal  anti-
porcine pepsin A-
peroxidase 
2ug/ml Goat Biodesign 
(W59117P) 
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2.4.6 Lactate dehydrogenase activity assay 
Cell lysis and death was assessed using a colorimetric cytotoxicity detection kit, 
based on the measurement of lactate dehydrogenase (LDH) activity released 
from the cytosol of damaged cells into the supernatant (Roche Applied Science, 
UK). LDH activity is determined by the LDH catalysed conversion of lactate to 
pyruvate, which in turn reduces NAD+ to NADH/H+. The catalyst (diaphorase) 
then transfers H/H+ from NADH/H+ to tetrazolium salt INT, which is then reduced 
to formazan. 
Cell culture supernatants were tested neat and assayed in duplicate (100µl/well) 
on a 96 well flat-bottomed plate (Corning, Costar). A 14-point standard curve 
was constructed from a high standard of 2U/ml, which was also run in duplicate 
(LDH, hog muscle, Roche, UK). A background control (assay medium alone) and 
low control (100µl cell culture media) was run on each plate. For 100 tests, 
250µl of ‘bottle 1’ was combined with 11.25µl of ‘bottle 2’ and mixed. This was 
added 1:2 (100µl) to each well and the plate was incubated with agitation at 20 
ºC for up to 30 mins. Absorbance was measured using a microplate reader (Bio-
tek) at 490nm and the standard curve constructed using KC Junior software. LDH 
activity was calculated from the standard curve. 
2.4.7 Alpha amylase activity assay 
A commercially available alpha amylase activity kit (Abcam) was used for 
measurement of alpha amylase activity in BAL supernatants. The assay is based 
on specific cleavage of ethylidene-pNP-G7 by alpha amylase to smaller 
fragments, which can be acted upon by alpha-glucosidase, leading to release of 
a chromophore which can be measured at an absorbance of 405nm. 
BAL supernatants (20µl volume) were assayed in duplicate. The samples were 
made up to 50µl volume with dH20. A six point nitrophenol standard curve of 20, 
16, 12, 8, 4 and 0 nM/well was also constructed in duplicate, all wells being 
made up to a final volume of 50µl. An alpha amylase positive control was 
reconstituted in 50µl assay buffer and run on each plate. A negative control of 
PBS was also run on each plate. Assay buffer and substrate mix were combined 
1:1 and 100µl was added to each well. The plate was analysed immediately in a 
microplate reader (Bio-tek) at 405nm for ‘T0’ values. The plate was then 
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incubated at 25 ºC with agitation and reanalysed by the plate reader every two 
mins for a total of ten mins. Reaction kinetics were observed and the optimal 
time for ‘T1’-‘T0’ to fall in the linear portion of the curve (for the majority of 
samples), was found to be 4 mins. Alpha amylase activity was calculated by 
applying the change in OD (‘T1’-‘T0’) to the standard curve to calculate a value 
of ‘B’ nM of nitrophenol generated between T1 and T0. Amylase activity (U/L) 
was then calculated by multiplying ‘B’ by the sample dilution factor and then 
dividing this by time between T1 and T0, multiplied by the pre-treated sample 
volume. 
This assay was not validated by the manufacturer for use with BAL supernatant 
samples. Therefore, previously described validation steps were performed. The 
intra-assay coefficient of variability was found to be 6.49% (n=20), the inter-
assay coefficient of variability was 7.04% (n=3) and the mean spike recovery was 
94.3% (n=3). 
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2.5 1D SDS-PAGE Gel Analysis and Western Blotting  
2.5.1 1D SDS-PAGE (Polyacrylamide Gel Electrophoresis) 
The spacer and short plates were secured in a casting frame and a 1mg/ml 
ammonium persulphate solution was prepared, prior to making the resolving gel 
solution. The resolving gel solution (enough for two gels) consisted of 4ml 30% 
acrylamide/bisacrylamide, 2.5ml 1.5M Tris (pH8.8), 50µl 10% Sodium Doecyl 
sµlphate (SDS) and 3.4ml ultrapure H20. When ready to pour, 75µl ammonium 
persulphate solution and 7.5µl TEMED was added. The solution was briefly mixed 
and then pipetted between the plates, filling the cavity to 1 cm from the top. A 
small volume of water-saturated butan-2-ol was added across the width of the 
gel before covering with cling-film and leaving for one hour to polymerise. 
Following this, excess butan-2-ol was poured off and 25µl ammonium 
persulphate (1mg/ml) and 2.5µl TEMED were added to the stacking gel buffer 
(0.65ml 30% acrylamide/bisacrylamide, 1.25ml 0.5M Tris (pH6.8), 50µl 10% SDS 
and 3.025ml ultrapure water). The solution was mixed prior to adding to the gels 
(filled to the top of the plates). The well comb was positioned and the casting 
frame was covered with cling-film for a further hour. 
SDS sample buffer (1.2ml 0.5M Tris (pH6.8), 5.3ml ultrapure water, 1ml glycerol, 
2ml 10% (w/v) SDS, 0.5ml 0.1% Bromophenol blue and 150mg dithiothreitol) was 
aliquoted and stored at -20 ºC until use. A broad range molecular weight marker 
(Bio-Rad) was pre-prepared by dilution 1:20 with sample buffer, heating to 95 ºC 
for 5 mins and storing in aliquots at -20 ºC. 5µl of marker was loaded in the first 
well, followed by the samples. Samples were prepared by mixing 1:1 with SDS 
sample buffer and heating to 95 ºC for 5 mins.  
A twenty-five millimolar (mM) electrophoresis buffer (10x solution–30.3g tris 
base, 144g glycine, 10g SDS, 1 litre ultrapure H20) was used and the gel was run 
at 200V for 30-45 mins, until the samples reached the bottom. The gel was 
stained using Coomassie R-250 and destained using a 10% methanol/10% acetic 
acid solution. Following adequate destaining, gels were imaged using an Epson 
Expression 1680 Pro scanner and Corel Photoshop Pro (v3). Densitometry analysis 
was performed on grey-scale images using TotalLab Quant software (TotalLab 
Ltd, Newcastle, UK). 
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2.5.2 Western blotting 
All Abs used in Western blotting analysis are listed in Table 2.3. 
2.5.2.1 Porcine Pepsin Western Blot 
12% mini-PROTEAN® TGXTM precast gels and a 4-gel mini-PROTEAN® tetra cell 
were used (Bio-Rad, UK). Samples were diluted 1:2 with sample buffer (62.5mM 
Tris pH6.8, 10% glycerol, 2% SDS, 100mM DTT, bromophenol blue) and heated to 
95 ºC for 5 mins. A Precision Plus Protein® Kaleidoscope Standard (Bio-Rad) was 
loaded into the first well (10µl) and samples were then loaded into the 
remaining wells. Following cell loading with 1x electrophoresis running buffer 
(10x buffer = 6.06g Tris, 28.8g glycine, 2g SDS in 200ml dH20), the gel was run at 
150 volts until the samples reached the bottom of the gel. 
Transblot® TurboTM MIDI PVDF transfer packs and the Transblot® TurboTM 
transfer system were used for gel blotting (Bio-Rad, UK). The gel was blotted on 
the seven minute turbo setting, following which the membrane was transferred 
into a tray in which it was blocked with 20ml 5% BSA in TBS-T for 1 hour. The 
membrane was then washed 7-8 times with TBS-T for 30 mins. The primary Ab 
incubation was for 1.5 hours at 1:5000 dilution (2ug/ml concentration) in 20ml 
3% TBS-T. The wash step was repeated for 30 mins. The secondary Ab incubation 
was for 1.5 hours at 1:10,000 dilution in 3% TBS-T, following which the wash step 
was repeated. AGFA fixative and developer solutions were used at 1:4 and 1:6 
dilutions respectively. Two ml of GE Healthcare ECL plus solution (25µl solution 
B:1ml solution A) were added to cover the membrane, laid flat on the bench. 
This was incubated for two mins, following which excess ECL was allowed to drip 
off and the membrane was wrapped in cling-film before being positioned in the 
developing cassette. In a completely dark room (using a red light head lamp), 
the blot was exposed to Amersham ECL Hyperfilm for 30 secs (optimised using a 
range of time-points). The film was then placed in the developer solution and 
agitated until bands were seen. Following a dH2O rinse, the film was placed in 
the fixing solution for 1 min and then rinsed. The film was imaged using a 
Syngene Ingenius gel documentation system and Genesnap image acquisition 
software (Syngene, UK). The lower limit of detection was found to be 10ng. 
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2.5.2.2 Human Pepsin Western Blot 
Human pepsin western blots were performed at the Otolaryngology research lab, 
University of Wisconsin (courtesy of Dr Tina Samuels and Dr Nikki Johnston). 
Sample buffer (4x concentration) was pre-prepared and stored at -20 ºC (4% SDS, 
20% glycerol, 500mM Tris-HCL (pH6.8), 200mM DTT and 0.001% bromophenol 
blue). 6.25µl sample buffer was added to 18.25µl sample (unless this would 
result in loading >30µg protein, in which case a smaller sample volume was used) 
and heated to 95ºC for 5 mins. 10% precast Tris-HCl gels (Bio-Rad) were used. 
Kaleidoscope Precision Protein Plus® standard was loaded into the first well 
(8µl, Bio-Rad) followed by a 4ng human pepsin positive control (isolated from 
human gastric juice, by ion exchange chromatography) and a 40ng pepsinogen 1 
negative control (Sigma, UK), followed by the samples. The gel was run at 120V 
for one hour, or until the samples reached the bottom of the gel. The PVDF 
transfer membrane (Bio-Rad) was pre-wetted in transfer buffer (10x buffer, 145g 
glycine, 29g tris base in 1L dH20) and a transfer sandwich was set up. This was 
placed in apparatus filled with transfer buffer and run at 30V. The membrane 
was removed and blocked with 20ml block buffer (5% non-fat dry milk in PBS) for 
1 hour. Three ten-minute washes were performed with PBS-T. All Abs were 
diluted in 5% non-fat dry milk/PBS-T. The blot was trimmed and 1.5ml primary 
Ab was pipetted to cover the membrane which was lying on parafilm on the 
bench top. Following this, the wash steps were repeated. Secondary Ab 
incubation was for 1 hour, followed by a final wash step. A Kodak fixer and 
developer was used in a darkroom (Kodak D-19). Equal volumes of ECL reagent 1 
and 2 were combined and 1.5ml was used to cover the membrane (Santa Cruz 
Western Blot Luminol Reagent). The membrane was incubated for 1 minute. 
Excess reagent was removed and the blot was exposed to Amersham ECL 
Hyperfilm. Exposures were usually for 15 secs and developing for 45 secs, until 
bands appeared on the film. The film was then washed in dH20 and fixed for 45 
secs until the film was clear. Membranes were also probed with a mouse anti-
beta-actin Ab (CP01, EMD Chemicals, USA) and an anti-mouse IgG-HRP secondary 
Ab (Dako, USA) as a loading control. This was purely for the purposes of 
demonstrating sample loading (assuming low numbers of host cells would still be 
present in supernatants) and was not for normalisation. The lower limit of 
detection of pepsin in sample matrix was 0.5ng. 
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Table 2-3 Antibodies used for porcine pepsin and human pepsin Western blot assays  
Ab Dilution Host Supplier 
Anti porcine pepsin (polyclonal) 5000 Goat Biodesign (USA) 
Anti goat/sheep IgG-HRP (monoclonal) 10000 Mouse Sigma (UK) 
Anti human pepsin (polyclonal) 350 Rabbit Johnston, N (Wisconsin) 
Anti-mouse IgG-HRP (polyclonal)  5000 Goat Dako (UK) 
 
2.5.3 Trichloroacetic acid sample precipitation 
Various experimental samples (Chapter 6) required a precipitation step in order 
to reduce the sample loading volume for subsequent 1D SDS-PAGE gel or Western 
Blot analysis. Trichloroacetic acid (TCA) precipitation is a widely used method 
(Jiang, He, & Fountoulakis, 2004). 
A stock solution of 60% TCA was prepared. A volume of this stock solution was 
added to the sample to result in a 5-15% (final v/v) TCA concentration. The 
sample was gently vortexed and then incubated at 4ºC for 15 mins. Following 
centrifugation (14,000rpm for 10 mins), the supernatant was removed from the 
protein pellet and discarded. The protein pellet was washed twice in diethyl 
ether. Following the second ether wash, the tube was placed in a heating 
cabinet at 37ºC to evaporate any remaining ether. The protein pellet was then 
ready for the addition of sample buffer and processing for gel loading, as 
detailed in the relevant sections. 
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2.6 Polymerase Chain Reaction 
2.6.1 RNA Extraction 
Lysate samples were thawed on ice and the 350µl sample volume was applied to 
a QIAshredder and spin column sitting in a 2ml collection tube (Qiagen Ltd, 
Crawley, UK). This was centrifuged at 14,000 rpm for 2 mins. An equal volume of 
ethanol was added to the resulting lysate and mixed. The 700µl sample was then 
added to an RNeasy mini column, placed in a 2ml collection tube (Qiagen). This 
was centrifuged at 10,000rpm for 15 secs. The flow through was discarded. 
Buffer RW1 (Qiagen) was added (350µl) and the centrifugation step was 
repeated, followed by discarding the flow through. DNase 1 (80µl, prepared by 
adding 10µl resuspended DNase 1 to 70µl buffer RDD (Qiagen)) was pipetted 
directly onto the column membrane and incubated at RT for 15 mins. A further 
wash with 350µl Buffer RW1 was performed followed by centrifugation as 
previously and replacement of the collection tube. The membrane was then 
washed twice with 500µl Buffer RPE (Qiagen). Following the second wash, the 
centrifugation time was increased to 2 mins at 10,000rpm. The flow through was 
discarded and then the sample was re-centrifuged at 14000rpm for 1 minute to 
ensure complete buffer removal. The column was transferred to a 1.5ml 
collection tube and 50µl RNase-free water was pipetted directly onto the 
membrane, followed by centrifugation at 10,000rpm for 1 minute to elute the 
RNA. A NanoDrop ND-1000 spectrophotometer was used for RNA quantitation 
using 1µl sample at 260nm. The A260/A280 ratio was assessed as an indicator of 
RNA purity (1.8-2.1 being acceptable). The RNA was then stored at -80°C. 
2.6.2 Reverse Transcription 
Following thawing on ice, 0.2 µg total RNA was used for first strand cDNA 
synthesis. The oligonucleotide primer was annealed to the RNA by adding 1 µl 
random primers (0.5 µg/µl Promega, Madison, WI, USA) and nuclease-free H2O to 
the volume of RNA to make a total volume of 15 µl in a micro-centrifuge tube. 
The mixture was incubated at 70°C for 5 mins and then put on ice. For the 
reverse transcriptase reaction, a master-mix of 1 µl M-MLV reverse transcriptase 
(Promega), 5 µl 5x M-MLV reverse transcriptase buffer (Promega), 0.5 µl 
ribonuclease inhibitor (Promega), 1.25 µl nucleotides (10 mM ATP, CTP, GTP, 
UTP) (Promega) and 2.25 µl nuclease-free H2O were added to the RNA and 
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oligonucleotide mixture and incubated at 42°C for 1 hour. The cDNA was then 
diluted 1:4 (final volume 100µl) with nuclease-free H2O and stored at -80 ºC until 
use. No further dilution was needed for the quantitative PCR (qPCR) experiments 
which followed. 
2.6.3 Quantitative Polymerase Chain Reaction 
Taqman® gene expression assays (Applied Biosystems, UK) were used for all 
qPCR experiments. All assays used are detailed in table 2.4. For all reactions, 
10µl 2x universal master mix, without UNG (Taqman®), 4µl H20, 5µl cDNA and 
1µl gene expression assay (Taqman®) were used and reactions were run in a 96 
well PCR plate. For each assay, a positive control and blank were always 
included in duplicate. The positive control for IL-8 and IL-6 mRNA expression was 
BEAS-2B cells exposed to 5µg/ml lipopolysaccharide for 24 hours and harvested 
for mRNA analysis (a gift from Dr Angela Fonceca, University of Liverpool) 
(Schulz et al., 2002). The positive control for TGF-1  mRNA expression was 
human lymphocyte cDNA (a gift from Dr Angela Midgely, University of Liverpool) 
(Kohut et al., 2009). For each sample, the assay of interest and a housekeeping 
gene assay appropriate to the BEAS-2B cell line (ribosomal protein L32) was run, 
in order to assess and correct for differences in cDNA loading (Elizur et al., 
2007). All mRNA target gene expression was normalised to this internal standard. 
Table 2-4 Details of gene expression assays used for qPCR analysis (Applied Biosystems, 
UK) 
 
Assay Assay Identifier Amplicon length Assay Design 
Interleukin-8 Hs00174103_m1 101 Probe spans exons 
Interleukin-6 Hs00985639_m1 66 Probe spans exons 
TGF-1 Hs00998133_m1 57 Probe spans exons 
Mitochondrial 
ribosomal protein L32 
H200388310_m1 81 Probe spans exons 
 
A MX3000P® Multiplex Quantitative PCR System (Agilent Technologies) was used 
and cycling conditions were - hold at 95 ºC for 10 mins followed 40 cycles of 95 
ºC for 15 secs and 60 ºC for 60 secs. MxPro software (Agilent) was used for 
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programming, data collection and analysis. Following viewing of amplification 
plots and setting of baseline and threshold values, the comparative CT method 
was used for data analysis. This compares the CT value of the target gene to 
another reference gene, using the formula 2ΔΔCT (Schmittgen & Livak, 2008). This 
method gives a fold change in mRNA expression rather than absolute 
quantification. For accuracy, the comparative CT method is reliant on 100% 
amplification efficiency, which can be assumed for Taqman gene expression 
assays. (Applied Biosystems, 2012) 
2.6.4 Bacterial DNA Extraction and OprL PCR for Pseudomonas 
aeruginosa 
PCR was performed for the detection of Pseudomonas aeruginosa (P.Aeruginosa) 
using a previously validated, specific PCR protocol based on an outer membrane 
lipoprotein gene (OprL) (DeVos et al., 1997). Analysis was performed on BAL 
supernatant that had been centrifuged for 5 mins at 6000 rpm and stored at -80 
ºC. Bacterial DNA was extracted from 0.2mls of BAL using the DNeasy Blood and 
Tissue Kit following the Gram Negative Bacterial DNA Extraction Protocol 
(Qiagen). In order to harvest the bacterial cells, the sample was spun at 14,000 
rpm for 10 mins in microfuge tubes. The supernatant was then discarded. 
Proteinase-K (Qiagen) was added to each sample (20µl) followed by thorough 
mixing and incubation at 56 ºC overnight. Following 15 secs of mixing using a 
vortex, 200µl Buffer AL (Qiagen) was added to each sample followed by 200µl 
100% ethanol (with mixing in between and after both steps). The mixture was 
then pipetted into the DNeasy Mini-Spin Column (Qiagen) which was placed in a 
2ml collection tube. The sample was centrifuged at 8000rpm for 1 minute, 
following which the flow through was discarded and the collection tube 
replaced. Buffer AW1 was added (500µl) and the sample was re-centrifuged at 
8000rpm for 1 minute. Following this, 500µl Buffer AW2 was added and the 
sample was centrifuged at 14000rpm for 3 mins, until dry. The collection tube 
was carefully removed, ensuring no ethanol carryover. The column was placed in 
a 1.5ml microcentrifuge tube and 50µl (optimised volume) of Buffer AE was 
pipetted directly onto the DNeasy membrane. This was incubated at RT for 1 
minute and then centrifuged at 6000g for 1 minute for DNA elution. DNA purity 
was assessed at 260nm using a NanoDrop ND-1000 spectrophotometer using the 
260/280 ratio.  
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The primer sequences were PAL1, 59-ATGGAAATGCTGAAATTCGGC and PAL2, 59-
CTTCTTCAGCTCGACGCGACG-39. Primers were custom ordered from Sigma 
Aldrich (UK), desalted, with a scale of synthesis of 0.025. They were used at 
10µM concentration. The PCR mix consisted of 5µl of GoTaq Flexi Buffer 
(Promega), 0.5µl 10mM dNTPs (Bioline), 0.75µl PAL1/18S forward, 0.75µl 
PAL2/18S reverse, 2.5µl MgCl2 (Promega), 0.25µl GoTaq Flexi DNA polymerase 
(Promega), 14.25µl H20 and 1µl DNA per reaction, as optimised by the Medical 
Microbiology Department, University of Liverpool. All experiments included a 
positive control of P. aeruginosa DNA taken from bacterial colonies (a gift from 
the Medical Microbiology Department), a known P. aeruginosa culture positive 
CF BAL cDNA sample (stored and processed by identical methods to the study 
samples), a negative control without cDNA to check for contamination and a 
negative bacterial control of Escherichia Coli DNA taken from bacterial colonies 
(a gift from the Medical Microbiology Department, Liverpool). All samples were 
run in duplicate. Previous literature documents a lower limit of detection of 2-3 
bacterial cells (DeVos et al., 1997). 
In order to confirm adequacy of DNA extraction, PCR for 18S ribosomal RNA 
(eukaryotic cell) was also undertaken. This assumed that host airway cells were 
contained in the BAL and hence DNA extracted from these. Since BAL may have 
been aseptic and hence not containing prokaryotic bacterial DNA, 16S PCR was 
not performed for these purposes. Primer sequences for 18S PCR were 18S 
forward TCCGATAACGAACGAGACTC and 18S reverse CAGGGACTTAATCAACGCAA 
(Sigma UK) and primers were used at a concentration of 10µM. 
The thermocycler (Techne) conditions used for both PCRs were 95ºC for 5 mins 
followed by 30 cycles of 95ºC for 40 secs and 57ºC for 1 minute (annealing) then 
72ºc for 2 mins (extension). This is followed by a final 10 mins at 72ºC. The 
samples were then removed and placed on ice. 10µl of the PCR solution was 
loaded into a 2.5% agarose electrophoresis gel in a Thermo EC Midicell Primo 
EC330, in 1 x TBE buffer (10x TBE buffer Tris 108g, boric acid 55g, EDTA 
disodium salt 9.3g). A 1 kilobase plus DNA ladder (Invitrogen, UK) was used. The 
gel was run at 90 volts for 45 mins and analysed using an InGenius gel 
documentation system (Syngene UK, Cambridge, UK) with the accompanying 
GeneSnap software  
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2.6.5 Molzym 
Personnel in the Molzym laboratories (Bremen, Germany) performed the Molzym 
SepsiTestTM analysis. Briefly, BAL was processed using the UMDTM-Liquid test 
(Molzym, Bremen, Germany), a variant of the SepsiTestTM kit designed for 
extraction of DNA and PCR analysis of body liquids other than whole blood. BAL 
samples (0.2ml) were made up to 1ml with dilution buffer, according to the 
manufacturer’s instructions. The UMDTM-Liquid test includes a sample pre-
treatment step by which human and/or dead microbial extracellular DNA is 
degraded, thus leaving DNA from living microbes to be extracted and purified, 
with a lower detection limit of </= 10 genome equivalents per PCR reaction 
(Wellinghausen et al., 2009). The PCR analysis comprises of universal rRNA gene-
based assay for bacteria. In the case of positive results, amplicons are purified 
and sequences analysed by Sanger sequencing techniques (Sanger, Nicklen, & 
Coulson, 1977)). Pathogen identification was made using the online SepsiTestTM 
BLAST tool. Genus identification was presumed in samples with sequence 
identities of ≥97% (family identification if <97%) and species identification was 
presumed in samples with ≥99% (Wellinghausen et al., 2009). 
For the majority of our samples, BAL was stored in sterile microfuge tubes and 
not the recommended Molzym UMDTM sample storage tubes. To ensure that this 
did not adversely affect results, we prospectively analysed paired BAL samples 
stored in microfuge tubes and UMD tubes for six patients. We could show that 
the same microbes were detected, but processing and storing samples in 
microfuge tubes decreased assay sensitivity, with microbe detection occurring a 
mean of four PCR cycles later (Appendix 5). Subsequently, in this study all PCR 
analysis was undertaken on BAL samples stored in microfuge tubes. 
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2.7 Airway epithelial cell culture 
BEAS-2B cells (Bronchial epithelial cell line - European cell culture collection) 
were grown and plated on 96 well plates (Corning Costar) for all airway 
epithelial cell experiments. Bronchial epithelial growth medium (Lonza, 
Wokingham, UK) was used and was supplemented with hormones at final 
concentrations as follows: 50ug/ml Bovine pituitary extract (Invitrogen UK), 
0.5ug/ml hydrocortisone (dissolved in 95% EtOH (Sigma Aldrich, Dorset, UK)), 
25ng/ml epidermal growth factor (Sigma), 0.5ug/ml epinephrine (dissolved in 
10mM HCl (Sigma)), 5ug/ml insulin (dissolved in 4M HCl (Sigma)), 10ug/ml 
transferrin (dissolved in BEGM (Sigma)), 6.5ng/ml triiodothyronine (dissolved in 
1N NaOH (Sigma)), 0.2ng/ml retinoic acid (dissolved in DMSO (Sigma), 50ug/ml 
gentamycin (Sigma) and 50ug/ml penicillin/streptomycin (Sigma). 
Cells were plated in T25 flasks coated with 0.01 mg/ml fibronectin (Sigma UK), 
0.03 mg/ml collagen (BD Biosciences Oxford, UK) and 0.01 mg/ml BSA (Sigma). 
They were seeded at a concentration of 30,000 cells per cm2 (cell counting as 
described in Section 2.3.2.1) and incubated in 15ml supplemented BEGM at 37 ºC 
with 5% CO2. The media was changed every 48 hours, following visual inspection 
for normal cell morphology and growth and any signs of contamination by phase-
contrast microscopy (Figure 2.4)  
At 80% confluence, the cells were re-plated. The flask was washed with 2 
aliquots of pre-warmed 20ml sterile PBS. Pre-warmed trypsin (3ml 25g/L Sigma) 
was then added to the flask and it was incubated at 37ºC for three mins. 
Following this, the trypsin was inactivated with 5ml BEGM. The 8ml mixed 
solution was removed from the flask using a sterile graduated pipette and put in 
a 10ml sterile tube for centrifugation at 1300rpm for 5 mins in order to pellet 
the cells. The supernatant was poured off and the cell pellet was resuspended in 
5ml pre-warmed supplemented BEGM. A trypan blue cell count was made (as 
detailed previously) and the cells were either re-plated onto a pre-coated T25 
flask at 30,000 cells/cm2 or in pre-coated 96 well plates for experimentation 
purposes. 
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Figure 2.5 Normal morphology of bronchial epithelial cell line (BEAS2B) cells in culture 
BEAS2B cells (purchased from the European Cell Culture Collection) were grown in 
collagen/fibronectin coated T25 flasks in supplemented BEGM media (Lonza). The cells were 
visualised by phase contrast microscopy. 
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2.8  Mass spectrometry analysis 
2.8.1 In Solution Tryptic Proteolysis 
The following protocol formed the basis for in solution digests detailed in this 
thesis and was adapted according to the specific experiment, as detailed in later 
chapters. 
Up to 100µg of protein was suspended in 25mM ammonium bicarbonate buffer 
containing a proprietary surfactant (0.05% RapigestTM, Waters, UK) to enhance 
proteolysis. This was incubated at 80ºC for 10 mins, with a brief mix after 5 
mins. Sample reduction was with 3mM dithiothreitol for 10 mins at 60ºC. 
Alkylation was with 9mM iodoacetamide for 30 mins at RT in the dark. 
Sequencing grade trypsin (Sigma, UK) was added at a concentration of 0.01µg/µl 
and samples were digested for a minimum of 18 hours at 37ºC. The reaction was 
stopped and the surfactant inactivated and precipitated by addition of 
trifluoroacetic acid to a final volume of 0.5% (v/v), incubated for 30-45 mins at 
37ºC. The samples were then centrifuged at 14,000rpm for 20 mins at a 
temperature of 4ºC to remove any residual precipitate. 
2.8.2  Peptide mapping 
The theoretical masses of peptides generated by trypsin cleavage of proteins 
(cleavage at C terminal side of lysine (K) or arginine (R), with exceptions) were 
calculated using PeptideMass (ExPASy Bioinformatics Resource Portal). Fixed 
carbamidomethyl modification for cysteine and variable oxidation modification 
for methionine were specified where applicable. 
2.8.3 MALDI-TOF analysis  
The matrix solution prepared for all MALDI-TOF analyses was 10mg/ml solution 
of alpha-hydroxy cinnaminic acid in 50% acetonitrile/0.1% tri-fluoroacetic acid 
(v/v). On addition of the alpha-hydroxy cinnaminic acid to the solvent, the 
mixture was vortexed well for 30 secs. It was then centrifuged at 14,000rpm for 
10 mins in order to pellet any un-dissolved solid. 1µl trypsin digested sample was 
applied to a ground steel target plate (Bruker, US), followed immediately by 1µl 
of matrix solution over the top. This was air dried at RT for ten mins. A peptide 
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calibration mixture (detailed in Appendix 6) was loaded in the same way as a 
sample.  
MALDI-TOF analysis was performed using the Bruker ultrafleXtreme MALDI 
TOF/TOF mass spectrometer. The calibration spot was analysed first with an 
initial laser energy set to 30%. The laser energy was subsequently adjusted as 
required to achieve optimum peak shape and baseline. Samples were then 
analysed in turn (MS), using a complete sample raster and 500 shots per 
spectrum. Spectra were analysed using Flex Analysis software (Bruker Daltonics, 
US). Spectra were searched manually if a specific m/z peak was being sought or 
the results could be exported and analysed using a MASCOT database search 
(Matrix Science). 
2.8.4 High Resolution Liquid Chromatography  
The digest solution was separated using a nanoAcquity UPLC™ system (Waters MS 
Technologies, Manchester, UK). The sample (of calculated volume for the 
experiment) was loaded onto the trapping column (Waters MS Technologies, C18, 
180 μm X 20 mm), using partial loop injection, for three mins at a flow rate of 5 
μl/min with 0.1% (v/v) tri-fluoroacetic acid. The sample was resolved on an 
analytical column (nanoACQUITY UPLC™ HSS T3 C18 75 µm x 150 mm 1.7 µm 
column) using a gradient of 97% A (0.1% formic acid) 3% B (99.9% ACN 0.1% 
formic acid) to 60% A 40% B at a flow rate of 300 nL/minute over 120 mins. 
2.8.5 Synapt G1 and G2 mass spectrometry analysis 
The nanoAcquity UPLC™ was coupled to either Synapt G1 or G2 mass 
spectrometers (Waters MS Technologies, Manchester, UK). These mass 
spectrometers were used (according to laboratory availability) to acquire high 
definition MS data as described in further detail Chapter 6. They acquired data 
using a data independent program with 1 second scan times and a collision 
energy ramp of 15 to 40eV for elevated energy scans. The mass spectrometer 
was calibrated before use against the fragment ions of glufibrinopeptide and 
throughout the analytical run at 1 minute intervals using the NanoLockSpray™ 
source with glufibrinopeptide. The data were processed and database searched 
using ProteinLynx Global Server v2.5 (Waters MS Technologies, Manchester, UK). 
The data were processed using a low energy threshold of 100 and an elevated 
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energy threshold of 20 and the processed spectra were searched against the 
appropriate database using MASCOT (Matrix Science). The automatic settings in 
PLGS for the precursor ion and fragment ion mass tolerance were used. The 
search thresholds used were: minimum fragment ion matches per peptide 3; 
minimum fragment ion matches per protein 7; minimum peptides per protein 1; 
and a false positive value of 4. The threshold score/expectation value for 
accepting individual spectra was the default value in the program, such that the 
false detection rate value was less than 4. 
2.8.6 Xevo™ mass spectrometry analysis (triple quadripole) 
The nanoAcquity UPLC™ was coupled to a Xevo™ TQ triple quadrupolar mass 
spectrometer (Waters), operated in scheduled Multiple Reaction Monitoring 
(MRM) mode with Q1 and Q3 operating at unit resolution. This analysis method 
was used for the development of an MRM assay for porcine and human pepsin 
detection (detailed in Chapter 6). MRM methods were built (including generation 
of fragment peptide lists and collision energies) using Skyline (MacCoss Lab 
Software). The program was set to acquire 15 data-points over a 15 sec 
chromatographic peak and minimum dwell time of 50ms was used. Specific 
details regarding fragment ions and collision energies used for fragmentation are 
detailed in Chapter 6. Data analysis was with Skyline software (MacCoss Lab 
Software, US). 
2.8.7 LTQ Orbitrap Velos (discovery run MSMS analysis) 
For discovery proteomics, the LTQ-Orbitrap Velos system (Thermo Scientific, UK) 
was used. For each digested sample, 100 ng of protein was injected onto a 75-
µm x 150-mm BEH C18 column, and the peptides were resolved over a 120 
minute linear organic gradient of 3–40% buffer B (0.1% formic acid in 
acetonitrile). Data acquisition was data-dependent, with the top twenty most 
intense peptides in each MS scan selected for fragmentation. The raw data files 
were processed initially using default parameters (s/n threshold =3, minimum 
peak count =6) in Proteome Discoverer (Thermo (1.3)) and searched against the 
Unihuman database in MASCOT (Matrix Science), as described below.  
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2.8.8 MSMS Database Searches 
Using the appropriate software for the analytical system, MSMS data files were 
submitted to MASCOT (Matrix Science), searching within the required database 
(for example, Unihuman). The basic search parameters were - fixed 
carbamidomethyl modification for cysteine and variable oxidation modification 
for methionine, one trypsin miscleavage allowed, 1.2Da peptide tolerance, 
0.6Da MSMS tolerance, 1+-3+ charge states and appropriate instrument specified. 
A minimum ion score was set (as suggested by MASCOT) along with an identity 
significance value of p<0.05. 
2.8.9 Progenesis LC-MS Nonlinear Dynamics software 
Progenesis LC-MS Nonlinear Dynamics software was used for discovery run 
proteomic analysis where label free relative protein quantification was required. 
This data analysis program enables identification and relative quantification of 
unlabelled proteins across samples. Raw MSMS data files for each sample were 
loaded into the program. Ion intensity maps were then created from each data 
file using peak models that retain all quantification and positional information. 
In order to perform comparative expression analysis, the results for each sample 
were then aligned by overlaying individual sample ion intensity maps on a chosen 
reference sample ion intensity map. This enabled correction for run variance in 
liquid chromatography separation. The aggregate data (containing information 
from all samples included in the analysis) was then combined and subsequently 
applied to all samples, allowing 100% peak matching. A complex peak picking 
algorithm is used and a list of peptide ions detected in the aggregate file was 
then generated. The top five MSMS peaks for each peptide ion were exported to 
MASCOT (Matrix Science) and searched in Unihuman as described in Section 
2.8.8. The identity significance value was set to p<0.05, minimum ion score was 
set to 30 and a search of a decoy database was used to monitor the false 
detection rate (aiming for under 4%). The data was then imported back into the 
Progenesis software. Survey scan ion abundance data were used for 
quantification, using only unique peptides ions to the protein of interest. 
Analysis of variance (ANOVA) and q values (method of correction for multiple 
comparisons) were used for statistical analysis of differences between samples in 
experimental groups. The q value is a measure of significance according to the 
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false discovery rate rather than the false positive rate (Storey & Tibshirani, 
2003). 
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2.9 Statistical analysis 
All statistical analysis was performed using SPSS for windows version 19 (IBM®). 
2.9.1 Clinical Data 
Due to the relatively small study numbers, all patient sample data were treated 
as non-parametric (Altman & Bland, 2009). Standard hypothesis tests were used 
to determine any demographic differences between the groups, using the Mann 
Whitney U test for continuous data and the Chi Squared test for categorical 
data. Data were expressed as median [IQR]. A Mann Whitney U test was used for 
comparison of continuous data between two groups. Correlation of two sets of 
continuous data was assessed using Spearman’s rank correlation. The Kruskal 
Wallis test was used for continuous data comparisons across more than two 
groups.  
2.9.2 Cell culture experiment data 
All cell line experimental data were assumed to be normally distributed. Data 
are expressed as mean [SEM]. The student t-test was used for comparison of 
continuous data between two groups. Within the SPSS analysis, Levene's test of 
equality of variances was used to assess whether equal variance could be 
assumed and the appropriate p value was subsequently referenced. A one way 
analysis of variance (ANOVA) was used where continuous data was analysed 
across more than two groups, with post hoc analysis to clarify where any 
differences between groups lay.  
2.9.3 The Coefficient of variation 
The coefficient of variation (% CV) is a measurement of the variability of 
quantitative assays. It is a relative standard deviation, which is calculated by 
dividing the standard deviation of the data points by the mean and multiplying 
by 100. This can be calculated for sample replicates within the same assay 
(intra-assay %CV) and also for replicates analysed on different plates (inter-assay 
%CV). Inter and intra-assay coefficients of variation should be <15% (Food and 
Drug Administration, 2001). 
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2.9.4  Graphical presentation of data 
Data are presented as bar, line, scatter, vertical scatter or box and whisker 
plots, created using SPSS for windows version 19 (IBM®) or Graphpad Prism® 
version 5. 
In box and whisker plots, the box represents the inter-quartile range values and 
the median is marked as a thick line. The whiskers represent the highest and 
lowest values that are not extreme values. Outliers (values that are between 1.5 
and 3 times the inter-quartile range) and extreme values (values that are more 
than 3 times the inter-quartile range) are represented by circles or asterisks, 
respectively, beyond the whiskers. 
On bar charts, the standard error of the mean is displayed by the error bars. On 
vertical scatter plots the median or mean value is marked as a horizontal line, as 
indicated in the legend.  
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  Chapter 3 – Clinical Characteristics 
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3.1 Introduction 
Respiratory disease is a major cause of morbidity and mortality in children with 
ND, accounting for over 35,000 hospital admissions in the US in 2006 (Berry et 
al., 2012). Previous studies providing information about respiratory disease in 
children with ND have largely focussed on incidence of acute deterioration or 
mortality (Mahon & Kibirige, 2004;Morton, 1999;Reid, 2012;Westbom, 
2011;Sullivan, 2006). However, it is likely that the daily burden of respiratory 
symptoms and the impact of these symptoms on quality of life are equally 
important issues for children with complex needs (and their carers), yet there 
doesn’t appear to have been a study which has attempted to quantify and 
characterise these  (Marks, 2008). This may be partly explained by the 
challenges of  objective respiratory assessment in these children. A reliable, 
non-invasive measure of patient/parent reported respiratory symptomatology, 
such as a respiratory symptom score, could potentially be an extremely useful 
clinical and research tool for use in children with ND. No validated respiratory 
score for assessment of symptoms currently exists for this group. 
Clinical management of respiratory symptoms in these children is challenging 
because it is complex to differentiate which factors cause their symptoms. Thus, 
it is important to consider respiratory symptoms alongside other potentially 
contributory co-morbidities. Level of mobility, swallowing dysfunction, GORD, 
chronic lung disease of prematurity and obstructive sleep apnoea all potentially 
impact on respiratory health in this group (J. L. Hutton et al., 2000; Marks, 
2008; Morton, Wheatley, & Minford, 1999; Seddon & Khan, 2003; K. Weir et al., 
2009). In view of this complexity, multi-disciplinary respiratory assessment 
would be the ideal, aiding early identification of modifiable contributory factors 
and thus maximising respiratory health (Waespi et al., 2000, Piccione, 2012). 
However, the evidence base supporting this approach is limited and indeed, 
much of respiratory management in children with ND is anecdotal. This can in 
part be explained by the lack of suitable outcome measures for high quality 
clinical trials (Cella et al., 2007; Rajendu Srivastava et al., 2009). In some 
centres, patients have access to multi-disciplinary care in specialist neuro-
respiratory clinics (Waespi et al., 2000). However, regional service provision and 
clinical management are variable and there is evidence that this may influence 
outcome (Westbom et al., 2011). 
 91 
This chapter describes the clinical characteristics of children with severe ND 
admitted to a large tertiary children’s hospital both at a time of respiratory 
deterioration (on admission to PICU) and when otherwise well (on admission for 
elective surgical procedures). Respiratory symptoms over the preceding three 
months were assessed using a respiratory symptom score (LRSQ), previously 
validated in other paediatric groups and modified for use in this study (Section 
2.2.1). Symptoms of gastro-oesophageal reflux disease (GORD) were assessed 
through use of a set of five questions, modified from the Reflux Symptom Index, 
as described in Section 2.2.2. Clinical data on previous interventions and current 
management were recorded for all study recruits. 
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3.2 Aims 
In order to assess the burden of respiratory symptoms, incidence of other co-
morbidities and current management, the aims of this chapter were to; 
1) Assess respiratory symptoms in children with severe ND at a time of stability 
and at a time of respiratory deterioration (on admission to PICU) compared to 
healthy controls, using a modified respiratory symptom questionnaire (LRSQ-
Neuro). 
2) Document clinical information about swallowing dysfunction, salivary 
management, GORD, symptoms of aspiration, surgical interventions and where 
possible, assess the relationship of these to respiratory symptom scores. 
3) Document any previous specialist respiratory assessment and intervention in 
ND patients. 
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3.3  Specific methods 
The data collection proforma used to document clinical information is shown in 
Appendix 1. Respiratory symptoms were assessed using a respiratory symptom 
score, which had previously been validated in other paediatric groups (Powell et 
al., 2002; Trinick, Southern, et al., 2012). No specific respiratory symptom score 
exists for children with ND and therefore, the LRSQ was modified for the 
purposes of this study, as described in Section 2.2.1. The questionnaire is 
included in Appendix 3 and a summary of the symptoms assessed is provided in 
Table 3.1. Symptoms of GORD were assessed using modified questions taken 
from the Respiratory Symptom Index, as detailed in Section 2.2.3 (Belafsky et 
al., 2002). The questions are included in Appendix 4. Statistical analysis was 
performed as described in Section 2.9. All data were treated as non parametric 
due to sample size. 
Table 3-1 Summary of symptoms assessed by the LRSQ-Neuro  
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3.4  Results 
3.4.1 Clinical characteristics 
Nineteen children with ND were recruited at a time of respiratory deterioration 
on PICU (PICU-ND) and 16 children with ND were recruited when otherwise well, 
on admission for routine elective surgery (Elective-ND). Eleven healthy control 
children were also recruited. There were no significant differences in median 
age or gender between the groups (Table 3.2). In the PICU-ND and Elective-ND 
groups, 42% and 56% of children had cerebral palsy, respectively. The remaining 
children had other central neurological diagnoses. All children with ND were in 
Gross Motor Function Classification Group V. Half of the children in the Elective-
ND group had a history of prematurity vs. 26% in the PICU-ND group. The median 
[IQR] time to recruitment and sample collection following PICU admission was 15 
[12-22] hours.  
Table 3-2 Study Participant Demographics  
No significant differences in age (p=0.175) or gender (p=0.383) were found between the groups 
included in the analysis 
 Healthy 
Controls 
Elective-ND PICU-ND 
N number 11 16 19 
Age (years) 5 [2-9] 10 [2.25-14.5] 7 [5-11] 
Gender (% male) 50 50 46 
GMFC IV (%)  0 0 
GMFC V (%)  100 100 
Cerebral palsy (%)  56 42 
Other ‘central’ cause of ND (%)  44 58 
Ex-premature (%)  50 26 
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3.4.2 Incidence of surgical feeding or anti-reflux interventions 
Previous surgical feeding or anti-reflux interventions were recorded for all ND 
patients. A total of 12 patients had no prior intervention, 14 patients had 
undergone gastrostomy alone, 8 patients had a gastrostomy and  fundoplication 
and 1 patient had a gastro-oesophageal dissociation (included from this point in 
the fundoplication group). Overall, more PICU-ND patients (18/19) had 
undergone a surgical intervention than Elective-ND patients (5/16) (p<0.001 
Figure 3.1a). 
3.4.3 Gastro-oesophageal reflux disease  
Assessment of the impact of GORD in study recruits was made firstly, through 
documentation of current and previous anti-reflux interventions. Secondly, 
symptoms of GORD over the previous three months were recorded through 
enquiry about five symptoms, derived from the Reflux-Symptom Index (Belafsky 
et al., 2002). 
Twenty out of thirty-five children with ND were currently receiving anti-reflux 
medication and overall 24/35 had received a surgical and/or medical 
intervention for treatment of GORD. 5/9 children who had undergone a surgical 
anti-reflux procedure continued to take anti-reflux medication (Figure 3.1b). 
Anti-reflux medication prescribed included Domperidone (13/20), Omeprazole 
(13/20), Gaviscon (2/20), Ranitidine (5/20) and feed thickeners (1/20). 
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Figure 3.1 Histograms to show frequency of (a) surgical and (b) medical anti-reflux 
interventions in ND patients  
Current medication and previous surgical intervention were recorded. Graph (a) shows frequency 
of surgical feeding and/or anti-reflux intervention between ND groups and graph (b) shows 
frequency of medical anti-reflux treatment in all children with ND. The bar division highlights the 
frequency of fundoplication within the two medical treatment groups.  
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Parents answered five questions about GORD symptoms on a Likert scale, scored 
from zero (not at all) to four (symptoms every day). Therefore, the maximum 
score possible was twenty. Median PICU-ND (5[2-8]) and Elective-ND scores (7[3-
10]) were significantly higher than median healthy control scores (0[0-0], 
p<0.001, Figure 3.2). ‘Cough with or following feeds’, ‘choking with or following 
feeds’ and ‘vomiting with or following feeds’ were the most commonly reported 
symptoms (25/35, 19/35 and 19/35 patients, respectively). Table 3.3 contains a 
summary of individual question scores for the ND groups. 
Table 3-3 Median [range] scores for questions about GORD symptoms in ND patient groups 
Symptom PICU-ND Elective-ND 
Cough 1 [0-4] 2 [0-4] 
Shortness of breath 0 [0-3] 0 [0-3] 
Choking 0 [0-3] 2 [0-4] 
Vomiting 1 [0-4] 0.5 [0-4] 
Pain 0 [0-4] 0 [0-4] 
No significant differences were observed in total score between PICU-ND vs. 
Elective-ND patients (p=0.464), ND patients who had a gastrostomy and  
fundoplication (n=9) vs. gastrostomy alone (n=14, p=0.326), ND patients who 
were orally fed (n=14) vs. non-orally fed (n=21, p=0.245), and ND patients on 
anti-reflux medication (n=20) vs. no anti-reflux medication (n=15, p=0.441). 
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Figure 3.2 Vertical scatter graph to show GORD symptom scores for all study groups 
Recruits were asked to answer questions about five symptoms of GORD on a likert scale from ‘not 
at all’ (score zero) to ‘symptoms every day’ (score four). Total scores are displayed for study 
groups. The median score is indicated by the horizontal line. * p<0.001  
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3.4.4 Swallowing assessment, oral feeding and medical 
management of salivary pooling 
Previous VFS results were recorded for all ND patients. Overall, 13/19 PICU-ND 
patients and 8/16 Elective-ND patients had undergone VFS assessment. Of those 
who underwent VFS examination, 10/13 PICU-ND patients and 6/8 Elective-ND 
patients were positive to some degree (clear aspiration or transient laryngeal 
penetration). Few patients in the PICU-ND or Elective-ND group were prescribed 
glycopyronnium bromide or hyoscine hydrobromide for control of salivary pooling 
(5/19 (26%) and 3/16 (19%), respectively). 
A higher proportion of PICU patients were nil by mouth and this was not 
necessarily guided by VFS results; 3 children with negative VFS results were 
exclusively gastrostomy fed (P<0.01, Figure 3.3). Possible explanations include 
clinical symptomatology or feed aversive behaviour. The limitations of VFS 
assessment are discussed in Chapter 1. Six out of eighteen children were orally 
fed despite a degree of aspiration being identified on VFS (Figure 3.3). 
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Figure 3.3 Histograms showing VFS results and related clinical interventions for ND patients 
Clinical data were recorded and where possible, results of clinical investigation were confirmed in 
the clinical notes. Graph (a) shows the frequency of VFS assessment and outcome between ND 
groups. The bar division highlights frequency of salivary medical management within these groups 
Graph (b) shows the frequency of VFS assessment and outcome between ND patients. The bar 
division highlights the frequency of oral feeding.  
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3.4.5 Respiratory symptom scores 
As expected, the PICU-ND group reported most respiratory symptoms over the 
three months prior to admission to hospital, with median [IQR] LRSQ-Neuro 
scores of 55[38-64]. However, high levels of respiratory symptoms were also 
reported in the Elective-ND group compared to healthy controls (Elective-ND, 
26[7-45] vs. Control, 4[0-7], p<0.01). Each questionnaire domain contained 
between three and five questions which were scored on a Likert scale from ‘not 
at all’ (score zero) to ‘every day’ (score four). Individual domain scores in 
Elective-ND patients were significantly higher than healthy controls across all 
domains, except ‘Symptoms with colds’. ‘Effect of symptoms on the family’ 
(p=0.001), ‘Other symptoms’ (p=0.001), and ‘Night-time symptoms’ (p=0.004) 
domain scores reached the highest levels of statistical significance (Figure 3.4) 
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Figure 3.4 (a.) Vertical scatter graph to show total LRSQ-Neuro scores across study groups 
and (b.) bar chart to show individual LRSQ-Neuro domain scores between groups 
All study participants completed a respiratory symptom score (LRSQ-Neuro) at the time of 
recruitment. Graph (a) shows total scores. The median total score is indicated by the horizontal 
line. Graph (b) shows individual domain scores. Mean and SEM are displayed for each group. 
Questionnaire domains contained between 3 and 5 questions, each question scored on a likert 
scale from ‘not at all’ (score zero) to ‘every day’ (score four).  
 103 
3.4.6 Relationship of LRSQ-Neuro scores and surgical feeding 
and/or anti-reflux interventions 
Significantly higher LRSQ-Neuro scores were observed in children who had 
undergone surgical feeding or anti-reflux interventions. Median total LRSQ-Neuro 
score was 17[5-32] in ND patients with no intervention vs. 37[13-55] in patients 
with gastrostomy only (p=0.001) and 40.5[7-62] in patients with gastrostomy & 
fundoplication (p=0.003, figure 3.5). 
3.4.7 Relationship of LRSQ-Neuro scores and VFS results  
Significantly higher total LRSQ-Neuro scores were recorded in Elective-ND 
children who had a positive VFS result (38[32-62], n=6) vs. those who had not 
been examined (13.5[5-20.5], n=8, p<0.05, Figure 3.5). 
3.4.8 Other comparisons 
A positive correlation was observed between GORD symptom score and total 
LRSQ-Neuro score in Elective-ND patients (r+0.66, P<0.01). Total LRSQ-Neuro 
scores were also significantly higher in Elective-ND patients who were taking 
anti-reflux medications (n=8) vs. those who were not (n=8, 35.5[13.75-59.25] vs. 
18[2.75-31.5] respectively, p=0.028). No relationship was seen between history 
of prematurity and total LRSQ-Neuro score (p=0.959) or prescription of 
medications for control of salivary pooling and total LRSQ-Neuro score (p=0.269) 
in Elective-ND patients. 
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Figure 3.5 Box and whisker plots to show (a) total LRSQ-Neuro scores for all ND patients 
grouped according to surgical feeding anti-reflux interventions and (b) total LRSQ-Neuro 
scores for Elective-ND patients grouped according to VFS examination results 
All study participants/families were asked to complete the LRSQ-Neuro on recruitment to the study. 
Clinical data regarding previous surgical interventions and VFS investigation were recorded on 
data collection proformas. Graph (a) * p=<0.01 Graph (b) * p<0.05 
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3.4.9  Previous respiratory input in children with ND 
Table 3.4 shows some of the microbiological and clinical characteristics of the 
Elective-ND and PICU-ND patients. Most PICU-ND patients had previous and/or 
current admission airway microbiology results. 12/19 had cultured P. aeruginosa 
(some on multiple occasions) on sputum or tracheal aspirate samples. 5/19 
cultured P. aeruginosa on tracheal aspirate on admission to PICU. Few patients 
were receiving anti-pseudomonal treatment. Most ND patients had never 
received a specialist respiratory paediatric opinion. Many of those being cared 
for by respiratory specialists were on home non-invasive ventilation or home 
oxygen. 10/19 PICU-ND patients were prescribed prophylactic antibiotics; 
treatment varied and included azithromycin (n=4), amoxicillin (n=2), co-
amoxiclav (n=1), trimethoprim (n=2), cefaclor (n=1). Most PICU-ND patients had 
been on treatment doses of antibiotics for more than 24 hours prior to 
admission. Only 1/16 Elective-ND patients had previous airway microbiology 
results. This patient had previous P. aeruginosa detected on multiple sputum 
and tracheal aspirate samples. 2/16 Elective-ND patients were prescribed 
antibiotic prophylaxis (cotrimoxazole (n=1), trimethoprim (n=1)). 
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Table 3-4 Table to show airway sample P.Aeruginosa microbiology results and current 
respiratory management in ND patients 
 Elective-ND PICU-ND 
Previous tracheal aspirate (ta) or sputum (s) 
samples M,C&S 
1/16 (ta) 16/19 (13 ta, 3 s) 
Previous P.Aeruginosa +ive 1/1 12/16 
P.Aeruginosa +ive current admission N/A 5/16 
Specialist respiratory paediatric care 1/16 7/19 
Home oxygen 0/16 7/19 
Home non-invasive ventilation 0/16 3/19 
Prophylactic antibiotics 2/16 10/19 
Anti-pseudomonal therapy 1/16 2/19 
Treatment dose antibiotics at recruitment 
(>24 hours) 
0/16 3/19 
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3.5 Discussion 
This is the first detailed characterisation of respiratory symptoms in individuals 
with severe ND. Importantly, data presented within this chapter has  shown that 
otherwise well children with ND have significant respiratory symptoms, 
particularly at night, that affect their families. The incidence of co-morbidity in 
this group is high and includes GORD, feeding difficulties and oral-motor 
discoordination. Respiratory symptom scores appear to correlate with some of 
these co-morbidities, although it is important to acknowledge that these are 
retrospective associations and may purely reflect severity of disability. 
Although it is well known to paediatric healthcare professionals that children 
with severe ND often have chronic respiratory symptoms, this is the first time 
that they have been formally quantified and documented. It is perhaps no 
surprise that children admitted to PICU with respiratory deterioration were more 
symptomatic in the three months leading up to their hospitalisation. However, it 
is noteworthy that Elective-ND children, considered well enough by both parents 
and anaesthetists to undergo a general anaesthetic, also had significant 
respiratory symptoms. Night-time symptoms were especially prominent and 
predictably correlated with Effect on Family scores (p<0.001). Interestingly, 
Other domain scores, which covered extra-thoracic/back of throat symptoms 
(symptoms previously shown to be important in predicting aspiration), were also 
significantly different. 
Recruitment targets were not achieved due to dependence on one researcher to 
recruit all patients, limiting recruitment opportunities. This may have reduced 
the power of the study to detect differences between study groups (increased 
type II errors), a significant limitation. All of the study recruits were in GMFC 
group V, indicating a high level of physical impairment across both study groups. 
However, the PICU-ND group had a higher incidence of surgical feeding and anti-
reflux interventions, reflecting a higher level of co-morbidity in this group. This 
bias is difficult to avoid when selecting study recruits from PICU.  
 
GORD is a well recognized phenomenon in children with ND and has previously 
been reported to affect up to 75% of those with severe cerebral palsy 
(Gustafsson & Tibbling, 1994; Mazzoleni et al., 1991). Data from this study were 
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in agreement, 69% of children with ND requiring GORD management. 
Interestingly, despite interventions, symptoms suggestive of reflux remained 
significantly higher in both ND groups when compared with healthy controls, 
highlighting the complexity of GORD management in children with ND. Initiation 
of any anti-reflux medication must be well considered in light of the limited 
evidence base and weighed against the possibility of side effects (Vandenplas et 
al., 2009). However, interpretation of the available clinical evidence is 
particularly difficult when treating children with ND, as this group have 
sometimes been actively excluded from studies of GORD treatment in order to 
limit the complexity of analysis (Peter B. Sullivan, 2008). In this study, the most 
commonly prescribed medications were proton pump inhibitors and the pro-
motility agent, domperidone. Whilst there is some evidence in support of PPI use 
in gastroenterological symptom control, there is little robust evidence to support 
the use of domperidone (Hassall, 2005, Pritchard, 2005). Unfortunately, no 
conclusions can be drawn about the efficacy of medical reflux management from 
this study as data collection was retrospective. Although some GORD symptoms 
clearly persist in many, it is possible that patients were more symptomatic prior 
to commencing anti-reflux medications. 
Children with ND are commonly referred for assessment for surgical anti-reflux 
procedures when GORD is considered to be pathological and symptoms persist 
despite medical management. Fundoplication remains the commonest surgical 
anti-reflux intervention (Lasser et al., 2006). In this study, 26% of ND recruits 
had undergone a surgical anti-reflux procedure. The complex relationship 
between GORD and respiratory symptoms makes assessment of the child with ND 
who predominantly has respiratory symptoms particularly challenging. In this 
study, analysis of respiratory symptoms in children with ND based on previous 
surgical intervention (nil, gastrostomy, gastrostomy & fundoplication) revealed a 
persistently high level of respiratory symptoms in those who have had both 
gastrostomy & fundoplication. Although these data cannot inform the debate 
regarding the efficacy of fundoplication for respiratory symptoms (due to 
recruitment bias), they do highlight the possibility that fundoplication may not 
always provide their complete resolution and many children continue to have a 
high level of respiratory symptoms despite gastrostomy & fundoplication. 
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Children may undergo gastrostomy placement either for feeding/nutritional 
difficulties or when there is concern about safety of swallow co-ordination. It is 
recommended that an anti-reflux procedure is considered at the time of this 
intervention if there are symptoms or signs of GORD. Forty percent of ND 
participants in this study had a gastrostomy without an anti-reflux procedure. 
Some literature has suggested that placement of gastrostomy alone is associated 
with an increase in GORD and respiratory morbidity (Jolley, Smith, & Tunell, 
1985; Strauss et al., 1997). However, more recent prospective studies have 
found no such increase in respiratory symptoms (P. B. Sullivan et al., 2005; P. B. 
Sullivan et al., 2006). Although an increase in GORD is observed in a small 
proportion of children, this is not significant enough to recommend universal 
anti-reflux procedures (Burd, Price, & Whalen, 2002; Viswanath et al., 2010; 
Wilson, van der Zee, & Bax, 2006;Langer, 1988). The optimal management of 
GORD post gastrostomy placement is debated within the literature. A recent 
Cochrane review (2007) concluded that the evidence comparing the efficacy of 
fundoplication vs. post operative medical management for those patients with 
GORD undergoing gastrostomy insertion is not robust and that high quality 
studies are needed (Vernon-Roberts & Sullivan, 2007). In this study, no 
difference was found in GORD symptom reporting or total LRSQ-Neuro score 
between those who had a gastrostomy alone (n=15) vs. those who had a 
gastrostomy & fundoplication (n=9), although this data is limited as it is 
retrospective. 
A significant correlation was observed between symptoms of GORD and LRSQ-
Neuro scores in Elective-ND patients. As discussed in Chapter 1, respiratory 
symptoms and complications of GORD include cough, shortness of breath, 
wheeze, and recurrent lower respiratory tract infection (Boesch et al., 2006). 
However, it can be difficult to establish whether the respiratory symptoms are 
due to GORD (through direct stimulation of the lower oesophagus or recurrent 
micro-aspiration), whether they are unrelated or alternatively, whether the 
respiratory symptoms themselves are causing or increasing gastro-oesophageal 
reflux episodes. Therefore, although a relationship is frequently observed it can 
be difficult to draw any conclusions regarding causation. Finally, there is some 
overlap between respiratory symptoms and GORD symptoms and therefore, it is 
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perhaps unsurprising to observe a correlation between GORD and respiratory 
symptoms. 
The high incidence of oral-motor dysfunction in children with ND is widely 
documented and swallowing assessment is advocated for children with ND who 
have feeding difficulties or symptoms of aspiration (Reilly, Skuse, & Poblete, 
1996 Weir, 2009). In this study, it was notable that over 75% of children who had 
undergone VFS were found to have clear aspiration or transient laryngeal 
penetration in both the Elective-ND and PICU-ND groups. Interestingly, 5/16 
children with positive VFS results had undergone VFS assessment on multiple 
occasions and had inconsistent negative and positive results. This highlights the 
limitation of VFS assessment in providing a limited ‘snap shot’ assessment of 
swallow co-ordination. Subsequently, there is potential to under estimate 
aspiration risk.  
Respiratory symptoms were significantly higher in the Elective-ND group who 
were positive by VFS compared to those who had not been assessed. It seems 
likely that these children were selected for assessment on the basis of their 
respiratory symptoms or symptoms of aspiration. This highlights the necessity of 
careful history taking and structured symptom documentation in these complex 
patients. However, it is also important to recognise that many children with ND 
aspirate ‘silently’ (Mirrett et al., 1994; K. A. Weir et al., 2011). Within the VFS 
positive group in this study, 66% reported cough with feeds (33% most or every 
day), 61% reported choking with feeds (39% most or every day) and 78% reported 
noisy breathing coming from the back of the throat (44% most or every day), a 
symptom known to be sensitive for aspiration of thin fluids (K. A. Weir et al., 
2011). Some children who had not been assessed by VFS also exhibited these 
symptoms whereas some children who were positive by VFS never or variably 
reported these symptoms. This may have been due to silent aspiration or 
management post VFS by gastrostomy feeding or thickened feeds, with 
subsequent improvement in symptoms. Information on feeding intervention 
directly following VFS was not consistently available and therefore, has not been 
included. It would be interesting to study respiratory symptom scores 
prospectively, pre and post any feeding intervention associated with VFS 
assessment, to assess the direct impact on respiratory symptoms.  
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Some parents chose to continue oral feeding despite positivity on VFS 
assessment. Interestingly these six children had significantly lower LRSQ-Neuro 
scores than those who were VFS positive but nil by mouth (29[4.5-58] vs. 
54.5[36.7-62.5], p<0.001). Modifications to feeds can be made to minimise 
aspiration risk, for example, alteration of food consistency or addition of 
thickeners to fluids. The severity of respiratory symptoms may well influence 
parental choices, particularly if the child gains pleasure from oral feeding. 
The evidence base for the management of salivary drooling and aspiration is 
limited and studies have generally focussed on drooling outcomes rather than 
respiratory outcomes (Walshe et al., 2012). The options for management include 
pharmacological (anti-cholinergic medications) and surgical interventions. In this 
study, very few patients were prescribed anti-cholinergic medications (8/35) and 
none had undergone surgical interventions. Three patients were prescribed 
Glycopyrrolate, four were prescribed hyoscine hydrobromide and one was 
prescribed both of these medications. The documented trials of these drugs have 
methodological limitations but generally conclude that statistically significant 
improvements are seen in drooling with glycopyrrolate or hyoscine hydrobromide 
treatment in ND patients. However, anticholinergic side effects including dry 
mouth, constipation, vomiting and behavioural changes were all reported and 
sometimes resulted in withdrawal of treatment (Eiland, 2012; Garnock-Jones, 
2012; Mato et al., 2010; Walshe et al., 2012; Zeller, Davidson, et al., 2012). A 
recent survey of paediatricians would suggest that few refer for surgical 
interventions (such as submandibular botulinum toxin injection or parotid duct 
ligation) due to limited resources (Parr et al., 2012). The evidence base for such 
interventions was found to be limited by a recent Cochrane review (Walshe et 
al., 2012). It is likely that salivary pooling was a significant issue for many 
children with ND who participated in this study. It is possible that the low 
frequency of active management was due to the limited evidence base to 
support interventions and concerns about side effects (Fairhurst & Cockerill, 
2011). Prospective comparative studies between pharmacological interventions 
and also between medical and surgical interventions are needed and it would be 
useful to include structured respiratory outcomes. The relative contribution of 
salivary aspiration to respiratory symptoms in children with ND is unclear 
however it was notable that those who were positive on VFS examination also 
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had significantly higher total LRSQ-Neuro scores. This association however, does 
not establish causality and respiratory symptoms may well have been the reason 
for selection for VFS assessment, thus introducing bias. 
Contributory factors to respiratory morbidity are likely to be multi-factorial and 
therefore, it would be beneficial for children with persistent respiratory 
symptoms to be assessed by a multidisciplinary respiratory team. In this study, 
only 1/16 patients in the elective group and 7/19 PICU patients had received 
specialist respiratory input. Notably, the majority of those receiving input were 
either receiving home oxygen or non-invasive ventilation, suggesting that this 
group of patients are referred to respiratory paediatricians late in the disease 
process. Our data suggests that clinicians should be more active in identifying 
and assessing these patients. Future studies should focus on the outcomes of 
early respiratory intervention in terms of child and family quality of life. 
This data is limited as it is retrospective and therefore, cause and effect cannot 
be established. However, it is useful in highlighting the complexity of this 
patient group, the need for structured multidisciplinary assessment and most 
importantly, in directing focuses for future prospective studies. 
3.6  Conclusions 
Children with severe ND often have high levels of chronic respiratory symptoms 
and complex co-morbidities. Early, tailored multi-disciplinary respiratory 
assessment may be useful in assessing and managing potentially modifiable 
contributory factors. Future studies need to prospectively assess the complex 
interactions of co-morbidities and respiratory symptoms with interventional 
studies using carefully selected, validated outcome measures. 
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  Chapter 4 Lower airway pathology in children 
with severe ND 
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4.1  Introduction 
Despite recognition of high levels of respiratory morbidity and mortality in 
children with ND, the underlying pathogenesis is poorly investigated within the 
literature (Reid et al., 2012; Westbom et al., 2011). The postulated cycle of 
recurrent aspiration, infection and chronic inflammation leading to airway 
damage is entirely based on clinical observation of a patient group who are 
inherently difficult to assess (Seddon & Khan, 2003). Aspiration and recurrent 
lower respiratory tract infections, although difficult to diagnose, are known to 
be common clinical problems in children with ND (Morton et al., 1999; Young et 
al., 2011). Piccione et al recently documented a high incidence of bronchiectasis 
(66%) in a large population of children with swallow study or airway endoscopy 
confirmed aspiration, occurring from an early age. Severe ND was identified as a 
significant risk factor for bronchiectasis on chest imaging (Piccione et al., 2012).  
However, little is known about lower airway microbiology or levels of 
inflammation in children with ND, either acutely during a respiratory 
exacerbation or when otherwise well. No previous studies have sought to analyse 
lower airway samples in order to further define and characterise the relative 
roles of aspiration, infection and chronic inflammation and their potential 
relationship to respiratory symptoms and quality of life. This approach may give 
direction for new therapeutic targets and expand the limited evidence base for 
management of these patients who currently are often treated anecdotally. 
In this chapter, several lower airway inflammatory markers are studied; 
bronchial lavage differential cell counts, Interleukin-8 (IL-8) and Transforming 
Growth Factor Beta-1 (TGF-1). Lower airway microbiology is studied through 
use of a 16S rRNA gene PCR assay (SepsiTestTM, Molzym) and a specific PCR assay 
for Pseudomonas aeruginosa (P. aeruginosa), based on the outer membrane 
lipoprotein gene, OprL (DeVos et al., 1997))(Handschur, Karlic, Hertel, 
Pfeilstöcker, & Haslberger, 2009). 
4.1.1 Interleukin 8 (IL-8 or CXCL8) 
IL-8, a potent neutrophil chemoattractant, is a key mediator of the pulmonary 
inflammatory response. A range of stimulants can induce production of this 
chemokine including bacteria, viruses, environmental factors and other pro-
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inflammatory cytokines, such as IL-1 and tumour necrosis factor-alpha (Mukaida, 
2003). Alveolar macrophages are the predominant cellular source of pulmonary 
IL-8 however, other sources include airway epithelial cells and fibroblasts 
(Kunkel, Standiford, Kasahara, & Strieter, 1991). Its key function is in enabling 
neutrophil transmigration and activation, which it performs through high affinity 
binding to CXCR1 and CXCR2 receptors on the neutrophil cell surface (Pease & 
Sabroe, 2002). 
Neutrophil infiltration is characteristic of various paediatric airway diseases and 
more specifically, has been shown to be central to the pathogenesis of 
bronchiectasis, the end stage respiratory outcome often seen in children with 
severe ND (Angrill et al., 2001, Piccione, 2012). Raised pulmonary IL-8 and 
neutrophil levels have also been correlated with BAL pepsin and bile acid levels, 
potential biomarkers of reflux-aspiration (D'Ovidio et al., 2005; McNally et al., 
2011; Starosta et al., 2007). Thus, measurement of pulmonary IL-8 is of interest 
in investigating the pathogenesis of the respiratory disease seen in children with 
ND, both in terms of potential contributory aetiological factors and pathological 
outcome. 
4.1.2 Transforming Growth Factor Beta-1 (TGF -1) 
TGF-1 is a member of the transforming growth factor beta cytokine super-
family. Three mammalian isoforms are recognised; TGF-1, TGF-2 and TGF-3. 
TGF -1 plays a central role in the regulation of airway remodelling (N. Khalil & 
Greenberg, 1991). 
Produced as a latent precursor complex by many cell types within the lung 
(including epithelial cells, endothelial cells, fibroblasts and various cells of the 
immune system), TGF-1 must be proteolytically or enzymatically activated (for 
example by proteases, reactive oxygen species or pH changes), in order to have 
physiological or pathological effects (Barcellos-Hoff & Dix, 1996; Camoretti-
Mercado & Solway, 2005; Lyons, Keski-Oja, & Moses, 1988; Q. Yu & Stamenkovic, 
2000). It functions through a specific heteromeric cell surface receptor complex 
(TGFR type 1 and 2), present on most cell types (Camoretti-Mercado & Solway, 
2005; LEASK & ABRAHAM, 2004). Key actions include control of cell growth, 
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proliferation, differentiation, and apoptosis (Dennler, Goumans, & ten Dijke, 
2002). 
TGF-1 expression has been demonstrated in epithelial cells and extracellular 
matrix from fibrotic lungs, localised to areas of repair and remodelling (N Khalil, 
O'Connor, Flanders, & Unruh, 1996). It is known to play roles in sub-epithelial 
fibrosis, airway smooth muscle changes and microvasculature changes as well as 
being a recognised driver of epithelial-mesenchymal transition (Camoretti-
Mercado & Solway, 2005; Willis & Borok, 2007). Airway remodelling processes 
are implicated in the pathogenesis of a number of chronic inflammatory 
respiratory diseases and correlations have been shown with disease severity 
(Arkwright et al., 2000; Brown et al., 2012). Additionally, increased BAL TGF-1 
has been noted in animal models of recurrent gastric juice aspiration and is 
induced in airway epithelial cell models on exposure to bile acids, a possible 
component of the refluxate (Li et al., 2008; Perng et al., 2007; Perng et al., 
2008). These studies justify investigating levels of TGF-1 in BAL samples from 
children with ND. 
4.1.3 16S PCR analysis 
Our understanding of microbial-host relationships has increased over recent 
years with the development of novel molecular methods of airway pathogen 
identification (E. S. Charlson et al., 2011). 16S PCR techniques are based on the 
isolation of the 16S ribosomal RNA (rRNA) gene, a universal component of all 
prokaryotic ribosomes. However, whilst bacterial rDNA carries nucleotide 
sequences common to all species, it also carries variable regions that are genus 
or species specific. It is therefore possible to identify bacterium by referencing 
bacterial sequence libraries through nucelotide sequencing of PCR products 
(Harris & Hartley, 2003). 
This technology removes the necessity (and subsequent bias) for ‘growing’ 
organisms on a culture plate and has highlighted the diversity and complexity of 
lower airway bacterial communities, both in health and disease, leading to 
rejection of the concept of a ‘sterile’ airway (E. S. Charlson et al., 2011; Emily 
S. Charlson et al., 2012; Huang, Lynch, & Wiener-Kronish, 2012). The traditional 
Sanger dideoxy sequencing methods have formed the basis of molecular 
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microbial identification for decades, leading to the identification of previously 
uncultured organisms and collection of large stores of phylogenetic data (Sanger 
et al., 1977). Newer pyrosequencing technologies are further advancing the 
field, allowing high throughput deep sequencing analysis and characterisation of 
complete microbial communities, rather than solely the predominant organisms 
(Petrosino, Highlander, Luna, Gibbs, & Versalovic, 2009). Broad microbial 
communities appear to differ in varying states of airway disease and with anti-
microbial treatments, implying potential contribution to disease progression. 
However, the actual clinical implications of these differences are, to date, not 
fully understood (Hilty et al., 2010). 
4.1.4 Pseudomonas aeruginosa 
P. aeruginosa is a gram negative, aerobic, rod shaped bacterium commonly 
found in soil, water and on the surfaces of plants. In humans, it is an 
opportunistic pathogen with the ability to infect almost any organ if defences 
are compromised, the commonest site being the lung (Iglewski, 1996). Common 
predisposing conditions are cystic fibrosis, mechanical ventilation, 
immunodeficiency and other pre-existing respiratory diseases. The pathogenicity 
of P. aeruginosa infection is complex comprising advanced epithelial adhesion 
mechanisms, protease and cytotoxin secretion, cell-to-cell communication 
(quorum sensing) and alginate secretion (Kipnis, Sawa, & Wiener-Kronish, 2006; 
Pritt, O'Brien, & Winn, 2007). Individuals with cystic fibrosis become colonised, 
initially intermittently with pseudomonas from early childhood, and then 
chronically in adolescence. Aggressive treatment is warranted to delay the 
development of a mucoid phenotype, which is associated with increased 
morbidity and mortality (Banerjee & Stableforth, 2000; Pritt et al., 2007). 
Children with ND often have abnormal, potentially pathogenic upper airway 
bacterial colonisation, particularly with P. aeruginosa (Thorburn et al., 2009). 
However, it’s presence and role in lower airway pathology in this group of 
children is unclear. There are no clear management guidelines and consequently 
clinical management strategies are varied amongst clinicians (S. Smith & Puri, 
2004). 
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4.2 Aims 
To determine the relationship between lower airway inflammation/infection and 
clinical symptoms in children with severe ND, this study aimed to; 
1. Assess lower airway inflammatory markers in BAL supernatant samples taken 
from children with severe ND at times of stability and during respiratory 
deteriorations on admission to PICU, in comparison to healthy controls. 
2. Characterise lower airway microbial colonisation/infection at a time of 
stability and respiratory deterioration in comparison to healthy controls using a 
16S rRNA gene PCR analysis and also a specific PCR for P. aeruginosa. 
3. Assess the relationship of lower airway inflammation and microbial 
colonisation/infection with chronic respiratory symptoms (as characterised by 
total LRSQ-Neuro scores). 
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4.3 Specific Methods 
Clinical data collection and bronchial lavage sampling were undertaken as 
described in Chapter 2. Differential cell counting was performed following Diff 
Quick staining (Reastain CE) of BAL cytospin slides, as detailed in Section 
2.3.2.3. BAL IL-8 and TGF-1 measurements were made using commercial ELISA 
kits (R&D systems), as described in Section 2.4. The laboratory methods for the 
SepsiTestTM (Molzym, Bremen) and OprL PCR techniques are detailed in Sections 
2.6.5 and 2.6.4, respectively. Further background information on these assays is 
detailed below. 
4.3.1 SepsiTestTM-16S/18S rDNA PCR with selective degradation 
of human DNA 
It is generally acknowledged that when using 16S technology, the high human to 
pathogen DNA ratio in clinical samples can lead to problems with sensitivity and 
crucially to false identifications, due to homologous sequence motifs between 
host (eukaryotic) and bacterial (prokaryotic) genomes (Cridge et al., 2006; 
Handschur et al., 2009). However, by electively degrading human DNA, it is 
possible to enrich pathogen DNA and thus increase PCR sensitivity (Molzym Life 
Science, 2013).  
SepsiTestTM differs from other commercially available 16S/18S PCR techniques in 
having a patented sample preparation step to remove human and extracellular 
bacterial DNA (MolYsis, Molzym, Bremen) (Horz, Scheer, Vianna, & Conrads, 
2010). It also only yields information about pathogens with intact cell walls. This 
tackles another recognised limitation of 16S/18S studies; the inability to 
differentiate intact microbial DNA from free microbial DNA, which again 
potentially biases results (E. S. Charlson et al., 2011; Rogers & Bruce, 2010; 
Rogers et al., 2008).  
Blood culture studies have demonstrated successful use of SepsiTestTM as a 
supplemental tool to accompany standard culture techniques in the diagnosis of 
septicaemia (Gebert, Siegel, & Wellinghausen, 2008; Wellinghausen et al., 
2009). A high level of agreement with positive blood culture results was 
observed and benefits included increased speed of diagnosis and additional 
information about pathogenic organisms, previously challenging to identify by 
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standard culture techniques. The sequencing technique (based on Sanger 
methods) focuses on identifying the most predominant organisms within a 
sample, rather than community characterisation, as with pyrosequencing 
techniques (Molzym Life Science, 2013). Both bacterial (16S) and fungal (18S) 
rDNA can be identified using SepsiTestTM. It has been used with other specimen 
types but has not been fully validated in BAL samples to date (Molzym Life 
Science, 2013). We are unaware of other 16S/18S rDNA PCR studies on BAL which 
have used a human DNA depletion step, although propidium monoazide has been 
used in a small number of studies to limit amplification of non-viable DNA 
(Rogers et al., 2008). Laboratory methods for this technique are documented in 
methods Section 2.6.5. 
4.3.2 OprL PCR 
This PCR technique is based on amplification of the OprL outer membrane 
lipoprotein gene (open reading frame 504bp). The OprL gene was previously 
validated as being specific to P. aeruginosa using various bacteria and twenty 
different fluorescent pseudomonad strains of both clinical sample and 
environmental origin (DeVos et al., 1997). The assay showed 100% sensitivity and 
74% specificity in comparison to culture, when testing respiratory specimens. 
Laboratory methods are documented in methods Section 2.6.4. 
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4.4 Results 
4.4.1 BAL characteristics 
A total of 46 BAL samples were collected which met sample adequacy criteria, 
based on ERS recommendations (de Blic et al., 2000; Suen et al., 1999). 
Nineteen samples were from children in the PICU-ND group, 16 were from 
children in the Elective-ND group and 11 were healthy control patient samples. 
Table 4.1 documents the BAL cellular component characteristics and BAL 
supernatant total protein levels. 
Significant differences in BAL cell concentration (cells/ml) were seen between 
the PICU-ND and healthy control group (p<0.001). Significant differences in BAL 
total protein concentration (ug/ml) were seen between the PICU-ND and 
Elective-ND groups (p=0.027), Elective-ND and Healthy Control groups (p=0.048) 
and PICU-ND and healthy control groups (P<0.01). 
Table 4-1 Table to show BAL cellular component characteristics and BAL supernatant total 
protein levels 
 PICU-ND Elective-ND Controls 
Number of samples 19 16 11 
Median (IQR) total cell 
concentration (x 106 cells/ml) 
3.9[1.3-7.4] 0.9[0.4-4.2] 0.6[0.3-0.9] 
Median (IQR) % neutrophils 82[72-86.6] 48.8[29.1-71.2] 6.8[3-18.5] 
Median (IQR) % alveolar 
macrophages 
15.7[10.4-
19.8] 
47.5[24-69] 89.5[78.2-94.3] 
Median (IQR) % lymphocytes 1.7[1.3-3.2] 2.0[1.3-3] 1.8[1.4-2.7] 
Median (IQR) % eosinophils 0.3[0-0.6] 0.3[0-0.6] 0.3[0.1-0.6] 
Median (IQR) total protein 
(ug/ml) 
579[180-1412] 124[83-694] 73[49-160] 
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4.4.2  Children with severe ND have chronic lower airway 
inflammation, even at times of stability 
BAL differential cell counts were made on 15/19 PICU-ND samples, 16/16 
Elective-ND samples and 10/11 healthy control samples. As anticipated, a 
marked neutrophilia was found in PICU-ND BAL (82% [77-86]). However, a higher 
neutrophil percentage was also found in Elective-ND BALs compared to healthy 
control samples (Elective-ND, 49% [29-71]; Control, 6.8% [3-18.5]: p<0.001) 
(Figure 4.1). 
IL-8 protein levels were measured in all BAL supernatant samples (46/46). BAL 
median [IQR] IL-8 concentrations were highest in PICU-ND BAL samples (5,641 
[2,024-14,703] pg/ml) but were also significantly raised in Elective-ND samples 
compared to healthy controls (Elective-ND, 646 [0-3633] pg/ml; Control, 0 [0-
222] pg/ml: p<0.05) (Figure 4.2). 
TGF-1 levels were measured in all BAL supernatant samples (46/46). TGF-1 
levels were also raised in PICU-ND BAL samples (157 [69-190] pg/ml; Control, 0 
[0-0] pg/ml: p<0.001) and Elective-ND samples (Elective-ND, 0 [0-143] pg/ml; 
p=0.051) (Figure 4.2).  
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Figure 4.1 Vertical scatter graph showing BAL neutrophils (expressed as % total BAL cells) 
by study group 
BAL differential cell counts were performed following cytospin slide preparation and Diff-Quick 
staining (Reastain CE). Neutrophil counts are expressed as % total BAL cells. * P <0.001. 
Horizontal line represents median value. 
 
Figure 4.2 Vertical scatter graphs showing (a) BAL IL-8 levels (pg/ml) and (b) BAL TGF1 
levels (pg/ml) by study group  
BAL supernatant IL-8 and TGF1 levels were measured using commercially available ELISA sets 
(R&D systems). * P<0.05 ** P<0.001. Horizontal line represents median value  
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4.4.3 Lower airway inflammatory levels may relate to LRSQ-Neuro 
scores in Elective-ND patients 
The relationships between total LRSQ-Neuro score and BAL neutrophil 
percentage, IL-8 and TGF-1 were examined in the Elective-ND group.  
No statistically significant relationships were found in this small patient cohort 
(n=16). However, it was notable that those patients with an LRSQ score >20 
invariably had an accompanying BAL neutrophilia (Figure 4.3).  
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Figure 4.3 Vertical scatter graph illustrating observed patterns of BAL neutrophilia in 
Elective-ND patients divided according to LRSQ-Neuro score, compared to healthy controls. 
BAL neutrophil counts were assessed following BAL cytospin slide preparation, Diff Quick staining 
and differential cell counting. All study recruits were asked to complete a respiratory symptom 
score (the LRSQ-Neuro) on admission to hospital. BAL neutrophils (% total BAL cells) were 
observed to be consistently raised in those Elective-ND patients with an LRSQ score >20. BAL 
neutrophil levels are plotted for Elective-ND patients (divided by LRSQ-Neuro score < or > 20) and 
healthy controls patients. Comparison of BAL neutrophil levels in Elective-ND patients with total 
LRSQ-Neuro score <20 vs. LRSQ-Neuro score >20, p = 0.09. * p < 0.01, ** p < 0.0001. 
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4.4.4 ‘Oral commensals’ are often identified in the lower airway 
Microbial rRNA gene 16S/18S (bacterial/fungal) analysis (SepsiTestTM Molzym, 
Bremen) was performed on 18/19 PICU-ND, 16/16 Elective-ND and 9/11 healthy 
control samples. The reason for not testing all samples was limitation of sample 
volumes. 
Microbial DNA was detected in BAL samples from 66% PICU-ND patients, 81% 
Elective-ND patients and 55% healthy controls. In PICU-ND patients, microbial 
DNA was detected in 54% (7/13) of those who had been prescribed antibiotics for 
>24 hours prior to admission to hospital, and in 100% (5/5) patients who had not 
been prescribed antibiotics.  
Various predominantly gram-positive bacteria were identified on sequencing 
(Figure 4.4). In both ND groups, microbial DNA from Staphylococcus aureus, 
Streptococcus mitis and Rothia mucilaginosa were most commonly detected. 
Streptococcus mitis and Rothia mucilaginosa were also identified in the two 
control patients in whom microbial DNA was detected <cycle 35. Despite P. 
aeruginosa being detected in airway secretions from multiple patients prior to 
this study, it was not detected in BAL samples from any patient using this assay. 
A total of 78% of the microbial identifications were with >97% sequence coverage 
and 22% were mixed sequences with the likely predominant species identified 
(71% Rothia species or Streptococcus species). In these cases, further detailed 
identification would require deep sequencing.  
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Figure 4.4 Bar charts showing predominant microbes with intact cell walls identified in BAL 
for (a) Elective-ND vs. healthy control patients and (b) PICU-ND vs. healthy control patients. 
BAL samples were analysed using a novel 16S/18S rRNA gene PCR assay (SepsiTest
TM) 
in the 
Molzym laboratories, Bremen, Germany. This assay incorporates a step to eliminate host and non-
viable bacterial DNA. Microbial identity (post sequencing and referencing using the SepsiTest
TM-
BLAST tool) for each patient sample analysed is displayed on the x axis and the PCR cycle at 
which they were identified is displayed on the y axis (each bar represents one sample). The 
bracketed numbers represent the PCR cycle at which the second indicated microbe was identified. 
The red line indicates the ‘cut off’ at which Molzym laboratories indicated ‘+/-‘ to microbe specific 
signal in the melt curve (i.e. the limits of confident detection). 
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4.4.5  Relationship between microbial DNA status,  respiratory 
symptoms and lower airway inflammation in elective 
patients 
The relationship between LRSQ-Neuro score, BAL neutrophilia and microbial DNA 
detection in Elective-ND and healthy control patients was examined. 
Total LRSQ score was generally higher in patients who had samples that were 
positive for microbial DNA, although this did not reach statistical significance 
(microbial DNA +ve, 15[5-32]; microbial DNA -ve, 5[0-9]: p=0.097). Median 
[range] BAL neutrophil levels were also higher in samples that were microbial 
DNA positive (33%[18-70]) compared to microbial DNA -ve (8%[4-38]: p=0.065). 
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Figure 4.5 Vertical scatter graphs showing (a) relationship between BAL neutrophil levels 
and microbial DNA status within Elective-ND and healthy control study groups and (b) 
relationship between total LRSQ-Neuro score and DNA microbial status in both elective 
study groups combined. 
BAL samples were analysed using a 16S/18S rRNA gene assay (SepsiTest
TM
)
 
in the Molzym 
laboratories, Bremen, Germany. This assay incorporates a step to eliminate host and non-viable 
bacterial DNA. BAL neutrophil counts were assessed following BAL cytospin slide preparation, Diff 
Quick staining and differential cell counting (expressed as % total BAL cells). All study recruits 
were asked to complete a respiratory symptom score (LRSQ-Neuro) on admission to hospital.  
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4.4.6 P. aeruginosa was not identified in lower airway samples of 
children with severe ND by OprL PCR 
Given that 12/19 PICU-ND patients had cultured P. aeruginosa from their airways 
at some point prior to this admission and that 5/12 PICU-ND patients had 
cultured P. aeruginosa on tracheal aspirate during this admission, we sought to 
verify the SepsiTestTM data using OprL PCR. This would also investigate the 
possibility that P. aeruginosa had been rendered unviable during the freeze 
thawing process. P. aeruginosa was not detected in any PICU-ND, Elective-ND or 
healthy control BAL sample by this technique. 
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Figure 4.6 18S and OprL PCR Gel Images 
Example PCR gel images showing (a) 18S PCR product at 315bp for 16 study samples (loading 
control) and (b) 18S and OprL PCR products at 315bp and 504bp respectively, for two positive 
control samples (Colony P. aeruginosa (Psae) and a culture positive cystic fibrosis (CF) sample) 
and three study samples. 
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4.5 Discussion 
In Chapter three, chronic respiratory symptoms were documented in otherwise 
well children with severe ND, which impact on quality of life. In this chapter, we 
have identified chronic lower airway inflammation in these same children and 
there appears to be a relationship with respiratory symptoms in Elective-ND 
patients. Using novel 16S/18S PCR technology that only detects microbes with 
intact cell walls, we have identified the predominant organisms present within 
the airways of these children at the time of sampling. Of note, Streptococcus 
mitis was found in nearly half of those samples in which an organism was 
detected. In contrast, P. aeruginosa was not found in any lower airway sample 
despite being cultured from other, predominantly upper airway sample types in 
these patients (documented in chapter three). Lastly, a trend for greater airway 
neutrophilia and respiratory symptoms in those elective patients with lower 
airway microbial positivity was observed, suggesting that lower airway infection 
may play a significant role in the respiratory morbidity experienced by children 
with severe ND.  
In this challenging group of patients, it is often difficult to elicit whether 
respiratory symptoms are coming from the lower or upper respiratory tract. The 
tendency for BAL neutrophil levels to be higher in those with more respiratory 
symptoms may indicate that at least some of these symptoms originate from the 
lower respiratory tract; in this study, patients with an LRSQ-Neuro score >20 
invariably had lower airway neutrophilia. This observation certainly warrants 
further investigation since these types of relationship are not often found. In the 
CF literature for example, most studies show that respiratory symptoms 
correlate poorly with lower airway inflammation, although few have used a 
structured validated tool to assess symptomatology (Brennan et al.; Nixon et al., 
2002; Stick et al.). It is important to acknowledge that any observations made 
within this study were significantly limited by study numbers. However, these 
preliminary results indicate that the LRSQ-Neuro may have potential as a non-
invasive indicator of lower airway inflammation, and it is not inconceivable that 
this quick, simple test could be used to screen patients who may benefit from 
specialist respiratory assessment or even as an outcome measure in clinical 
trials. For this to happen, further psychometric validation is required, 
particularly with regard to sensitivity to change (US Department of Health and 
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Human Services Food and Drug Administration, 2006) . Future studies should 
include larger study numbers and children with ND with a range of disability 
levels rather than only those with GMFCS V.  
The levels and type of inflammation recorded may provide some insight into why 
many of these children die early from respiratory complications in adolescence 
and early adulthood (Piccione et al., 2012). As well as finding significant airway 
neutrophilia and increased IL-8 levels, we also found elevated levels of TGF1, 
an important driver of airway remodelling and fibrosis, which is induced by 
neutrophil elastase (K.-Y. Lee et al., 2006). It is feasible that chronic 
inflammation and infection may be important in the development of airway 
damage seen in these patients in the end stages of their respiratory disease. 
However, in order to implicate TGF1 in the mechanism of chronic airway 
damage the data would need further consolidation. TGF1 ELISA kits usually 
measure ‘active’ TGF1 and therefore in order to measure total sample TGF1, 
an ‘activation’ step (usually by acidification followed by neutralisation) is 
required. The finding of raised TGF1 levels by ELISA quantification is 
interesting: future work would ideally investigate TGF1 activity in airway 
epithelial cells using, for example, immunohistochemical staining for pSMAD2/3 
as a measure of TGF1 signalling (Lim et al., 2009).  
The 16S/18S PCR results (SepsiTestTM) provide a record of the predominant 
pathogens with intact cell walls, populating the airways of participants at the 
time of bronchoalveolar lavage. Interestingly, broadly the same microbes, often 
considered oral commensals, were found in the airways of children with and 
without severe ND. These groups did however differ in the timing of PCR cycle 
positivity. The microbes identified in healthy control samples generally came up 
after 35 PCR cycles whereas those within the ND samples came up before 35 
cycles. The company classed any positivity above cycle 35 as +/- in terms of 
microbe specific signal in the melt curve and therefore, this ‘cut off’ line was 
drawn for comparison of samples between groups. Unfortunately, no firm 
conclusions can be drawn about relative microbial abundance from this 
observation. In any future study it would be interesting to formally assess this 
through use of standard curves. 
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Streptococcus mitis was the organism identified most commonly within the 
samples. This gram-positive organism is generally considered an oral commensal, 
and while thought to pose little threat to the immuno-competent, it is a 
significant cause of endocarditis and septicaemia in neutropenic and immuno-
compromised individuals (Mitchell, 2011). Streptococcus mitis uses a variety of 
strategies including expression of adhesins, immunoglobulin A proteases and 
toxins, and modulating the host immune response, to colonise the human 
oropharynx. In neuro-disabled individuals lacking adequate airway protection, it 
is possible that these same strategies could also allow the colonisation of the 
lower respiratory tract. The pulmonary inflammatory potential of organisms 
which are regarded as oral flora requires further study, an issue also raised by 
Gangell ‘et al’ in a traditional culture study of CF BAL specimens (Gangell et al., 
2011).  
A potential limitation of this work was that sheathed equipment was not used for 
BAL collection, increasing the risk of carryover of microbes from the upper to 
the lower respiratory tract (E. S. Charlson et al., 2011; Goddard et al., 2012). 
Nevertheless, the same collection technique was used for all patient groups. 
Therefore, the differences observed in timing of PCR cycle positivity are still 
valid, particularly as organisms (specifically P. aeruginosa) known to have been 
present in the upper airway of several PICU patients, do not appear to have been 
carried over to lower airway specimens. It would be useful to make direct 
comparisons of upper and lower airway sample microbiology in future studies, 
using sheathed equipment and fresh suction circuits to collect lower airway 
samples. 
Microbial diversity is noticeably limited in results from this study compared to 
other lower airway 16S rRNA gene studies (E. S. Charlson et al., 2011; Hilty et 
al., 2010)). Sanger sequencing targets identification of the dominant species, 
rather than documentation of whole microbial communities. Newer 
pyrosequencing techniques offer superior depth of sequencing and enable 
monitoring of the broader lower airway microbiome, including information about 
low abundance species which may play important roles in disease pathogenesis 
(M. J. Cox et al., 2010). The use of deep sequencing would also allow clearer 
identification of organisms in cases where there is not a predominant species (as 
seen in 22% of microbial DNA identifications in this study). Other researchers 
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have found it useful to use these sequencing techniques in tandem (Flanagan et 
al., 2007). 
Another potential explanation for differences in results between this study and 
other studies is the removal of host DNA and extracellular bacterial DNA (Rogers 
et al., 2008). Potential difficulties with molecular detection of both intact and 
extracellular bacterial DNA include increased signal to noise and increased rates 
of false microbial identification. Also, ability to judge the clinical relevance of 
species detected at the time of sampling may be influenced by the rate of DNA 
clearance from the lower airway (known to be delayed in conditions such as 
cystic fibrosis) (Stressmann et al., 2011). Similarly, effects of recently used 
antimicrobials may become difficult to assess (Rogers & Bruce, 2010; Sibley, 
Peirano, & Church, 2012). Of note, in this study, no microbes were detected in 
6/13 PICU-ND samples from children who had received antibiotics in the 
preceding 24 hours, whereas they were identified in all 5 PICU patients who did 
not have antibiotics. 
However, this strength in solely detecting organisms with intact cell walls may 
also be a limitation. Children often receive antibiotic treatment before sampling 
and this could decrease the ability of SepsiTestTM to detect microbial causes of 
symptoms (Flanagan et al., 2007). The relative abundance of gram-positive 
organisms in our samples was surprising given the likely prevalence of reflux 
aspiration in our ND patients and theoretical potential for gram-negative 
infection (Morton et al., 1999). This may have been due to the purification step, 
in which human cells are lysed while viable bacterial cells ideally remain 
unaffected. A recognised limitation of this sort of process is that bacteria with 
less robust cell envelopes, such as gram-negative microbes, may also be lysed in 
this step, biasing the reported micro-flora (Horz, Scheer, Huenger, Vianna, & 
Conrads, 2008; Horz et al., 2010). Equally, this may have been influenced by 
how we stored our samples, as gram-negative bacteria are known to have lower 
survival following freezing (Miyamoto-Shinohara, Sukenobe, Imaizumi, & 
Nakahara, 2006). Future studies should analyse samples fresh, where possible. 
Finally, this may reflect a low relative abundance of gram-negative organisms in 
these patients, limiting detection via the sequencing technique used. 
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The advantages offered by molecular microbial detection over traditional 
culture are counter-balanced by potential confounders relating to the effects of 
sample processing, nucleic acid extraction efficiency, purification, 
amplification, depth of sequencing and analysis (Rogers & Bruce, 2010; Sibley et 
al., 2012). All this needs to be considered in interpretation of molecular studies 
and in research study planning. It would certainly be of interest to conduct BAL 
studies with culture and molecular techniques (including and excluding non-
viable DNA) in tandem in the future. This was not performed in the current study 
as the original study aims did not include microbiological analysis and therefore, 
microbiological analysis was retrospective. This approach may also be useful in 
further validating the use of SepsiTestTM in BAL samples (previously validated in 
serum samples) (Gebert et al., 2008; Wellinghausen et al., 2009). However, 
validation in respiratory samples, which unlike serum samples would be 
expected to contain microbes under normal circumstances, would be more 
challenging. A deeper sequencing approach would need to be employed, as 
organisms grown on the culture plate may not be the ‘predominant’ species 
identified by Sanger sequencing.   
Given the literature, and that so many of our ND cohort cultured P. aeruginosa 
on cough swab or tracheal aspirate (as recorded in chapter three), it was 
surprising that this organism was not detected on 16S analysis or PCR of the OprL 
gene (S. Smith & Puri, 2004; Thorburn et al., 2009). There are a number of 
possible explanations for this. It is well-recognised that microbial growth may 
differ between lobes of the lung and therefore, it is possible that in ‘blindly’ 
sampling the lower respiratory tract, we have missed P. aeruginosa infected 
lobes (Gilchrist et al., 2011). However, it is equally possible that our results 
accurately reflect lower airway microbiology and inferences about lower 
respiratory microbiology have been based on upper airways pseudomonal 
infection. Many of these children have regular upper airways suction and poorly 
coordinated swallows, a situation that provides the perfect opportunity and 
environment for P. aeruginosa to be introduced and then to colonise the 
oropharynx. Also, one would expect that tracheal aspirates would be more prone 
to contamination from the oropharynx than lower airway BAL samples. This 
potentially important clinical observation should be considered when treating 
respiratory exacerbations in these children, and certainly warrants further study 
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and investigation. Again, the same points regarding methodological bias apply 
and it would be useful to use culture and molecular techniques in tandem on 
paired tracheal aspirate and BAL samples to investigate this further in future 
studies (Deschaght, Van daele, De Baets, & Vaneechoutte, 2011). In particular, 
the sensitivity of the OprL PCR technique compared to culture should be 
revalidated within our laboratory.  
The absence of BAL viral PCR results is a potential criticism of the data 
presented in this chapter. Viral infection may have triggered a respiratory 
deterioration and generated a lower airway inflammatory response in many of 
the PICU-ND group. However, the electively recruited patients were the main 
focus of conclusions drawn from this chapter. At the time of recruitment, all 
electively recruited patients were ‘well’ from a respiratory perspective. It was 
felt clinically unlikely that active viral infection was a relevant factor in 
generating airway inflammation and symptoms at this time and therefore,  viral 
PCR testing was not pursued. However, it must be acknowledged that subclinical 
viral infection could potentially have contributed to the lower airway 
inflammation observed.  
The trend for airway neutrophilia and symptoms to be greater in those electively 
recruited patients with lower airway microbial positivity points toward infection 
being the cause of respiratory symptoms and morbidity. This raises the clinical 
question as to whether antibiotic prophylaxis would be beneficial in this group of 
patients. There have been no high quality studies to date and little is known 
about antibiotic resistance patterns in neuro-disabled children. Within our 
region, there is an inconsistent approach (as documented in Chapter 3), with 
those attending joint neuro-respiratory clinics more likely to be prescribed 
antibiotic prophylaxis. Formal randomised controlled trials are needed to further 
assess this, possibly using the LRSQ-Neuro as an outcome measure: development 
of microbial resistance will be a key consideration in such studies. 
4.6 Conclusions 
Children with severe ND often have high levels of chronic respiratory symptoms, 
which possibly relate to levels of lower airway inflammation. This needs to be 
explored further in a larger patient cohort. Bacterial airway colonisation, 
 138 
particularly with oral commensals, may play a role in both symptom generation 
and inflammation but requires further detailed investigation. Early tailored 
respiratory assessment of children with ND and chronic respiratory symptoms 
may be useful and further well-designed clinical studies are needed to 
determine the risks and benefits of prophylactic therapy in this group. 
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 Chapter 5 – Biomarkers of Aspiration in 
Bronchial Lavage Fluid 
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5.1 Introduction 
The aetiology of respiratory disease in children with severe ND is undoubtedly 
multi-factorial, however recurrent pulmonary aspiration is thought to play a 
significant role (Seddon & Khan, 2003). Gastro-oesophageal reflux disease and 
oral-motor discoordination are known to be common problems in ND patients 
(Mazzoleni et al., 1991; Morton et al., 1999; K. A. Weir et al., 2011). The high 
incidence of these co-morbidities means that children with severe ND represent 
a patient group at ‘high risk’ of recurrent direct and reflux pulmonary 
aspiration. Data presented in Chapter Three suggest that this is also true of 
recruits to this study. 
Differentiating direct aspiration (of food and saliva) and gastric reflux aspiration 
is difficult. This is particularly the case when children present with 
predominantly respiratory symptoms, where there may be direct aspiration, 
reflux aspiration, neither, or both. This conundrum hinders clinical decision 
making, particularly concerning invasive procedures such as fundoplication 
(Shields et al., 2011). Clinical biomarkers to identify and quantify both reflux 
aspiration and direct aspiration would therefore be useful in clinical assessment, 
and may also be applicable as outcome measures for interventional trials. 
Longitudinal studies using validated biomarkers would further inform our 
understanding of the impact of aspiration on pulmonary health in children with 
severe ND and also clarify associations between other respiratory pathologies 
and GORD (Havemann, Henderson, & El-Serag, 2007; King, Iyer, Leidi, & Carby, 
2009; McNally et al., 2011). 
Useful biomarkers of direct or reflux pulmonary aspiration ideally need to be 
non-invasive, quantifiable, specific to the aspirate (gastric juice or saliva), not 
normally present within the lungs and detectable for sustained periods following 
aspiration (McNally et al., 2011). BAL fluid analysis, although invasive, provides a 
good starting point for the study of biomarkers of pulmonary aspiration. The 
significant limitations of the lipid laden macrophage index were discussed at 
length in Chapter One (Boesch et al., 2006). However, despite these limitations, 
this test continues to be used in clinical practice, as no other biomarker of 
reflux-aspiration currently exists (Reid-Nicholson et al., 2010). Various novel 
biomarkers of aspiration have been proposed in the literature. Two such markers 
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are BAL pepsin (reflux aspiration) and BAL alpha amylase activity (direct 
aspiration) (Abou Jaoude, Knight, Ohtake, & El-Solh, 2010; Clarke, Bain, & 
Davies, 1981). To date, clinical studies of BAL alpha amylase as a biomarker of 
direct aspiration have been limited; however, studies of pepsin as a biomarker 
of reflux aspiration have been much more extensive (reviewed in Chapter 
1)(Clarke, Bain, & Davies, 1981; Nandapalan, McIlwain, & England, 1995; 
Nandapalan, McIlwain, & Hamilton, 1995). Interestingly, despite this, no firm 
conclusions have been drawn about the utility of BAL pepsin as a clinical test for 
a number of reasons. The first is that there is no diagnostic gold standard against 
which to compare results. Clinicians currently make the diagnosis of aspiration 
based on an accumulation of clinical evidence (Boesch et al., 2006). Therefore, 
it would be helpful to study BAL pepsin in a ‘high risk’ group by current 
diagnostic standards, such as children with severe ND. Secondly and as discussed 
in Chapter One, a number of different assay techniques have been used to 
measure BAL pepsin, potentially contributing to discrepancies in results between 
studies. Critical analysis of methods, to ensure high standards of protein 
identification and quantification across study samples, is needed and subsequent 
standardisation of methods is essential in order to conduct meaningful, 
longitudinal studies of these biomarkers. 
The aims of this chapter were to study the relationships between BAL biomarkers 
of reflux and direct aspiration (lipid laden macrophages, pepsin and amylase) 
and respiratory symptoms, previous clinical investigation results and lower 
airway inflammatory markers, in children with severe ND compared to healthy 
controls. Specifically, the study took a   critical approach to each analytical 
method used, utilising standard techniques (as described in Section 2.4) to 
assess assay validity across PICU and healthy control samples, and using a 
minimum of two analytical methods to assess each biomarker. 
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5.2 Aims 
In order to assess BAL biomarkers of direct and indirect aspiration in children 
with severe ND, the chapter aims were to: 
1) Assess the frequency of BAL LLM positivity in children with ND at a time of 
stability and at a time of respiratory deterioration (on admission to PICU) 
compared to healthy controls, also observing the relationship of positivity to (a) 
respiratory symptoms (b) symptoms suggestive of GORD (c) evidence of 
swallowing dysfunction (d) novel biomarkers of reflux-aspiration. 
2) Critically assess previously published methods of BAL pepsin and amylase 
measurement in BAL across a range of clinical samples (PICU and healthy 
control), using (a) standard methods of assay validation and (b) a second method 
of measurement to corroborate results. 
3) Assess the relationship of robust measurements of BAL alpha amylase activity 
and pepsin (as established in aim 2) to respiratory symptom scores, lower airway 
inflammatory markers and other clinical evidence of direct/reflux aspiration risk 
in children with ND (at a time of stability and at a time of deterioration), 
compared to healthy controls. 
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5.3 Specific methods 
Clinical data collection and bronchial lavage sampling were undertaken as 
described in Chapter 2. Differential cell counting was performed following Diff 
Quick staining (Reastain CE) of BAL cytospin slides, as detailed in Section 
2.3.2.3. BAL IL-8 and TGF-1 measurements were made using commercial ELISA 
kits (R&D systems, Section 2.4). All data relating to clinical samples was treated 
as non-parametric for statistical analysis due to small study group size (Section 
2.9). 
5.3.1 Lipid laden macrophage staining 
The widely recognised limitations of the lipid laden macrophage index as a 
marker of reflux-aspiration were discussed in Chapter 1 (Boesch et al., 2006). 
Following concerns about inter and intra-rater reliability in reporting a lipid 
laden macrophage index and the limited overall specificity of the finding of lipid 
laden macrophages in BAL samples, it has been suggested that laboratories 
establish their own ‘cut offs’ for reporting lipid laden macrophage slide 
positivity (Ahrens et al., 1999; Colombo, Sammut, & Hallberg, 1986; Reid-
Nicholson et al., 2010). 
In this study, slides with any degree of alveolar macrophage lipid positivity by Oil 
Red O staining (Section 2.3.2.4) were forwarded to cytopathology for 
interpretation by a specified experienced cytopathologist, according to local 
guidelines. A positive or negative result was issued rather than a lipid laden 
macrophage index, which would require expert interpretation. 
5.3.2 Identification and quantification of pepsin in BAL 
Previously published laboratory techniques used to measure pepsin in BAL 
include ELISA, WB and enzymatic methods (Samuels & Johnston, 2010). All of 
these methods have strengths and weaknesses, as discussed in Chapter 1. The 
enzymatic method of analysis of pepsin A has various limitations, not least it’s 
inability to differentiate pepsin activity from that of other aspartic proteases 
known to be produced locally in the lung and to be increased in pulmonary 
inflammatory conditions (Bewley et al., 2011; Kimura et al., 2005; Koslowski, 
Knoch, Kuhlisch, Seidel, & Kasper, 2003; Trinick, Johnston, Dalzell, & 
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McNamara, 2012). Immunological methods of pepsin analysis, such as ELISA and 
WB, offer potential for increased specificity. A variety of ‘in house’ assays have 
been used to measure pepsin in BAL with little published cross validation. Two 
widely used ELISA methods (one indirect and one sandwich ELISA using polyclonal 
antibodies to porcine pepsin A, shown to be cross reactive with human pepsin A) 
and one Western blot method (using a polyclonal antibody to human pepsin) 
were chosen for use in this thesis (Farrell et al., 2006; Rosen, Johnston, Hart, 
Khatwa, & Nurko, 2012; Tasker et al., 2002a). 
5.3.2.1 ELISA methods for measurement of pepsin in BAL 
The two published ELISA methods selected for analysis both used porcine pepsin 
antibodies (shown to be cross reactive with human pepsin A) to quantify human 
pepsin A in BAL. They followed different ELISA formats: ELISA 1 used an indirect 
ELISA technique whereas ELISA 2 used a sandwich ELISA technique.  
Indirect ELISAS rely on the primary step of the antigen of interest being non-
specifically adsorbed onto a microtiter plate. Blocking of residual binding sites 
on the plate is usually achieved by adding a formulation of protein that does not 
react with the antigen of interest or the antibody. A specific antibody for the 
antigen of interest is then added which binds to the antigen and following this, 
any residual antibody is washed off. An enzyme labelled secondary antibody is 
then added which, on addition of a substrate, gives off a colour signal which can 
be read using a spectrophotometer and is directly proportional to the amount of 
enzyme (and consequently antigen) on the plate. Non-specific binding of the 
secondary antibody was checked in pepsin ELISA 1 by running the samples in 
duplicate, with and without the addition of the capture antibody and subtracting 
any fluorescence resulting from non-specific binding of the secondary antibody 
from the results. 
The most robust ELISA format (and hence, the common format of commercial 
assays) is the ‘sandwich’ ELISA. This utilises two primary antibodies to different 
epitopes of the antigen of interest, increasing the specificity of the assay. The 
first antibody is immobilised onto the plate and used to capture the antigen of 
interest. Following a wash step, to remove any unbound antigen, the second 
enzyme labelled antibody is added. The enzyme dependant colour change is 
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observed and can be measured by spectrophotometer on addition of the 
substrate solution (Figure 5.1). 
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Figure 5.1 Schematic diagram to show the difference between an indirect and sandwich 
ELISA format 
The antigen is labelled ‘Ag’. The primary antibody is labelled red and the secondary antibody is 
labelled green. HRP is an abbreviation for horseradish peroxidase, the common enzyme used for 
detection in ELISA assays. 
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5.3.3 Western blotting 
WB analysis provides the advantage of being able to differentiate positive signal 
due to pepsin, pepsinogen, or other interfering proteins because proteins are 
separated by molecular weight. Therefore, any difficulties with non-specific 
binding are clearly visible on analysis, an advantage over ELISA. However, the 
main disadvantage of WB is that it is only semi quantitative. The assay used for 
sample analysis in this chapter utilises a polyclonal anti-human pepsin A 
antibody. Johnston et al previously demonstrated that this antibody does not 
cross react with gastricsin or cathepsin D and has very low level cross-reactivity 
with pepsinogen A (N. Johnston, Knight, Dettmar, Lively, & Koufman, 2004). Any 
cross reactivity with pepsinogen A in samples would be clearly visible by 
differences in molecular weight on WB.  
5.3.4 Alpha-amylase activity assay 
Alpha-amylase is an enzyme, which has various isoforms and is predominantly 
found in pancreatic juice or in saliva in humans (Ferey-Roux et al., 1998; Hirtz 
et al., 2005). It’s function in saliva is to start the digestive process through 
hydrolysis of alpha bonds in large polysaccharides (such as starch and glycogen) 
(Ragunath et al., 2008). In this study, a commercially available alpha amylase 
activity kit (Abcam) was used for measurement of alpha amylase activity in BAL 
supernatants. The assay is based on specific cleavage of ethylidene-pNP-G7 by 
alpha amylase to smaller fragments, which can be acted upon by alpha-
glucosidase, leading to release of a chromophore. Chromogenic methods offer 
superior linearity, sensitivity and precision over previous saccharogenic 
(measuring the production of maltose or glucose) or amyloclastic (measuring the 
disappearance of a substrate) methods (Foo & Rosalki, 1986). Of the 
chromogenic methods available, specific cleavage of ethylidene-pNP-G7 and its 
subsequent reaction with alpha-glucosidase has been approved as the method of 
choice for unambiguous, robust measurement of alpha amylase (Lorentz, 2000). 
 148 
5.4 Results 
5.4.1 Lipid laden macrophages 
1/16 PICU-ND, 6/12 Elective-ND and 2/10 healthy control BAL specimens showed 
occasional alveolar macrophage cytoplasm lipid staining. None of these slides 
reached the criteria for a positive report on review by the local cytopathologist. 
5.4.2 Published ELISA methods for measurement of pepsin in 
BAL are not robust 
Standard curves generated for pepsin ELISA 1 and 2 were found to be consistent 
and reproducible (Figure 5.2 (a)). 
Spike and retrieval experiments were carried out as detailed in Section 2.4. 
Mean [SD] % spike recovery was found to be 16.4% [23.3] for ELISA 1 and 80.8% 
[46.9] for ELISA 2 on assessment in three samples (performed in at least 
duplicate). Figure 5.2 (b) shows that mean (SD) percentage spike retrieval 
improved with dilution of samples when analysis was performed using ELISA 1 
and that recovery was worse with concentrated PICU samples. These results 
imply that BAL sample matrix interferes with antibody function and that this 
interference is reduced with sample dilution. Serial dilution (neat, 1:2, 1:5 and 
1:10) of two PICU patient samples for analysis using ELISA 2 revealed poor 
linearity of dilution and subsequently Figure 5.2 (c) shows an apparent rising 
reported pepsin level with higher sample dilution (following correction for 
dilution). 
The intra-assay coefficient of variation was calculated for 37-40 results (a range 
of PICU and healthy control samples), assayed in duplicate on the same plate 
and was found to be 3.94% for ELISA 1 and 9.05% for ELISA 2. The inter-assay 
coefficient of variation was calculated from repeated analysis of 3 samples on 
different days and was found to be 30.56% for ELISA 1 and 62.68% for ELISA 2. 
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Table 5-1 Table to show spike and recovery data and inter/intra-assay coefficients of 
variation for pepsin ELISA 1 and pepsin ELISA 2 
 Pepsin ELISA 1 Pepsin ELISA 2 
Inter-assay coefficient of variation (%CV 
(n=3/assay) 
30.56 62.68 
Intra-assay coefficient of variation (%CV 
(n=37-40/assay) 
3.94 9.05 
Spike retrieval (mean % (SD) (n=4-
6/assay) 
16.4[23.33] 80.8[46.9] 
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Figure 5.2 Published ELISA methods for measurement of pepsin are not robust when used 
with paediatric BAL 
(a) Example standard curves for ELISA 1 and ELISA 2 (b) Bar chart to show mean (SD) pepsin 
spike retrieval following spiking two samples (a PICU sample and a healthy control sample) at a 
range of dilutions, compared to retrieval of an identical spike in reagent diluent using pepsin ELISA 
1. Spike retrieval was worse in the PICU sample and improved in both the PICU and control 
samples with sample dilution. (c) Line graph to show pepsin measurements in two PICU samples, 
assayed in duplicate at various dilutions. Poor linearity of dilution was seen and therefore, on 
correction for dilution, rising reported pepsin levels were observed at higher dilutions. 
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Following concern about the validity of ELISA 1 and 2 for analysis of pepsin in 
paediatric BAL (specifically, poor linearity of dilution and spike retrieval and 
high inter-assay variability), samples were analysed by WB analysis using a 
polyclonal human pepsin antibody. Disagreement was observed on comparison of 
results for three samples analysed by the three pepsin assays (two ELISAS and 
one WB) both in reporting the presence or absence of pepsin and in the 
quantification of pepsin (Figure 5.3 (a)).  
5.4.2.1 Anti-porcine pepsin antibodies used in published pepsin 
ELISAs are susceptible to non-specific binding to other 
BAL proteins 
Ten microlitres of four different BAL samples were analysed by WB for pepsin A 
(porcine pepsin antibody WB protocol, Section 2.5.2.1) using primary (1:5000 
dilution) and secondary antibodies from ELISA 1 and ELISA 2 and also secondary 
antibodies alone (to assess any non-specific binding of the secondary antibody). 
The primary antibody in ELISA 1 showed non-specific binding to a BAL protein 
with a higher molecular weight than porcine pepsin (Figure 5.3 (b)). Notably, 
the extent of non-specific binding was variable across samples. Both the primary 
and secondary antibodies in ELISA 2 showed variable non-specific binding to a 
BAL protein with a higher molecular weight than porcine pepsin (Figure 5.3 (c)).  
Ten microlitres of three BAL samples spiked with 100ng porcine pepsin were also 
analysed by porcine pepsin WB (Section 2.5.2.1). The protein which the 
antibodies non-specifically bind to was clearly shown to be at a higher molecular 
weight than porcine pepsin (Figure 5.3 (d)).  
One hundred nanograms of human pepsin and porcine pepsin were ‘spiked’ into 
(a) dH20 and (b) BAL (P80) and analysed by porcine pepsin WB. Human pepsin 
was shown to run at a slightly lower molecular weight compared to porcine 
pepsin on WB. The unidentified protein was unlikely to be pepsinogen as the 
lower limit of detection of the porcine pepsin WB was 10ng. Therefore, levels of 
over 1000ng/ml would need to be present for detection on loading a 10ul 
sample. 
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Figure 5.3 WB images and histogram to show (a) conflict between BAL pepsin results using 
ELISA and WB analysis (b-e) non specific binding of porcine pepsin antibodies used in 
published ELISA assays to other BAL proteins 
(a) Histogram to show pepsin measurements in three BAL samples (two Elective-ND samples and 
one PICU-ND sample) by quantification using ELISA 1 and ELISA 2. Western blot image showing 
results of the same three samples analysed by WB, using a polyclonal antibody to human pepsin. 
Conflicting results are demonstrated in both identification of pepsin (between ELISA and WB 
methods) and quantification of pepsin (between ELISA methods 1 and 2). (b) (c) WB images to 
show analysis of four 10ul aliquots of different BAL samples (P4, P7, P24, P80) and a 100ng 
porcine pepsin control (C) by WB using (b) antibodies from pepsin ELISA 1 and (c) antibodies from 
pepsin ELISA 2. No pepsin was detected in the samples using this method (lower limit of detection 
optimised to 10ng porcine pepsin). However, variable cross reactivity was observed between 
porcine pepsin antibodies used in ELISA 1 and 2 and another BAL protein (shown by bands which 
appear to be at a higher molecular weight than pepsin). (d) WB image (porcine pepsin WB 
methods) to show analysis of 10ul of three BAL samples, spiked with 100ng porcine pepsin (2,3,4) 
compared to a porcine pepsin control in water (1). Variable non-specific binding to a protein at a 
higher molecular weight to pepsin is clearly shown. (e) WB image (porcine pepsin WB methods) 
showing identification of 100ng porcine pepsin (1) and 100ng human pepsin (2) at approximately 
35kDa. Human pepsin is identified at a slightly lower molecular weight than porcine pepsin by this 
method and analysis of two BAL sample aliquots (10ul) spiked with 100ng porcine pepsin (3) or 
100ng human pepsin (4) clearly demonstrates that the BAL protein which the porcine pepsin 
antibodies cross react with is not human pepsin. 
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5.4.3 Pepsin WB results 
Forty four BAL samples were tested for the presence of pepsin using a WB 
technique with a polyclonal antibody for human pepsin. 6/19 PICU-ND samples 
(32%), 1/10 (10%) healthy control samples and 1/16 (6%) Elective-ND samples 
were positive. All samples which were positive had bands of greater density than 
a 5ng human pepsin loading control. PICU-ND patients who were positive had 
been ventilated for between 2 and 27 hours. 3/6 BAL pepsin positive PICU-ND 
patients had undergone a fundoplication procedure and 2/3 of these patients 
still had symptoms suggestive of GORD. 1/3 did not report symptoms suggestive 
of GORD but remained on anti-reflux medication. No significant differences were 
observed in BAL inflammatory markers, LRSQ-Neuro scores or GORD symptom 
scores between pepsin positive and negative PICU-ND patients. The BAL pepsin 
positive healthy control patient had no respiratory symptoms, no GORD 
symptoms and did not have raised lower airway inflammatory markers. 
A spike-recovery experiment was conducted to test whether pepsin band density 
was equal for identical pepsin spikes in healthy control and PICU samples, in 
order to verify whether densitometry could be used to give an indication of the 
level of pepsin positivity in samples. 2ng and 1ng of pepsin were spiked into 
dH20, a healthy control sample and a PICU sample (with high protein content). 
Figure 5.4 demonstrates that although the spikes were visible in all samples, 
the band density appeared to be affected by sample protein content. Therefore, 
no inferences could be made about the level of pepsin in patient samples using 
densitometry and normalisation to a loading control. Figure 5.4 also 
demonstrates that the non-specific binding experienced with the porcine pepsin 
antibodies in BAL did not occur with the human pepsin antibody. 
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Figure 5.4 Western blot image (a) and corresponding ponceau stained PVDF membrane (b) 
to show effect of sample protein content on pepsin spike WB band density.  
1 and 2ng purified human pepsin were spiked into water, a 10ul healthy control sample (1ug total 
protein in 10ul) and a 10ul PICU-ND sample (9ug total protein in 10ul). Image (a) shows WB 
analysis of 1. dH20, 2. dH20 + 1ng human pepsin, 3. dH20 + 2ng human pepsin, 4. 10ul healthy 
control sample, 5. 10ul healthy control sample + 1ng human pepsin, 6. 10ul healthy control sample 
+ 2ng human pepsin, 7. 10ul PICU-ND sample, 8. 10ul PICU-ND sample + 1ng human pepsin, 9. 
10ul PICU-ND sample + 2ng human pepsin. The lower band density in the spiked PICU-ND 
samples implies sample interference with antibody binding. Image (b) shows the PVDF membrane 
post ponceau staining and confirms the increased protein content of the PICU-ND sample (lanes 7, 
8 and 9).  
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5.4.4 Measurement of alpha amylase activity in BAL  
Standard validation methods (as described in Section 2.4) were used to assess 
the function of the alpha amylase activity assay (Abcam UK, methods as detailed 
in Section 2.4.7) across a range of PICU and healthy control BAL samples. Good 
spike recovery and low inter and intra-assay variability were shown. Further 
validation of results by a second method of alpha amylase measurement is 
detailed in Section 5.4.4.1. 
5.4.4.1 Significant correlation is observed between BAL alpha 
amylase activity levels and label free relative quantification 
of alpha amylase peptide ion intensity by LC-MSMS 
analysis 
BAL alpha amylase activity results for eight preliminary samples were compared 
to results of discovery run proteomic analysis of the same eight samples using 
the LTQ Orbitrap Velos (as described in Section 2.8.7) followed by label free 
quantitative analysis of relative ion abundance using Progenesis LC-MS Nonlinear 
Dynamics software (as detailed in Section 2.8.9). Alpha amylase protein was 
identified in all samples by detection of five unique peptides to alpha amylase, 
post trypsin proteolysis. Figure 5.5 (c) shows a significant correlation between 
alpha amylase activity and combined relative ion intensity for the unique 
peptides used in the identification of alpha amylase by MSMS analysis (r +0.91, 
p=0.002). 
5.4.4.2 Median BAL alpha amylase activity is significantly 
increased in Elective-ND patients compared to healthy 
controls 
Alpha-amylase activity was measured in BAL supernatants from healthy control 
patients (n=10), Elective ND patients (n=16) and PICU ND patients (n=18). Alpha-
amylase was detected in 97.8% samples. Median activity was significantly 
increased in Elective-ND patients compared to healthy controls (100.2[46.4-597] 
vs. 26.9[9-71.4] U/L, p=0.012). There was no statistically significant difference 
between PICU ND samples (54.2[14.8-254.4] U/L) and healthy controls (p=0.415). 
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5.4.4.3 Median BAL alpha-amylase activity is significantly lower in 
ND patients receiving anti-cholinergic medications 
Median BAL alpha-amylase activity levels were compared between those children 
with ND who were taking anti-cholinergic medications (n=8) and those who were 
not on any medical salivary management (n=27). There was no significant 
difference in time since intubation between those PICU-ND children who were on 
salivary management (n=5) compared to those who were not (n=13, p=0.754). 
Therefore, the Elective ND and PICU ND groups were combined for this analysis 
without concern about differences in ventilation time (and subsequent relative 
airway protection) between groups. Median BAL alpha amylase activity levels 
were significantly lower in those who were on medical salivary management 
compared to those who were not (11.5[1.5-51.2] vs. 78.1[44.8-434.5] U/L 
respectively, p=0.010). 
5.4.4.4 Relationship between time since intubation in PICU-ND 
patients and BAL alpha amylase activity  
Time since intubation (hours) was noted on recruitment of PICU-ND patients. On 
plotting this against measured BAL amylase activity, no correlation was observed 
(r=-0.114 p=0.652). 
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Figure 5.5 Results of alpha-amylase activity measurement in BAL 
(a) Vertical scatter graph showing significantly increased median BAL amylase activity levels 
(measured using an ethylidene-pNP-G7 assay (Abcam, UK)) in Elective-ND patients compared to 
healthy control patients (100.2[46.4-597] vs. 26.9[9-71.4 U/L, p=0.012). (b) Vertical scatter graph 
showing significantly lower BAL amylase activity levels in those patients with ND who were 
prescribed anti-cholinergic medications compared to those on no medical salivary management 
(11.5[1.5-51.2] vs. 78.1[44.8-434.5] U/L, p=0.010). (c) Scatter graph showing a positive correlation 
between BAL alpha amylase activity and relative ion intensity for peptides used in the identification 
of alpha amylase by MSMS analysis of eight BAL samples (r +0.91, p=0.002). (d) Scatter graph to 
show a trend towards negative correlation between BAL alpha amylase activity levels and time 
since intubation in PICU-ND patients. 
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5.4.5 BAL inflammatory markers correlate with BAL alpha 
amylase activity levels in Elective-ND patients 
BAL alpha-amylase activity levels positively correlated with BAL neutrophil levels 
in Elective-ND patients (n=16, r +0.81, p<0.001). BAL IL-8 and TGF-1 levels also 
positively correlated with BAL alpha-amylase activity levels in this group (n=16, r 
+0.77, p<0.001 and r+0.66, p=0.005, respectively) (Figure 5.6 (a), (b) and (c)).  
5.4.6 Relationship between BAL alpha amylase activity levels and 
microbial DNA positivity in elective patients 
Alpha-amylase activity levels were compared between BAL microbial rDNA 
positive elective patients (n=18) and BAL microbial rDNA negative elective 
patients (n=7). Microbial rDNA detection was assessed using SepsiTestTM (Molzym, 
Bremen), as detailed in Section 2.6.5. There was no statistically significant 
difference in median BAL alpha amylase activity level between the groups 
(70.7[15.7-546.3] vs. 51.2[16.9-72.6] U/L, p=0.495). However, the ranges were 
markedly different (7.06-929.2 U/L vs. 10.8-72.6 U/L) (Figure 5.6 (d)). 
5.4.7 Relationship of BAL alpha amylase activity levels and VFS 
assessment results 
There were insufficient patient numbers in the Elective-ND group who had 
undergone VFS assessment to make meaningful comparisons of BAL alpha 
amylase activity levels between VFS positive and negative patients. 
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Figure 5.6 BAL inflammatory markers correlate with BAL alpha amylase activity levels in 
Elective-ND patients 
Scatter graphs to show positive correlations between BAL alpha amylase activity and (a) BAL 
neutrophils (r+0.81, p<0.001), (b) BAL IL-8 (r+0.77, p<0.001) and (c) BAL TGF-1 in Elective-ND 
patients (r+0.66, p=0.005). (d) Vertical scatter graph to show the relationship of BAL microbial 
rDNA status with BAL alpha amylase activity in all elective patients (healthy control and Elective-
ND groups).  
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5.5 Discussion 
In this chapter, a thorough investigation of two novel BAL biomarkers of reflux 
and direct aspiration has been presented. Concerns were highlighted about the 
validity of two published pepsin ELISA assays when used with paediatric BAL 
samples and furthermore, disagreement between results from pepsin analysis by 
WB and ELISA techniques was documented. WB results indicated a higher 
frequency of BAL pepsin positivity in ND patients ventilated on PICU with a 
respiratory deterioration, suggesting pepsin may be useful as a biomarker of 
acute reflux aspiration. However, no firm conclusions can be drawn about the 
utility of this biomarker until an accurate method of BAL pepsin quantification is 
validated, due to occasional detection of pepsin in asymptomatic controls. Thus, 
the presence or absence of BAL pepsin becomes less relevant in the investigation 
of pepsin as a biomarker of pathological reflux aspiration and the question of 
whether there are significant differences in BAL pepsin load in those who are 
symptomatic becomes more important. Contrastingly, the alpha amylase activity 
assay (Abcam, UK) appears to be robust when used with paediatric BAL. We 
found significantly increased BAL alpha amylase levels in Elective-ND patients 
compared to healthy controls, suggesting this may be a useful biomarker of 
chronic direct aspiration. The correlation between BAL alpha amylase activity 
and lower airway inflammatory markers in Elective-ND patients suggests that the 
degree of chronic aspiration may be directly linked to lower airway pathology in 
these patients. 
It was surprising not to find any BAL lipid laden macrophage positivity in this 
study, particularly considering the finding of likely aspiration in some study 
participants, as indicated by clinical assessments and other biomarkers. This 
could be explained by the need for conservative reporting of lipid laden 
macrophage positivity due to it’s poor specificity as a test for aspiration, now 
widely acknowledged within the literature (Reid-Nicholson et al., 2010). Most 
authors support the view that lipid laden macrophage positivity can, at best, be 
viewed as supporting evidence of aspiration rather than diagnostic (Boesch et 
al., 2006). However, nine slides were reviewed by a local cytopathologist due to 
occasional staining of lipid laden macrophages (none of which ultimately fulfilled 
the criteria for a positive report); none of these samples were positive for pepsin 
by WB analysis and there was no correlation with BAL amylase. These findings 
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support previous researchers’ conclusions about the poor specificity and 
sensitivity of BAL lipid laden macrophages as a biomarker of reflux aspiration 
(Colombo et al., 1986; Ding et al., 2002; Knauer-Fischer & Ratjen, 1999; Reid-
Nicholson et al., 2010; Rosen et al., 2008). 
When clinical specimens are analyzed by ELISA, antibody interference is always 
possible and particularly so when dealing with potentially thick and 
proteinaceous samples such as BAL or sputum. A standard method of assay 
validation involves ‘spiking’ samples with known amounts of the protein of 
interest and then measuring retrieval (Administration). One study, reporting the 
validation of a pepsin ELISA, showed reasonable retrieval of high concentration 
spikes, but inadequate and, importantly, variable recovery at lower 
concentrations (100 ng/mL 50%-93% recovery; 10 ng/mL 27%-82% recovery) 
(Knight et al., 2005). This highlights how clinical samples from different 
individuals can interact and interfere variably with assay efficiency. We 
conducted similar experiments using two published ELISAs on paediatric BAL 
samples. We found evidence of variable non-specific antibody binding and 
sample interference as well as high inter-assay variability. These findings are 
important, particularly considering the wide range of methods used for 
measuring pepsin within the literature and incongruity of study results, as 
discussed in Chapter 1. 
The anti porcine pepsin antibodies used in ELISA 1 and 2 are known to be cross 
reactive with pepsinogen A. Although researchers have previously tested for 
cross reactivity with selected serum proteins (albumin, fibrinogen and gamma 
globulins), specific cross reactivity testing with other acidic proteases known to 
be present within the lung (such as pepsinogen C and cathepsin D) has not been 
documented (Tasker et al., 2002a). Recent BAL proteomic studies have 
highlighted the complexity of respiratory samples (Plymoth et al., 2006). 
Therefore, selective testing of antibody cross reactivity with predominant serum 
proteins would seem inadequate, particularly when utilising ELISA techniques, 
where non-specific antibody binding may not be easily recognised. We found 
variable non-specific binding of these antibodies to other unidentified proteins 
in BAL when used in WB analysis. These findings concur with those of He et al 
who documented non-specific binding of one of the porcine pepsin A antibodies 
used in both ELISA 1 and 2 to an unidentified serum protein at a slightly higher 
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molecular weight than pepsin (He et al., 2007). A commercial human pepsin 
ELISA (USCN life sciences) has recently become available and has been utilised in 
a small number of clinical studies. Lee et al recently documented a high overall 
incidence of BAL pepsin positivity in adults with idiopathic pulmonary fibrosis. 
However, no validation data was published for use of this ELISA with BAL (by 
either the manufacturer or the authors) and cross reactivity with pepsinogen is 
acknowledged by the manufacturers (J. S. Lee et al., 2012). ‘Peptest’ (RD 
Biomed, Hull, UK), a lateral flow device using two monoclonal human antibodies, 
has also recently become available for pepsin analysis. Again, no specific 
detailed BAL validation data was available on informal enquiry in 2010 and there 
has been no publication of specific data to support validation since this time. 
WB analysis offers increased transparency where there are concerns about non-
specific antibody binding, due to the separation of proteins by molecular weight. 
We undertook WB analysis using a polyclonal human pepsin antibody, previously 
shown not to cross-react with gastricsin or cathepsin D and to have very low 
cross reactivity with pepsinogen A (N. Johnston et al., 2004). Figure 5.4 
demonstrates that this antibody does not seem to be susceptible to non-specific 
binding to other BAL proteins on analysis by WB, despite high protein loads. This 
is in stark contrast to commercially available porcine pepsin antibodies, as 
highlighted in Figures 5.3 and 6.9. Unfortunately, WB analysis is semi 
quantitative at best and furthermore, Figure 5.5 demonstrates that BAL sample 
protein load can influence the density of the band visualised by WB for identical 
pepsin spikes, even when using a highly specific antibody. Therefore, attempts 
to partially quantify pepsin by WB techniques using densitometry would 
potentially yield misleading results. 
Our finding of 32% pepsin positivity in the PICU-ND group compared to a mean of 
8% in the electively recruited groups suggests that pepsin may be a useful 
biomarker of acute reflux aspiration. PICU-ND patients had been ventilated for 
various time periods before sampling and therefore, it is possible that the 
frequency of pepsin positivity may have been higher at the time of intubation. 
However, pepsin was detectable in one study recruit 27 hours post intubation, 
suggesting it may remain in the lungs for some hours post aspiration. The 
possibility of ongoing gastric aspiration during ventilation on PICU also needs to 
be considered, as highlighted by a series of studies by Methany et al who 
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measured pepsin (by WB) in serial tracheal aspirates in ventilated patients and 
suggested a potential for ongoing gastric aspiration over the period of ventilation 
(Kathleen L. Meert et al., 2002; K. L. Meert, Daphtary, & Metheny, 2004; N. A. 
Metheny et al., 2006; Norma A. Metheny, Schallom, Oliver, & Clouse, 2008). 
These studies also highlighted that acute gastric aspiration may occur in other 
patient groups ventilated on PICU. Therefore, without a PICU control group, we 
are unable to draw conclusions about either the risk of gastric aspiration during 
ventilation on PICU in ND patients compared to other patient groups or whether 
gastric aspiration was the cause of deterioration in children with ND in this study 
(or alternatively, whether it was a result of clinical deterioration and 
mechanical ventilation). Unfortunately, we were unable to recruit a PICU control 
group due to competing studies and limited patient numbers. Interestingly, BAL 
amylase activity levels within the PICU-ND group did not correlate with pepsin 
positivity and median BAL amylase activity was not significantly higher in the 
PICU-ND group compared to healthy controls, in contrast to the Elective-ND 
patient group who had significantly raised BAL amylase activity level. This might 
imply that the airway is actually reasonably well protected from further 
aspiration during paediatric ventilation, as one would expect continued salivary 
aspiration to accompany any gastric aspiration.  
It is noteworthy that the Elective-ND group had a low incidence of pepsin 
positivity (6%) by WB analysis. This could imply that regular micro aspiration of 
gastric contents is not common or alternatively that pepsin is not a good 
biomarker of chronic reflux aspiration. The latter seems more likely in view of 
the high incidence of GORD and salivary aspiration in this group. A potential 
limitation of pepsin as a biomarker of chronic reflux aspiration is that pepsin 
detection and quantification will be influenced by time since the last reflux-
aspiration event. Knowledge of the rate of clearance of pepsin from the lungs 
after an aspiration event is limited to animal data (Badellino et al., 1996; N. A. 
Metheny et al., 2004). Therefore, although the theoretical specificity of pepsin A 
as a biomarker of reflux-aspiration is high, the sensitivity may be limited. Large 
studies using reliable quantitative assays are needed to draw conclusions about 
whether there are significant differences between the level of BAL pepsin 
detected in healthy, asymptomatic individuals and those with likely pathological 
reflux-aspiration. Subsequently, robust conclusions could potentially be drawn 
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about the utility of pepsin as a clinical biomarker of acute or chronic aspiration 
and it’s clinical relevance could be studied through longitudinal studies. 
Our validation data supports the suitability of Abcam’s alpha amylase activity 
assay (based on amylase specific cleavage of ethylidene-pNP-G7) for use in BAL 
analysis. Previous studies of alpha amylase as a biomarker of direct aspiration 
have been limited (Clarke, Bain, Davies, et al., 1981; Nandapalan, McIlwain, & 
England, 1995; D. D. Smith & McNamara, 1976). Nandapalan et al clearly 
documented the presence of low levels of alpha amylase in the normal lung in 
their comparative study of undiluted tracheo-bronchial and salivary secretions in 
laryngectomized patients (Nandapalan, McIlwain, & England, 1995). In this 
study, salivary amylase activity measurements between 20-35,000 U/L were 
documented and the ratio of salivary to bronchial amylase in paired samples was 
30-600:1. The levels recorded in undiluted tracheo-bronchial secretions were 
unlikely to have been of serum origin in the population studied (no pancreatic 
disease) and the authors concluded that amylase is produced locally in the lung. 
We have recorded (for the first time) alpha amylase activity control 
measurements in paediatric BAL, collected according to ERS guidelines. Alpha 
amylase activity was detectable in 98% of all samples and this is in keeping with 
the presence of low levels of amylase in the normal lung, as well as the 
potential for minor salivary contamination of the sample following intubation 
and for minor aspiration during sleep (Gleeson et al., 1997). Significantly higher 
levels of amylase activity were observed in Elective-ND patients in comparison to 
healthy controls. All patients in the two elective groups were intubated under 
controlled conditions, following which BAL was collected using standardised 
techniques. Therefore it seems reasonable to conclude that differences in BAL 
amylase activity are likely to represent increased salivary aspiration in the 
Elective-ND group rather than contamination at intubation. The high levels 
reported in some Elective-ND patients (1000 U/L) also support the salivary origin 
of the amylase, taking into account the BAL dilution factor. Interestingly, 
median amylase activity in PICU-ND samples was not significantly raised 
compared to healthy controls, raising the possibility that airway protection by 
intubation may have led to lower BAL amylase activity levels in this group of 
patients, who were matched by age and disability level to the Elective-ND 
group. A negative correlative trend between amylase activity and time since 
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intubation was observed, although this did not reach statistical significance. 
Clearly, levels of BAL amylase activity at intubation would be varied between 
patients (as displayed in the Elective-ND group) and therefore, it would be more 
useful to investigate this through serial sampling in a larger PICU population. 
The correlation observed between BAL alpha amylase activity and inflammatory 
markers in Elective-ND patients is interesting and implies a direct relationship 
between degree of aspiration and lower airway inflammation. Fedrowitz et al 
documented anti-proliferative effects of alpha-amylase on rat mammary 
epithelial cells. However, there is no literature documenting the effects of alpha 
amylase on airway epithelial cells and further investigation of this is warranted 
(Fedrowitz, Hass, Bertram, & Löscher, 2011). It may be that alpha amylase is not 
directly damaging to airway epithelial cells and that other elements of the 
aspirate, such as bacterial and gastric contents are the cause of aspiration 
associated lower airway inflammation. Further study of the relationship of BAL 
alpha amylase activity and microbiology would be of interest and this is 
supported by the relationship between BAL amylase levels and microbial rDNA 
positivity observed in this study.  
When assessing alpha amylase as a biomarker of direct aspiration it is essential 
to consider conditions in which pulmonary amylase levels are known to be 
raised. Pulmonary hyperamylasaemia has been shown (on direct testing of 
pulmonary effusions) in a variety of conditions including pancreatic disease, 
pulmonary malignancy, tuberculosis and parapnuemonic effusions (Joseph et al., 
1992; G. D. Lee et al., 2003; Villena et al., 1995; Villena et al., 2002). However, 
the amylase activity levels recorded in effusions from patients with pancreatic 
or malignant disease were by far the highest in a series of 841 patients studied 
by Villena et al; effusion amylase activity levels in infective and cardiac causes 
being consistently lower (<500U/L). Considering that amylase activity levels of 
double this were measured in dilute BAL samples in certain patients in our study, 
it seems likely (on the basis of the available literature) that the BAL amylase 
activity measured was of salivary rather than pulmonary origin. Furthermore, 
the finding of no significant difference in BAL amylase activity between PICU-ND 
and healthy control patients also provides supportive evidence that local 
production of pulmonary amylase is not consistently triggered by lower airway 
inflammation/infection. However, in order to draw firm conclusions, further 
 166 
study of BAL alpha amylase activity levels would need to be conducted in a large 
cohort of paediatric patients at high and low risk of aspiration and with a range 
of pulmonary conditions, using standardised BAL collection techniques. If clear, 
definable differences were demonstrable between ‘normal’ BAL alpha amylase 
levels and BAL alpha amylase levels in those at high risk of aspiration, then BAL 
alpha amylase may evolve into a useful clinical and research marker of direct 
aspiration. 
Future work should focus on the development of robust quantitative techniques 
for measurement of pepsin in BAL. Researchers should subsequently aim for 
standardisation of measurement techniques across studies in order to draw firm 
conclusions about the utility of pepsin as a biomarker of acute or chronic gastric 
aspiration. Further research investigating alpha amylase as a potentially useful 
biomarker of direct aspiration should focus on development of paediatric and 
adult normative values. Subsequent longitudinal study of clinical outcomes in 
relation to BAL alpha amylase levels and their relationship to lower airway 
microbiology would potentially increase knowledge of the clinical consequences 
of aspiration in children with ND and also other patient groups, for example, in 
the study of ventilator associated pneumonia in intensive care patients.  
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  Chapter 6 - Development of a novel assay for 
quantification of pepsin in BAL 
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6.1 Introduction 
Designing an assay for accurate quantification of specific proteins in clinical 
samples is challenging, due to the effects of other substances within the sample 
matrix. We have highlighted how clinical samples from different individuals can 
interact and interfere variably with assay efficiency and accuracy, 
demonstrating contrasting results from three different immunological pepsin 
assays on repeated BAL sample analysis (Chapter 5). 
Key properties of a high quality clinical assay are confident protein 
identification, accurate quantification and consistency across all samples. 
However, the previously published ELISA assays for measurement of pepsin in 
BAL showed susceptibility to variable non-specific antibody binding (limiting 
reliability of pepsin identification) and sample interference with antibody 
function (limiting accuracy of quantification) (Ervine et al., 2009; Stovold et al., 
2007). Western blotting is potentially a more robust method of BAL protein 
analysis, although this technique is semi-quantitative at best (Rosen et al., 
2012). In investigating pepsin as a biomarker of reflux aspiration, it is essential 
to establish an accurate quantitative assay technique because low levels of 
pepsin may be detected in healthy, asymptomatic individuals; there is a high 
incidence of physiological gastro-oesophageal reflux in children and the 
aspiration of nasopharyngeal secretions is common during sleep (Gleeson et al., 
1997; Ramaiah et al., 2005). Following quantitative assay development, clear 
demonstrable differences in BAL pepsin level between those with physiological 
reflux-aspiration who are asymptomatic and those who have pathological reflux 
aspiration would need to be demonstrated in order for pepsin to be hailed a 
useful BAL biomarker of reflux aspiration. Authors have highlighted assay 
standardisation as a priority, so that normative values can be established for 
paediatric and adult age groups (Davis et al., 2010). 
In view of the limitations of antibody-based assays for detection of pepsin in 
BAL, this chapter focuses on the development of an assay that uses mass 
spectrometry, the gold standard for protein identification (Pusch, Flocco, Leung, 
Thiele, & Kostrzewa, 2003). Mass spectrometers analyse the mass to charge ratio 
(m/z) of ionised molecules. Protein identification is by matching acquired 
peptide m/z to those in a database of theoretical protein digests; peptide 
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fingerprint mapping (Nielsen, Savitski, & Zubarev, 2005). Neubert et al recently 
developed a nanoflow liquid chromatography-tandem mass spectrometry (LC-
MSMS) assay for measurement of pepsin A and its precursor, pepsinogen A, in 
saliva (Neubert, Gale, & Muirhead, 2010). They utilised a peptide immuno-
affinity enrichment technique and multiple reaction monitoring (MRM) to 
increase assay sensitivity and specificity. 
The aim of this chapter was to develop a similar LC-MRM-MS assay but with an 
affinity enrichment step using the potent inhibitor of pepsin, pepstatin A. To our 
knowledge, inhibitor affinity enrichment has not been used for these purposes 
previously and it offers potential advantages over immuno-affinity methods, as 
discussed in Section 1.1.2. A number of preliminary experiments were required 
in order to confirm the feasibility of this proposed method prior to more 
detailed LC-MS assay development. The results of these experiments are 
presented in this chapter.  
6.1.1 Pepsin 
Pepsin, an aspartic protease, is the primary proteolytic enzyme of the digestive 
system. There are two broad categories of pepsin in human gastric juice; pepsin 
A (four different isoforms: pepsin 1, pepsin 3a, pepsin 3b and pepsin 3c) and 
pepsin C (gastricsin). Previous studies have established a high degree of 
homology between the four pepsin A isoforms (A. T. Jones & Roberts, 1992). 
Pepsins 3b and 3c differ only by one amino acid substitution and are the 
products of genes PGA5 and PGA3, respectively. Pepsin 3a differs by three amino 
acid residues and corresponds to gene PGA4. A much lower degree of homology 
is seen between gastricsin (gene PGC) and other human pepsins (A. T. Jones & 
Roberts, 1992). High performance ion exchange chromatography of human 
gastric juice has highlighted pepsin 3b as the most abundant gastric pepsin 
(66%), followed by gastricsin (20%) and lastly pepsins 3a, 3c and 1 (14%) (A. T. 
Jones, Balan, et al., 1993). 
The chief cells within the stomach lining produce pepsin as an inactive precursor 
to prevent host tissue damage and self-autolysis. Pepsinogen A and pro-gastricsin 
are the precursors of pepsin A and C, respectively (A. T. Jones, Keen, & Roberts, 
1993). These precursors, which are released on eating, have a ‘pro-segment’ at 
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their N terminus (47 residues in the case of pepsinogen A) that blocks the active 
site of the enzyme. Under acidic conditions (< pH 3), the pro-segment is 
autolytically removed, leaving a functional active site (Richter, Tanaka, & Yada, 
1998). The pH dependence of the conversion of these zymogens to their active 
form is proposed to be due to the electrostatic interaction of basic residues in 
the pro-segment and acidic residues in the active enzyme (Richter et al., 1998). 
The enzymatic activity of human pepsin A is pH dependent, having maximal 
activity at pH 2, becoming inactive at pH 6.5 and remaining structurally stable 
up to pH 8 (Nikki Johnston et al., 2007). Johnston et al found that human pepsin 
3b retains approximately 79% of its enzymatic activity on re-acidification 
following exposure to pH 7 for twenty-four hours (Nikki Johnston et al., 2007). 
Pepsin A is potentially a useful biomarker of gastric aspiration, as it is not known 
to be produced in extra-gastric tissues. However, pepsinogen C (the precursor of 
gastricsin) has been shown to be produced by type 2 alveolar cells where it has a 
role in the proteolytic processing of surfactant protein B (Elabiad & Zhang, 2011; 
Foster et al., 2004; Gerson et al., 2008). Cathepsin D, another aspartic protease 
sharing a high degree of homology with pepsin, is also known to be produced 
within the lungs and furthermore, to be increased in inflammatory and infective 
pulmonary conditions (Bewley et al., 2011; Plymoth et al., 2006; Shewale & 
Tang, 1984). It is essential therefore, that any assay used to investigate pepsin 
as a biomarker of gastric aspiration is capable of confidently differentiating 
progastricsin and cathepsin D from pepsinogen A and pepsin A, a little-
recognised limitation of some previous enzymatic and immunological methods 
(Rosen et al., 2012; Samuels & Johnston, 2010). 
Interestingly, there is a high degree of homology between human pepsin 3b and 
porcine pepsin A, indicating the potential use for porcine pepsin A, which is 
readily commercially available, as a surrogate for human pepsin 3b in assay 
development (Figure 6.1) (A. T. Jones & Roberts, 1992). 
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Figure 6.1 Amino acid sequence alignment for porcine pepsin and human pepsinogen A 
(PGA 5, corresponding to human pepsin 3b). 
a. Amino acid sequence alignment (produced using ClustalW2 (www.ebi.ac.uk/Tools/clustalw2)) of 
porcine pepsin (PEPA_PIG) and human pepsinogen A (PEPA5_HUMAN), following retrieval of 
protein sequences from the Universal Protein Resource (Uniprot (www.uniprot.org)). Key: (*) 
identical. (:) conserved substitution. (.) semi-conserved substitution. (red) small, hydrophobic, 
aromatic, not Y. (blue) acidic. (magenta) basic. (green) hydroxyl, amine, amide, basic.  
b. Graph to show the degree of similarity between the amino acid sequences of porcine pepsin 
(PEPA_PIG) and human pepsinogen A (PEPA5_HUMAN), created using Expasy SIM (alignment 
tool for protein sequences, available at web.expasy.org/sim/) and Lalnview (a graphical program for 
visualising local alignments between two sequences, available at pbil.univ-
lyon.fr/software/lalnview.html). A similarity score of 1706, identity of 83.9% and gap frequency of 
0.8% was reported.  
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6.1.2  Affinity enrichment 
Although there are concerns about antibody production and selectivity, ELISA 
methods continue to offer superior sensitivity over mass spectrometry (MS) 
techniques (Shi et al., 2012). Strategies employed to increase MS sensitivity and 
limit matrix effects of proteinaceous samples include multiple reaction 
monitoring (MRM, discussed in Section 6.3.3.3) and immuno-affinity techniques. 
Ackermann and colleagues describe the use of these techniques to enable 
quantitative MS analysis of sub-nanogram levels of low abundance proteins in 
clinical samples (Ackermann & Berna, 2007). 
Affinity enrichment entails isolation of the protein or peptide of interest from 
the sample matrix, allowing presentation in a purified (reducing matrix effects) 
and concentrated (increasing sensitivity) format for MS analysis. Antibodies are 
commonly utilised for this purpose. Neubert et al (2010) achieved affinity 
enrichment and MS quantification of human pepsinogen A/pepsin A in salivary 
samples using endoproteinase AspN for sample digestion, then enrichment at the 
peptide level using an antibody which was directed against a human pepsinogen 
A and subsequently, pepsin A C-terminal sequence. However, the authors 
acknowledged that their technique relied upon the ability to consistently 
generate an anti-peptide antibody of high quality (Neubert et al., 2010). 
It was hypothesised that pepstatin A, a potent inhibitor of pepsin, could similarly 
be used for affinity enrichment at the protein, rather than the peptide, level. 
This would theoretically allow both selective retrieval of pepsin with an active 
site and eliminate the need for high quality antibody generation.  
6.1.3 Pepstatin A 
Pepstatin A is a potent inhibitor of the aspartic proteases pepsin, cathepsin D, 
renin and chymosin. It non-covalently binds pepsin by a complex interaction at 
the active site of the protein. Pepsin subsequently undergoes a conformational 
change to enclose the inhibitor tightly (Figure 6.2) (Fujinaga, Chernaia, 
Tarasova, Mosimann, & James, 1995). 
The potential use of bead immobilised pepstatin A for affinity enrichment offers 
selectivity for retrieval of pepsin with an active site. Critical assessment of novel 
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biomarkers of reflux-aspiration includes questioning the specificity (gastric 
origin) of the biomarker. Although pepsinogen A has not been shown to be 
produced by extra-gastric tissues, it is present at low levels in serum (Oishi et 
al., 2006). Therefore, previous researchers have gone to lengths to demonstrate 
no antibody cross reactivity with pepsinogen A when using antibody based 
methods for pepsin detection (Knight et al., 2005; Rosen et al., 2012). 
Pepstatin-A affinity enhancement offers selectivity for activated pepsin; it is 
unable to bind pepsinogen A unless it has encountered low pH values (<pH3) and 
been converted to active pepsin (Campos & Sancho, 2003). Production of 
pepsinogen A at a higher pH (extra-gastric) would lead to sustained active site 
blockage by the pro-peptide sequence. Therefore, it is reasonable to conclude 
that pepsin retrieved by pepstatin A is likely to originate from the stomach.  
Should gastric pepsin be aspirated into the lungs, it will encounter pulmonary 
epithelial lining fluid (pELF). A review of available evidence suggests that pELF 
pH is likely to be mildly acidic (Fischer & Widdicombe, 2006). BAL samples 
collected from recruits to this study ranged from pH 5.5-7.4. Researchers have 
demonstrated (via spectroscopic structural characterisation studies) that despite 
a structural change in pepsin to an intermediate conformation between pH 4 and 
pH 6.5, the strength of subsequent pepsin-pepstatin binding remains unchanged 
(Campos et al 2003). However, their studies indicated that pepsin-pepstatin 
binding might not occur at pH 9, likely due to irreversible protein denaturation 
(Campos & Sancho, 2003). 
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Figure 6.2 Schematic diagrams of human pepsin A structure and it’s interaction with 
pepstatin  
a.b. Human pepsin/pepsinogen A ‘identification’ peptides QYFTVFDR and ANNQVGLAPVA are 
highlighted in orange and green (explained in Sections 6.5.1 and 6.5.2). All atoms are labelled for 
the four disulphide bonds. Pepstatin is represented in blue spheres, showing it’s position of 
interaction within the active site of pepsin.  
c. Shows pepsin with a rendered surface, demonstrating how pepsin (grey) tightly encloses 
pepstatin (blue spheres) within the active site. All images generated using Pymol (http://pymol.org). 
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6.2 Aims 
To establish the feasibility of using immobilised pepstatin A to extract active 
pepsin from paediatric BAL matrix for subsequent LC-MRM-MS analysis, we aimed 
to: 
(i) Identify the predicted peptides generated by trypsin digestion of human and 
porcine pepsin A and their suitability for MS analysis, subsequently providing 
‘proof of concept’ through preliminary experiments using porcine pepsin A, 
pepstatin A agarose beads and MALDI-TOF mass spectrometry analysis. 
(ii) Optimise conditions for (a) binding porcine pepsin A to pepstatin A agarose 
beads in paediatric BAL matrix and (b) subsequent release of pepsin from beads 
for LC-MSMS analysis, using SDS-PAGE gel and Western blot (WB) analysis. 
(iii) Establish an LC-MRM-MS assay for detection of porcine pepsin (for proof of 
concept) and subsequently human pepsin in BAL. 
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6.3 Specific methods 
6.3.1 Peptide mapping 
Trypsin is the most commonly used enzyme for proteolysis in mass spectrometry 
(Rodriguez, Gupta, Smith, & Pevzner, 2008). The theoretical masses of peptides 
generated by trypsin cleavage of proteins (cleavage at the C terminal side of 
lysine (K) or arginine (R), with exceptions) were calculated using PeptideMass 
(ExPASy Bioinformatics Resource Portal), as described in Section 2.8.2. MRM 
methods were built (including generation of fragment peptide lists and collision 
energies) using Skyline (Maccoss Lab Software 
https://sites.google.com/a/uw.edu/maccoss/) as detailed in Section 2.8.6. 
6.3.2 Reversed phase chromatography 
Liquid chromatography is an analytical chemistry technique used to separate 
compounds within a solution based on physical properties, using a ‘stationary’ 
phase and a ‘mobile’ phase (Dorsey, Cooper, Siles, Foley, & Barth, 1996). The 
type of chromatography described in this chapter is reversed phase 
chromatography, which separates molecules based on relative hydrophobicity 
(Amersham Biosciences, 1999). A non-polar stationary phase (silica column with 
immobilised hydrophobic alkyl chains: in this case, C18) binds the analytes, 
injected within an initial mobile phase, which is designed to favour hydrophobic 
binding (aqueous solution). The concentration of organic solvent (for example, 
acetonitrile or methanol) in the mobile phase solution is then gradually 
increased to encourage desorption of the analytes from the stationary phase (on 
the column), back into the mobile phase. This can occur at variable points in the 
gradient, giving a specific column ‘retention time’ for each molecule, depending 
on it’s individual hydrophobicity (Biosciences, 1999). The mobile phase is also 
usually acidic to improve chromatography and subsequent MS performance. The 
retention times of the peptides of interest are used to schedule MRM assays 
(described in Section 2.2.3.3). 
6.3.3 Mass spectrometry (MS) 
The first step of MS analysis involves ionisation of the analyte: a liquid or solid 
sample is converted to gas-phase ions by the appropriate ionisation technique 
(commonly electron spray ionisation (ESI) in the case of liquid samples and 
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matrix assisted laser desorption/ionisation for solid samples) (Takáts, Wiseman, 
& Cooks, 2005). Compound ions are then separated in a mass analyser by 
electrostatic fields according to their m/z ratio, and then measured by a 
detector.  
6.3.3.1 Tandem mass spectrometry 
Tandem MS (MSMS), as the name suggests, consists of two stages of MS analysis. 
The mass selected ions (precursor ions) are isolated, undergo a dissociation step 
(for example, by high energy collision with an inert gas) and then the resulting 
fragment ions are subjected to a second MS analysis (Figure 6.3). This can occur 
‘in space’ (where two mass spectrometers are used in tandem) or ‘in time’ 
(where there are discreet steps of selection, fragmentation and detection within 
the same machine) (Gross JH, 2011). This technique, coupled to liquid 
chromatography, offers excellent specificity and good sensitivity (Pitt, 2009). 
This has superseded older techniques such as liquid chromatography and radio-
assays, and is used in both research and clinical settings (Carvalho, 2012). 
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Figure 6.3 Pictorial representation of tandem mass spectrometry (MS-MS) process 
This figure shows the process of sample entry into a mass spectrometer, followed by ionisation and 
subsequent separation by m/z ratio. When performing tandem mass spectrometry, a precursor ion 
is selected (e.g. in a human pepsin MSMS assay, ions with m/z 538.26 would be selected - this is 
the m/z ratio of the peptide QYFTVFDR, which is generated following trypsin digestion of human 
pepsin). This ion would be isolated and then further fragmented (by collision induced dissociation) 
to produce product fragment ions (figure 6.13). The ions would be separated by m/z ratio and then 
measured by the detector. The tandem mass spectrometry technique offers high specificity as both 
the precursor ion and predicted product ions must be isolated for identification of the protein. 
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6.3.3.2 Matrix-assisted laser desorption/ionisation (MALDI) 
MALDI is a laser-based ionisation method where the analyte is embedded in a 
chemical matrix. The choice of matrix is important and is selected on the basis 
of the type of sample and laser to be used; for example, alpha cyano-4-
hydroxycinnamic acid is considered the ‘gold standard’ for use with a UV laser 
(Leszyk, 2010). The matrix crystals absorb the laser energy, transfer this energy 
to the analyte and subsequently, a small amount of the sample vaporises. 
Sample preparation and matrix crystal formation are key to maximise quality of 
resolution and subsequent sensitivity and reproducibility (S. L. Cohen & Chait, 
1996). Various methods are discussed in the literature (S. L. Cohen & Chait, 
1996). The dried droplet method was used in the work presented here (described 
in Section 2.8.3).  
The ionised sample (mostly in the singly charged state) enters the mass analyser. 
Here, ions are often separated by ‘time of flight’ (the length of time it takes the 
ions to move down the flight tube to reach the detector, which is governed by 
m/z ratio).  
6.3.3.3 Multiple reaction monitoring (MRM) 
The complexity of clinical samples can limit the sensitivity of mass spectrometry 
analysis for low abundance proteins. Mass spectrometers can detect a limited 
number of peptides in a given time window and therefore, when ‘discovery’ 
mode is used with a complex sample the machine may detect dominant signals 
from major proteins, failing to trigger an MS/MS scan on low abundance ions. 
However, MRM experiments are designed to maximise the sensitivity for targeted 
compounds, using knowledge of their mass and structure to predict the 
precursor m/z ratio and subsequently, those of predicted fragment ions (D. M. 
Cox et al., 2005). In contrast to conventional MS-based analysis, trigger-
dependent acquisitions are undertaken, only scanning each individual 
programmed transition with narrow m/z windows (D. M. Cox et al., 2005; Shi et 
al., 2012). In a triple quadrupole mass spectrometer, the precursor ion is 
selected in the first quadrupole (Q1). Fragmentation of this selected precursor 
ion then occurs by collision-induced dissociation in the second quadrupole (Q2) 
and finally, specified fragment ions are selected in the third quadrupole (Q3) 
(Shi et al., 2012). These are then detected and the protein can be identified. 
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This approach not only increases assay sensitivity (by limiting the signal to noise 
ratio) but also increases specificity, as compounds must be identified not only by 
HPLC retention time and precursor mass but also by identification of expected 
fragment ions. The use of this technique in low abundance biomarker research is 
well established (Kitteringham, Jenkins, Lane, Elliott, & Park, 2009; Shi et al., 
2012). 
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6.4  Assay development  
6.4.1 Assay concept 
The proposed assay is based on the concept of using pepstatin A, immobilised on 
agarose beads, to bind all pepsin with an active site in a BAL sample; thus 
performing an affinity enhancement step. Having bound pepsin to the pepstatin 
A agarose beads, the rest of the sample would be discarded, leaving only the 
protein of interest (and possibly other aspartic proteases) attached to the 
washed beads. The protein would then be removed from the beads using an 
enzymatic digestion step (for example, with trypsin) and the resulting digest 
solution would be analysed using tandem mass spectrometry (specifically MRM) 
methods (LC-MRM-MS analysis). A quantitative assay could subsequently be built 
using a labelled peptide as an internal standard, the gold standard for LC-MRM-
MS quantification (Figure 6.4) (H. Zhang et al., 2011). Porcine pepsin A was 
used for initial assay development as it shares a close homology with the 
predominant human gastric pepsin A isoform, 3b (Figure 6.1, Table 6.1). 
This assay concept would offer advantages over previous assays in being able to 
(a) selectively isolate aspartic proteases from the rest of the sample matrix 
using pepstatin A (b) provide reassurance that pepsin detected is of gastric 
origin, as the pro-peptide must have been cleaved in a low pH environment in 
order to bind to pepstatin and (c) clearly differentiate pepsinogen C and 
cathepsin D (both known to be produced locally in the lung) from pepsin A by LC-
MSMS analysis. Affinity enrichment and MRM analysis techniques would also 
increase assay sensitivity, potentially to levels that could rival immunological 
assays (Ackermann & Berna, 2007). 
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Figure 6.4 Pictorial representation of novel pepsin assay concept  
This figure outlines the proposed novel method for the quantification of human pepsin A in BAL, 
using an inhibitor affinity enhanced LC-MSMS assay. Pepstatin A agarose beads (Sigma, UK) bind 
all aspartic proteases (with an accessible active site) in the BAL sample. The attached proteins are 
then digested off the beads using enzymatic proteolysis (for example, with trypsin). The resulting 
peptide solution is then analysed by LC-MSMS, looking specifically for precursor and fragment 
peptides produced by trypsin digestion and MSMS analysis of human pepsin. This method 
potentially offers excellent specificity and high sensitivity.  
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6.5 Identification of assay peptides 
In order to confirm the feasibility of the proposed assay, information about 
protein amino acid sequences and theoretical masses of peptides produced by 
trypsin digestion were collected, as detailed below. 
6.5.1 Porcine and human pepsin are theoretically identifiable, 
post trypsin digestion, by mass spectrometry  
Peptide Mass (ExPASy Bioinformatics Resource Portal –http://web.espasy.org/ 
peptide mass) was used to compute the theoretical masses of generated 
peptides following trypsin digestion of porcine pepsin A (PGA) and human pepsin 
3b (PGA5) (with cysteine residues alkylated (carbamidomethylated) with 
iodoacetamide, methionine residues variably oxidised and allowing for no missed 
cleavages). Likely candidates for identification in a mass spectrometry analysis 
(based on m/z ratio) are highlighted in Table 6.1. The Swissprot database 
(www.uniprot.org) was searched using the online Basic Local Alignment Search 
Tool (BLAST http://blast.ncbi.nlm.nih.gov) to check that the two potential 
human pepsin 3b ‘identification’ peptides generated by trypsin digestion 
(QYFTVFDR and ANNQVGLAPVA) are unique to human pepsin A. Both peptides are 
specific to human pepsin A (PGA3, PGA4, PGA5; relating to isoforms 3c, 3a and 
3b) or human pepsinogen A (as they are located at the C terminal end of the 
protein), with 100% query coverage and identity.  
Table 6-1 Two peptides are highlighted as possible ‘identification’ peptide candidates in MS 
analysis for both (a) porcine pepsin A and (b) human pepsin A quantification. 
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6.5.2 Human pepsinogen A and pepsinogen C are differentiable 
by mass spectrometry 
In order to confirm that the targeted ‘identification’ peptides for human pepsin 
A are not also predicted on trypsin digestion of pepsinogen C, the amino acid 
sequences of pepsinogen A (PGA5 gene (3b isoform)) and pepsinogen C (PGC 
gene) were checked using the Universal Protein Resource (www.uniprot.org). 
Figure 6.5 shows that peptides QYFTVFDR and ANNQVGLAPVA would not be 
generated by trypsin digestion of pepsinogen C. 
 
Figure 6.5  Amino acid sequences for (a) human pepsinogen A and (b) human pepsinogen 
C, illustrating potential for differentiation by mass spectrometry analysis  
a. The potential ‘identification’ peptides for pepsinogen A (and by inference human pepsin A (3b)) 
are highlighted in orange and green at the C-terminus of the protein. b. The corresponding 
peptides generated by trypsin digestion at the C-terminus of human pepsinogen C are also 
highlighted in orange and green. 
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6.6 Proof of assay concept 
The aim of this experiment was to establish the feasibility of using immobilised 
pepstatin binding followed by LC-MS to detect pepsin in human BAL. The 
protocol below is for an artificial, in vitro experiment using relatively high, non-
physiological quantities of pepsin. The volume of pepstatin agarose beads (Sigma 
Aldrich, UK) used in the experiment was calculated from the manufacturer’s 
indication of bead binding capacity (20-40mg pepsin/ml beads, settled wet 
volume). 
A 10µM solution of porcine pepsin A (Sigma Aldrich, UK) was made in 50mM 
acetic acid. A 50µl aliquot of pepstatin A agarose beads (Sigma Aldrich, UK) was 
centrifuged at 6000rpm for 3 minutes. The saline fraction was removed and the 
bead pellet was re-suspended in 50µl 50mM acetic acid. A 50µl aliquot of 10µM 
porcine pepsin A solution (500pmol) was mixed with 2µl of resuspended 
pepstatin A agarose beads (enough to bind >1000pmol pepsin based on the 
manufacturer’s estimation of binding capacity) in an Eppendorf tube. This was 
incubated in an Eppendorf mixer (Thermomixer Comfort) for 1 hour at RT, 1200 
rpm. Incubation time and temperature were optimised during preliminary 
experiments: temperature ranges of 21-400C and incubation times of 1-6 hours 
were assessed by SDS PAGE gel analysis for bead-pepsin binding (as described in 
Section 6.7.2). 
Following incubation, the pepsin/pepstatin bead suspension was centrifuged at 
6000rpm and the supernatant was discarded. The beads were washed three 
times in 200µl MilliQ H20, and re-pelleted by centrifugation; the supernatant 
fraction was discarded. A 500µM solution of non-sequencing grade porcine 
trypsin (Sigma Aldrich, UK) was made in 25mM ammonium bicarbonate buffer, 
pH8.5 (AmBic) and 25000pmol (50µl) aliquot was subsequently added to the 
beads (protein:trypsin ratio 50:1). The solution was incubated in an Eppendorf 
mixer (Thermomixer Comfort) at 370C, 1200rpm overnight. Following 
centrifugation, the supernatant was removed from the beads and 0.5% (final v/v) 
trifluoroacetic acid (TFA) was added to stop the reaction. A positive control of 
500pmol pepsin in 50µl 25mM AmBic in solution digest and a negative control of 
pepstatin A agarose bead binding and digestion but with no pepsin added was 
conducted. MALDI-TOF MS analysis of the resulting digest solutions was made 
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using a Bruker UltrafleXtreme MALDI TOF/TOF mass spectrometer, as detailed in 
Section 2.8.3. Theoretically, 10pmol pepsin A peptides (1µl digest solution) were 
loaded onto the MALDI target (for the experimental bead pepsin digest and 
positive control). 
Figure 6.6 displays proof of the assay concept: identification of the m/z 1091 
peak (relating to peptide QYYTVFDR, [M+H]+) on analysis of the in-solution 
porcine pepsin A digest and the digest from pepstatin agarose beads post 
incubation with porcine pepsin A solution. This peak was not identified in the 
pepsin negative bead digest control. The other peak observed in all three 
samples (m/z 2163) was a porcine trypsin autolysis peak. The amount of trypsin 
used in subsequent experiments was reduced to 25:1 (protein:trypsin) and 
sequencing grade trypsin was used. The relative signal intensity of trypsin to 
pepsin was noted to differ between the ‘pepsin digested off beads’ and ‘pepsin 
digested in solution’ samples. This was possibly due to incomplete pepsin 
retrieval with 2ul pepstatin agarose beads and was further investigated in 
Section 6.7.2. 
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Figure 6.6 Proof of assay concept  
MALDI chromatograms (generated using an UltrafleXtreme MALDI TOF/TOF mass spectrometer 
and Flex Analysis software, Bruker). Peak m/z 1091 (indicated by blue arrows) was identified in the 
porcine pepsin A in solution digest control and in the washed pepstatin agarose bead digest post 
incubation with porcine pepsin A. However, it was not seen in the pepsin negative bead digest 
control sample. This is the m/z of QYYTVFDR ([M+H]
+
), predicted post porcine pepsin A digestion 
with trypsin (trypsin autolysis peak m/z 2163, indicated by red arrows). 
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6.7  Optimisation of pepstatin A agarose bead binding of 
porcine pepsin A 
Following proof of concept, experimental conditions were explored in further 
detail to ensure maximum efficiency of porcine pepsin A binding to pepstatin A 
agarose beads in BAL sample matrix. 
6.7.1 Pepstatin agarose beads are capable of binding porcine 
pepsin at an acidic or neutral pH 
The aim of this experiment was to test whether pepstatin agarose bead binding 
of porcine pepsin A was affected by pH. This question is important because 
epithelial lining fluid may be mildly acidic or neutral and the pH of patient BAL 
samples ranged from pH 5.5-7.4 (Fischer & Widdicombe, 2006). 
The experiment described in Section 6.6 was repeated, in duplicate, with two 
pH conditions: (a) porcine pepsin A dissolved in 50mM acetic acid (pH3.0) and (b) 
porcine pepsin A dissolved in 50mM HEPES (pH 7.4). The resulting bead digests 
were analysed in quadruplicate by MALDI-TOF analysis, using a raster pattern (as 
described in Section 2.8.3). The mean area under the m/z 1091 curve and 
standard deviation was calculated for each pH condition. 
No significant difference was seen in the area under the m/z 1091 curve 
between acidic and neutral pH conditions (p=0.696, Figure 6.7). It is not 
possible to make a direct comparison between unrelated spots on a MALDI target 
however, despite this, we felt that this experiment provided convincing 
evidence that pepstatin agarose beads are able to bind porcine pepsin A at a 
neutral pH. From this point, all experiments were performed at pH 7.4, as this 
was the highest pH measured in recruit BAL fluid samples. 
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Figure 6.7 Pepstatin agarose bead binding of porcine pepsin A is not affected by alteration 
of sample pH. 
Porcine pepsin (500pmol) (Sigma, UK) dissolved in acidic (pH 3) and neutral (pH7.4) solutions was 
incubated with 2µl resuspended pepstatin A agarose beads (Sigma, UK) for 1 hour at RT. 
Following bead trypsin digestion, MALDI-TOF MS analysis was performed on the digest solution, 
using an UltrafleXtreme MALDI TOF/TOF mass spectrometer and Flex Analysis software (Bruker). 
Two experimental replicates were performed and each sample was analysed in quadruplicate. The 
mean area under the curve of m/z 1091 peak was compared for acidic and neutral pH conditions 
(limitations discussed in Section 6.7.1). No significant difference was found (data presented as 
mean and standard deviation, p=0.696). 
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6.7.2  Bead binding capacity 
The aim of this experiment was to establish pepstatin A agarose bead (Sigma, 
UK) binding capacity under optimised experimental conditions.  
Increasing volumes (2-40µl) of resuspended pepstatin A agarose beads (as 
described in Section 6.6) were added to 500pmol porcine pepsin (Sigma, UK) in 
solutions of increasing concentration, enabling equal total sample volume (50µl) 
across all experimental conditions. Following incubation and centrifugation, the 
supernatant fraction was removed from each bead pellet and precipitated using 
15% TCA (v/v), as described in Section 2.5.3, to allow loading of the complete 
supernatant sample for SDS-PAGE gel analysis (as described in Section 2.5.1). 
Any unbound pepsin would be visualised by this technique. 
The experiment was repeated in triplicate and 35µl of pepstatin A agarose beads 
was required to consistently bind 500pmol porcine pepsin (figure 6.8 (b)). 
6.7.3 Pepsin autolysis does not occur during the time taken to 
incubate the sample with pepstatin A agarose beads. 
The aim of this experiment was to check that there was no loss of pepsin protein 
(through autolysis) during the time spent incubating the sample with pepstatin A 
agarose beads (one hour). Variations in pepsin activity curves have been 
observed and it has been suggested that this is due to variation in the method of 
measuring activity and the origin of the pepsin (Piper & Fenton, 1965).  
Therefore, although pepsin autolysis is unlikely at pH7.4, I sought confirmation 
of this within the following experimental protocol.  
Binding of two aliquots of 500pmol porcine pepsin A to 16µl pepstatin A agarose 
beads was performed, as previously described in Section 6.6. The supernatant 
fraction was removed from the beads post centrifugation and TCA precipitated 
(15% v/v), as previously described (Section 2.7.2). The beads and supernatant 
fractions were loaded onto a polyacrylamide gel for SDS-PAGE gel analysis, with 
a 500pmol porcine pepsin control. The entire experiment was also performed 
without the addition of pepsin, as a negative control. Densitometry analysis was 
performed on protein bands post Coomassie R-250 staining, using TotalLab Quant 
software.  
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Figure 6.8 (a) demonstrates that the starting amount of pepsin was fully 
accounted for at the end of the experiment (it was either attached to the beads 
or remained in the supernatant). Therefore, no obvious autolysis had occurred. 
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Figure 6.8 a. SDS PAGE gel (and accompanying band densitometry) to demonstrate that all 
pepsin protein was accounted for within the bead binding experiment (no degradation). b. 
SDS PAGE gel (and accompanying band densitometry) showing the effect of increasing 
volumes of pepstatin agarose beads on porcine pepsin A retrieval. 
a. Porcine pepsin A (500pmol in 50µl 50mM HEPES, pH7.4) was incubated with 16µl pepstatin A 
agarose beads (Sigma, UK). The washed beads (2) and the supernatant protein (3) were analysed 
by SDS-PAGE gel. A 500pmol pepsin control was included (1) as well as bead and supernatant 
controls from an identical experiment with no pepsin added (4 & 5, respectively). Densitometry 
analysis was performed using TotalLab Quant software. The sum density of the bands visualised in 
lanes 2 and 3 was equal to the band density in lane 1, i.e. the starting amount of porcine pepsin A 
protein was fully accounted for (on the beads or in the supernatant) at the end of the incubation 
period. 
b. Pepstatin A agarose beads (2-40 µl, Sigma, UK) were added to 500pmol porcine pepsin A in 
solutions of increasing concentrations, allowing equal total sample volume across all samples. 
Following incubation, supernatants were analysed by SDS-PAGE gel analysis (looking for residual 
‘unbound’ protein) and densitometry was performed using TotalLab Quant software. Following 
three experimental repeats, it was concluded that 35µl of pepstatin A agarose beads were needed 
to consistently bind 500pmol porcine pepsin.  
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6.7.4 Pepstatin-pepsin binding is not disrupted by prolonged 
exposure to pH conditions similar to those in the human 
lung 
The aim of this experiment was to investigate whether prolonged exposure of 
porcine pepsin A to pH 7.4 (24 hours) would disrupt subsequent binding with 
pepstatin A agarose beads. This was important to establish, as pepsin A may be 
present in the pulmonary pH environment for several hours prior to sampling. 
500pmol porcine pepsin A (in 50µl 50mM HEPES, pH 7.4) was incubated for 24 
hours. The pH of the solution was checked at the beginning and end of the 
incubation period. Following this, the same binding experiment as detailed 
previously (Section 6.6) was performed, using 35µl re-suspended pepstatin A 
agarose beads for pepsin retrieval. Subsequently, the beads, supernatant and a 
500pmol control were analysed by SDS-PAGE analysis.  
Figure 6.8 demonstrates that 35µl pepstatin A agarose beads are able to 
completely bind 500pmol porcine pepsin A, even after exposure to pH 7.4 for 24 
hours. This result is in keeping with the literature that pepsin is held in a ‘static’ 
state at pH 7.4 and is not denatured until pH >8 (Nikki Johnston et al., 2007). 
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Figure 6.9 Exposure of porcine pepsin A to pH 7.4 for 24 hours does not preclude 
subsequent complete binding of 500pmol pepsin to 35µl pepstatin agarose beads. 
This SDS PAGE gel image shows bands of equal density in lane 1 and 2 for (1) 500pmol porcine 
pepsin loaded directly onto the gel and (2) pepstatin agarose A beads loaded onto the gel post 
incubation with 500pmol porcine pepsin A pre-exposed to pH 7.4 for 24 hours. There is no band 
visible in lane three (supernatant of porcine pepsin A solution post incubation with pepstatin A 
agarose beads), indicating that all pepsin was retrieved by the pepstatin A agarose beads. 
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6.7.5  Pepstatin agarose A beads are capable of retrieving 
physiological levels of porcine pepsin A in water and BAL 
matrix 
The aim of this series of experiments was to establish whether porcine pepsin A, 
at physiologically relevant levels (based on currently available literature), could 
be retrieved by pepstatin A agarose beads, in water and also in BAL matrix 
(McNally et al., 2011). 
Experiment 1: The first experiment involved repeating the experiment 
performed in Section 6.6 but with much lower levels of pepsin (dissolved in 50µl 
50mM HEPES). The amounts of pepsin used were 100ng (2.9pmol), 50ng 
(1.45pmol) and 20ng (580fmol). A smaller volume (5µl) of pepstatin agarose 
beads was used, as the potential pepsin load was smaller. Beads were incubated 
in the solutions as previously described (Section 6.6). Following this, the beads 
and the remaining supernatant were loaded onto a 12% precast Tris-glycine gel 
(Biorad) for subsequent Western blot (WB) analysis (as described in Section 
2.5.2.1), to assess bead pepsin retrieval. A positive control for each pepsin 
amount was also loaded.  
Figure 6.10 (1) demonstrates pepstatin A agarose bead retrieval of 
physiologically relevant levels of pepsin in 50mM HEPES (pH 7.4). 
Experiment 2: A similar experiment was repeated in BAL matrix. Porcine pepsin 
A (2.9pmol) was spiked into (a) 20µl water (b) 20µl 1:2 pre-diluted BAL (c) 20µl 
1:5 pre-diluted BAL and (d) 20µl 1:10 pre-diluted BAL. The retrieval experiment 
was repeated using 5µl pepstatin A agarose beads, as previously described 
(Section 6.6). A 2.9pmol porcine pepsin A control and the beads and 
supernatants from all conditions were analysed by porcine pepsin WB, as 
previously described (Section 2.5.2.1). 
Figure 6.10 (2) demonstrates that retrieval of 2.9pmol pepsin was incomplete in 
BAL matrix at 1:2 dilution but improved with further BAL matrix dilution. 
Experiment 3: Three 50µl aliquots of three different BAL samples were taken 
and diluted 1:10. One aliquot of each BAL sample was spiked with 2.9pmol 
pepsin and one was unspiked. The third was set to one side to run directly on 
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the WB gel. Pepstatin A agarose bead binding experiments were performed on 
unspiked and spiked BAL samples, as previously described (Section 6.6). The 
washed beads and the BAL supernatant were then collected post bead incubation 
and analysed by porcine pepsin WB analysis, as previously described (Section  
2.5.2.1). The supernatants were precipitated with 15% (final v/v) TCA to load 
onto the gel. The volume of pepstatin agarose A beads needed for efficient 
pepsin retrieval was increased to 15µl during optimisation of this experiment. 
Figures 6.10 (3a) and (3b) demonstrate that 15µl pepstatin agarose A beads 
could efficiently retrieve 2.9pmol porcine pepsin from three clinical samples. A 
small amount was left behind in one sample and this may need further 
optimisation, using MS quantification of pepsin retrieval. Retrieval and detection 
of an unidentified protein, of a slightly higher molecular weight than pepsin, was 
demonstrated in all samples. This unidentified protein was not human pepsin 
(Chapter 5, Section 5.4.2.1) and was non-specifically bound to the beads 
(Section 6.8.5). Variable (sample dependent) non-specific binding of porcine 
pepsin antibodies to other unidentified BAL proteins was seen during these 
experiments, the extent of non-specific binding increasing with higher BAL 
protein load (further discussed in Chapter 5).  
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Figure 6.10 Series of WB images demonstrating recovery of physiologically relevant levels 
of porcine pepsin A under various conditions 
 
1. Pepstatin A agarose beads are capable of recovering physiologically relevant levels of 
porcine pepsin A in 50mM HEPES buffer  
Methods described in text. Lanes: 1 - 2.9pmol porcine pepsin, 2 - washed pepstatin agarose A 
beads post incubation with 2.9pmol porcine pepsin (in 50mM HEPES), 3 - pepsin solution 
supernatant post incubation with beads. Lanes 4-6, as for lanes 1-3 with 1.45pmol porcine pepsin. 
Lanes 7-9, as for lanes 1-3 with 580fmol porcine pepsin.  
 
2. Pepstatin A agarose beads are capable of recovering small amounts of porcine pepsin in 
BAL. The efficacy of this process is improved by BAL dilution.  
Methods described in text. Lanes: 1 – 2.9pmol porcine pepsin, 2 - pepstatin agarose beads post 
incubation with 2.9pmol porcine pepsin in 50mM HEPES, 3 – Porcine pepsin/50mM HEPES 
solution supernatant post incubation with beads, 4 - pepstatin agarose beads post incubation with 
2.9pmol porcine pepsin in BAL diluted 1:2, 5 – Porcine pepsin/BAL (1:2 diluted) solution 
supernatant post incubation with beads, Lanes 6-7 as for 4-5 except 1:5 diluted BAL, Lanes 8-9 as 
for 4-5 except 1:10 diluted BAL. 
3. Efficient pepstatin A agarose bead recovery of pepsin from BAL is demonstrated in three 
inflammatory, proteinaceous BAL samples (1:10 diluted). 
(a) Methods as described in text. Lanes: 1 – 2.9pmol porcine pepsin control, 2 – beads alone, 3 – 
2.9pmol pepsin on beads in water, 4 – water supernatant post incubation with beads, 5 – P80 
direct on gel, 6 – P80 non-spiked on beads, 7 – P80 non-spiked supernatant post incubation with 
beads, 8 - P80+2.9pmol porcine pepsin on beads, 9 - P80+2.9pmol pepsin supernatant post 
beads.  
(b) Methods as described in text. Lanes: 1 – 2.9pmol porcine pepsin control, 2 – 100µl P30 direct 
on gel, 3 – P30 on beads, 4 - P30+2.9pmol porcine pepsin on beads, 5 - P30+2.9pmol pepsin 
supernatant post beads, 6 – 100µl P71 direct on gel, 7 – P71 on beads, 8 - P71+2.9pmol pepsin on 
beads, 9 - P71 +2.9pmol pepsin supernatant post beads. 
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6.7.6 Rapigest, heat, reduction, alkylation and trypsin digestion 
are required for complete release of pepsin from pepstatin A 
agarose beads  
The aim of this experimental series was to establish the conditions required for 
complete removal of porcine pepsin A from pepstatin A agarose beads. 
Experiment 1: The first experiment used trypsin digestion alone for > 18 hours, 
at 370C and with a protein:trypsin ratio of 25:1. Four 500pmol aliquots of 
porcine pepsin A were each bound to 35µl pepstatin agarose beads, as previously 
described. Trypsin digestion was performed on two aliquots and 25mM AmBic 
buffer alone was added to the other two aliquots (digestion negative controls). 
Two 500pmol porcine pepsin A aliquots were also digested directly in solution, 
using equal protein:trypsin ratios and equal digest volumes to those used for the 
bead samples. Following centrifugation, the digest solution was removed and 
stored (following addition of 0.5% (v/v) TFA to stop the reaction). A 500pmol 
pepsin control and the two sets of non-digested and digested beads were 
analysed directly by SDS page gel (as described in Section 2.5.1), to assess any 
residual pepsin left on the pepstatin agarose A beads. The bead digest 
supernatants and in solution 500pmol pepsin digests were assessed by MALDI-TOF 
analysis (as described in Section 2.8.3). A 16pmol Glu-1-fibrinopeptide B (Glu-
fib) spike was diluted 1:10 in 9.5µl of each digest solution. Glu-fib:pepsin ratios 
were then assessed and compared to assess m/z 1091 ion retrieval in the bead 
digests compared to the in solution digests. 
The SDS-PAGE gel and MALDI-TOF supernatant analyses highlight incomplete 
digestion of pepsin from beads by trypsin proteolysis (Figures 6.11 1(a) and 2). 
Experiment 2: Six bead samples with 500pmol porcine pepsin attached were 
produced, as previously. A bead digestion pre-step was added to the previous 
protocol. A proprietary surfactant (0.1% (final v/v in 25mM AmBic) RapigestTM, 
Waters, UK), which enhances proteolysis, was added to the previous protocol for 
four samples. Two of these samples were incubated, with agitation, at 800C and 
two samples were incubated at 950C for five minutes. Pepsin contains four 
disulphide bonds and therefore, samples were also reduced and alkylated. All 
four samples underwent reduction with 3.3mM dithiothreitol for 10 minutes at 
600C. Alkylation was with 9.6mM iodoacetamide for 30 minutes at RT in the 
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dark. Finally, sequencing grade trypsin (Sigma, UK) was added (protein:trypsin 
ratio 25:1). All samples were digested overnight for 18 hours at 1200rpm in an 
ependorf shaker at 370C . The final two samples were ‘undigested’ in 50µl AmBic 
as a negative control. Following processing (as previously described), beads were 
run on an SDS PAGE gel and supernatants were assessed by MALDI-TOF analysis. 
A reduction in Glu-fib:pepsin ratio was seen with this digestion protocol. 
Increased temperature during incubation with RapigestTM (950C) appeared to 
have a beneficial effect (Figure 6.11 1(b)). However, despite this, the SDS PAGE 
gel still showed some residual pepsin bound to the beads. 
Experiment 3: The final experiment involved increasing the RapigestTM 
incubation time to 10 minutes (950C). Samples were also directly agitated 
(through vortexing and brief centrifugation to return the beads to the bottom of 
the tube) on two occasions during the 18 hour digestion period. Samples were 
analysed as previously described. 
Figures 6.11 1(c) and 2 show that the increased RapigestTM incubation time 
resulted in complete digestion of porcine pepsin A from pepstatin A agarose 
beads. 
6.7.7 Optimised bead digestion protocol 
Add 22.5µl 25mM AmBic to washed beads with 2.5µl 1% rapigest. Incubate at 
950C for 10 minutes with brief vortexing twice during incubation. 
Add 16.5µl AmBic and then 2.5µl DTT (9.2mg in 1ml 25mM AmBic). Incubate at 
600C for 10 minutes with direct agitation after 5 minutes.  
Add 2.5µl IAN (33mg in 1ml) then incubate in the dark at RT for 30 minutes with 
agitation half way through. 
Add trypsin at 25:1 (protein:trypsin) and digest overnight for at least 18 hours 
with two direct agitations with vortexing.  
Following digestion, centrifuge at 6000rpm for 5 minutes. Remove the digest 
supernatant and add 0.5% TFA (final v/v). Incubate at 370C for 30 minutes.
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Figure 6.11 Complete removal of porcine pepsin A from pepstatin agarose beads is 
achieved with 10 minutes incubation in 0.1% Rapigest at 95
0
C, reduction and alkylation and 
then trypsin digestion at a ratio 25:1 (protein:trypsin) for >18 hours, with agitation. 
Methods as described in text. 
(1a) Lane 1 – 500pmol pepsin, lanes 2+3 – 500 pmol pepsin on beads, lanes 4+5 – beads + 
residual pepsin post trypsin digestion.  
(1b) Lane 1 - 500pmol pepsin, lanes 2+3 - 500pmol pepsin on beads (digestion negative), lanes 
4+5 - residual pepsin on beads post 0.1% Rapigest at 80
0
C for 5 minutes, reduction & alkylation 
and trypsin digestion, lanes 6+7 – residual pepsin on beads post 0.1% Rapigest at 95
0
C for 5 
minutes, reduction & alkylation and trypsin digestion. 
(1c) Lane 1 – 500pmol pepsin, lanes 2+3 – 500pmol pepsin on beads, lanes 4+5 - 500pmol pepsin 
on beads post 0.1% Rapigest at 95
0
C for 10 minutes, reduction & alkylation and trypsin digestion. 
(2) Bar chart to show mean (SD) glu-fib:pepsin ratio (area under curve:area under curve). Lane 1 - 
in solution digest 500pmol porcine pepsin, lane 2 - bead digest post trypsin digestion alone, lane 3 
- addition of Rapigest (0.1%) 80
0
C for 5 minutes, lane 4 - addition of Rapigest (0.1%) 80
0
C for 5 
minutes and reduction and alkylation, lane 5 - addition of Rapigest (0.1%) 95
0
C for 5 minutes and 
reduction and alkylation, lane 6 - addition of Rapigest (0.1%) 95
0
C for 10 minutes and reduction 
and alkylation 
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6.8 Identification of pepsin by tandem mass spectrometry 
6.8.1  Detection of porcine and human pepsin by LC-MSMS 
analysis 
The aim of this experiment was to confirm MS detection of the two predicted 
‘identification’ peptides for both porcine and human pepsin.  
Porcine pepsin A (Sigma, UK) and human pepsinogen 1 (Cell Sciences, US) were 
digested in solution, using sequencing grade trypsin (protein:trypsin, 25:1), 
calculated to give a final digest concentration of 1000fmol/µl. Following 
dilution, 100fmol of each was loaded onto a nanoAcquity UPLC™ system (Waters 
MS Technologies, Manchester, UK) and eluted over a 1 hour gradient. MSMS 
analysis was performed using a Synapt G1 or Synapt G2 mass spectrometer, as 
described in Section 2.8.5. 
The chromatograms in Figure 6.12 confirm that the predicted ‘identification’ 
peptides were observed for porcine pepsin and for human pepsin. All peptides 
are easily observed at 100fmol however, there appears to be a higher sensitivity 
for the C terminus peptides VGLAPVA (porcine) or ANNQVGLAPVA (human). It 
was noted that the VGLAPVA was singly charged whereas ANNQVGLAPVA was 
doubly charged.  
 202 
 
Figure 6.12 (a) Porcine and (b) Human pepsin ‘identification’ peptides are visible when 
loading 100fmol onto column for LC-MSMS analysis using a nanoAcquity UPLC™ system 
and Synapt G1 or Synapt G2 mass spectrometers (both Waters MS Technologies, 
Manchester, UK) 
a. Following in solution digestion, 100fmol porcine pepsin (Sigma) was loaded onto a nanoAcquity 
UPLC™ system (Waters MS Technologies, Manchester, UK) and eluted on a 1 hour gradient. A 
Synapt G2 Mass spectrometer (Waters) was used for analysis. Predicted peaks relating to 
VGLAPVA (m/z 626.38 ([M+H]
+
)) and QYYTVFDR (m/z 546.26 ([M+2H]
2+
)) were seen at 22 and 23 
minutes, respectively. Extracted ion chromatograms shown (created using Origin software) 
b. Following in solution digestion, 100fmol human pepsinogen 1 (Cell Sciences) was loaded onto a 
nanoAcquity UPLC™ system (Waters MS Technologies, Manchester, UK) and eluted on a 1 hour 
gradient. A Synapt G1 Mass spectrometer (Waters) was used for analysis. Predicted peaks relating 
to ANNQVGLAPVA (m/z 527.28 ([M
+
2H]
2+
)) and QYFTVFDR (m/z 538.26 ([M
+
2H]
2+
)) were 
observed at retention times of 22 and 25 minutes, respectively. Extracted ion chromatograms 
shown. 
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6.8.2 Building an MRM assay for pepsin identification 
MRM methods were built (including generation of fragment peptide lists and 
collision energies) using Skyline (MacCoss Lab Software). The fragment peptide 
lists for the precursor peptides targeted for detection of porcine and human 
pepsin are listed in Figure 6.13. A minimum of five fragment peptides were 
selected for each precursor. Fifteen data-points were acquired over a 15 second 
chromatographic peak and the minimum dwell time was 50 milli-seconds. The 
collision energies (eV) suggested by Skyline for fragmentation of the precursor 
peptides were human pepsin; QYFTVFDR – 19, ANNQVGLAPVA – 38, porcine 
pepsin; QYYTVFDR – 19, VGLAPVA – 22. LC-MSMS methods are detailed in Section 
2.8.6. The Xevo™ TQ triple quadrupole mass spectrometer (Waters) was used for 
MS analysis. 
 
Figure 6.13 Fragment ion transitions for porcine pepsin peptides QYYTVFDR and VGLAPVA 
and human pepsin peptides QYFTVFDR and ANNQVGLAPVA.  
Fragment ion transition lists were generated using Skyline software (MacCoss Lab Software). 
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6.8.3 100fmol porcine pepsin A is detectable by LC-MSMS using 
MRM transitions, following bead retrieval from BAL matrix 
Having established that the proposed ‘identification’ peptides are detectable by 
LC-MSMS analysis, the aim of this experiment was to establish whether 100fmol 
porcine pepsin A could be retrieved from BAL matrix onto pepstatin agarose 
beads and detected by selected ion monitoring for precursor and predicted 
fragment ion transitions (Skyline, MacCoss Labs), using the Xevo™ TQ triple 
quadrupole mass spectrometer (Waters). 
Therefore, 2.9pmol porcine pepsin A was spiked into a 100µl BAL sample. The 
BAL sample was diluted 1:10 with HPLC water and incubated with 15µl pepstatin 
agarose beads for 1 hour, as previously described (Section 6.7.5). Trypsin bead 
digestion was performed in a final volume of 50µl (optimised protocol detailed in 
Section 6.7.7), theoretically yielding 57fmol/µl porcine pepsin peptides if bead 
retrieval was complete. The bead digest solution (2µl, approximately 100fmol 
porcine pepsin peptides) was loaded for LC-MSMS analysis. MRM transitions were 
programmed using Skyline software. The collision energies used were QYYTVFDR 
– 19 eV, VGLAPVA – 22 eV. 
Figure 6.14 shows a chromatogram which illustrates detection of the porcine 
pepsin peptide QYYTVFDR ion (m/z 538.26) at 23 minutes and accompanying 
detection of five predicted fragment ions of this precursor at the same retention 
time. Five predicted fragment ions of the VGLAPVA precursor ion were identified 
at 22 minutes (chromatogram not shown). The next step in creation of an MRM 
assay would be to insert time windows to scan only for QYYTVFDR precursor and 
fragment ions at 23 minutes and VGLAPVA ions at 22 minutes. 
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Figure 6.14 2.9pmol porcine pepsin spiked into 100µl BAL, retrieved onto pepstatin agarose 
beads and digested off beads according to an optimised protocol is clearly identifiable by 
LC-MRM-MS  
Analysis of 2µl bead digest (theoretically 114fmol porcine pepsin) on Xevo
TM
 TQ MS (Waters) by 
selected ion monitoring for precursor peptide ion 538.26 (QYYTVFDR) and it’s predicted fragment 
ions. Chromatogram shows a peak at 23.98 minutes for precursor ion m/z 538.26. Five predicted 
fragment ion peaks were detected at the same retention time. 
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6.8.4  100fmol human pepsin is detectable LC-MRM-MS analysis 
The aim of this experiment was to visualise the predicted fragment ions of the 
peptides QYFTVFDR and ANNQVGLAPVA by programming an MRM transition 
experiment, using the Xevo TQ triple quadripolar mass spectrometer (according 
to methods described in Section 2.8.6). An in solution trypsin digest was 
performed on human pepsinogen 1 (Cell Sciences, US) and 100fmol was loaded 
onto the LC column.  
Figure 6.15 displays identification of peptide ANNQVGLAPVA at 22 minutes with 
detection of 4 fragment peptides and identification of peptide QYFTVFDR at 27 
minutes with detection of 6 fragment peptides. Completion of MRM assay 
development would include insertion of time windows.  
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Figure 6.15 100fmol of trypsin digested human pepsinogen 1 (Cell Sciences) is detectable 
by LC-MSMS (Xevo TQ) using MRM transitions for the two ‘identification’ peptides 
ANNQVGLAPVA and QYFTVFDR and their predicted fragment ions.  
The main chromatogram (a.) displays clear peaks at 22 minutes (m/z 527.28) and 27 minutes (m/z 
538.26) relating to the precursor m/z values for the ‘identification’ peptide precursor ions. The 
smaller chromatograms display the pattern of fragment ion peak intensity detected for each peptide 
((b.) ANNQVGLAPVA, (c.) QYFTVFDR). 
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6.8.5  Improvement in bead washing protocol enables increased 
sample loading 
The next stage would be to identify human pepsin extracted from patient 
samples (known to contain pepsin as shown by human pepsin WB (Chapter 5)). In 
an initial experiment, 100µl of sample P8 (strongly positive by WB (results shown 
in Figure 5.3)) was taken, diluted 1:10 and pepsin retrieval was attempted as 
described in Section 6.8.3. Pepsin was not detected on LC-MSMS analysis (XevoTM 
TQ). A possible explanation would be that the levels were below the lower limit 
of detection. Sample loading could not be increased because LC-MSMS analysis 
(Synapt G1) revealed a high total ion count, indicating large amounts of non-
specifically bound protein were present in the bead digest. Therefore, the aim 
of the following set of experiments was to improve the bead washing procedure, 
in order to enable increased sample loading for XevoTM TQ analysis. 
Experiment 1: Four 50µl aliquots of the same BAL sample were spiked with 
2.9pmol porcine pepsin (Sigma) and diluted 1:10, pre incubation with 15µl 
pepstatin A agarose beads. Post centrifugation, the supernatant was removed 
from all samples, as previously. Two bead samples were set aside to analyse 
directly by SDS PAGE gel. The other two bead samples were washed five times 
with 500µl 200mM NaCl. Between each wash, the beads were re-pelleted by 
centrifugation and the wash supernatant was removed and TCA precipitated 
(15% final v/v) for analysis. The first set of samples were analysed by SDS PAGE 
gel and the second set were analysed by porcine pepsin WB. 
Figures 6.16 (1a and b) illustrates that 200mM NaCl washes remove non-
specifically bound protein but do not displace porcine pepsin from pepstatin 
agarose beads. No benefit was demonstrated in performing more than three 
washes. 
Experiment 2: Four 50µl aliquots of the same BAL sample (diluted 1:10) were 
incubated with 15µl pepstatin agarose beads, as previously. Following pelleting 
and supernatant removal, the bead samples were washed three times with 
either (a) 500µl 200mM NaCl or (b) 500µl ultra-pure water. Each wash was kept 
for SDS PAGE gel analysis, as previously. The beads, pre- and post- three washes 
were also analysed. 
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Figure 6.16 (2) demonstrates that three 200mM NaCl washes are more effective 
in removing non-specifically bound protein from pepstatin agarose beads than 
three water washes.  
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Figure 6.16 (1) SDS PAGE gel and WB images to show that repeated 200mM NaCl pepstatin 
agarose bead washes do not displace pepsin from pepstatin agarose beads. (2) SDS PAGE 
gel image to show 200mM NaCl washes are more effective in removing non-specifically 
bound protein from pepstatin agarose beads than three HPLC H20 washes.  
 
(1) For methods see text. (a.) SDS PAGE gel analysis.and (b.) porcine pepsin WB analysis. Lane1 
– 2.9pmol porcine pepsin, Lane 2 - BAL +2.9pmol porcine pepsin on unwashed beads, lane 3 - 
wash1, lane 4 - wash 2, lane 5 - wash 3, lane 6 - wash 4, lane 7 - wash 5, lane 8 – BAL + 2.9pmol 
porcine pepsin on beads post washing.  
(2) For methods see text. Lane 1 – BAL on beads pre wash, lane 2 – 200mM NaCl wash 1, lane 3 
– 200mM NaCl wash 2, lane 4 – 200mM NaCl wash 3, lane 5 – BAL on beads post 3x 200mM 
NaCl washes, lane 6 –BAL on beads pre wash, lane 7 – H20 wash 1, lane 8 – H20 wash 2, lane 9 – 
H20 wash 3, lane 10 – BAL on beads post 3x H20 washes. 
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6.9  Discussion 
In this chapter, the feasibility of using an immobilised inhibitor to recover pepsin 
with an active site from paediatric BAL samples was demonstrated. Specifically, 
a pepsin inhibitor (pepstatin A) immobilised on agarose beads was shown to 
effectively isolate pepsin from the patient sample BAL matrix. Pepsin-pepstatin 
binding and release protocols were optimised, using porcine pepsin A as a 
surrogate for human pepsin 3b (which is not commercially available). Two 
unique peptides to porcine pepsin A (post trypsin digestion) were identified for 
the purposes of experimental MS optimisation as well as two human pepsin A 
peptides, which were demonstrated to be unique to human pepsin A and 
detectable by MS techniques. Successful bead retrieval of a porcine pepsin A 
spike in paediatric BAL matrix was shown, and subsequent digestion and 
detection by LC-MSMS with selected ion monitoring. This now needs to be 
achieved with human pepsin in patient samples. Following this, an MRM method 
could be further optimised and a labelled peptide based quantification method 
included. 
The major challenges in the preliminary stages of this work surrounded the 
various potential effects of BAL sample matrix on pepstatin function and bead 
circulation. Early experiments established that probable pulmonary pH 
conditions and known BAL sample pH ranges do not inhibit pepstatin-pepsin 
binding (Fischer & Widdicombe, 2006). This is in keeping with previous literature 
where despite structural changes in pepsin exposed to conditions above pH 4, 
continued pepstatin binding ability has been demonstrated (unless the protein 
has been irreversibly denatured by pH conditions above pH8.5) (Campos & 
Sancho, 2003). The sticky, mucin rich consistency of BAL samples also posed 
challenges for both efficient bead circulation and bead function (due to non-
specific protein binding) (Spicer & Martinez, 1984). Sample dilution experiments 
established that a 1:10 dilution of even the most challenging PICU samples 
allowed almost complete bead retrieval of a porcine pepsin spike. Difficulties 
with non-specific protein binding meant the number of beads required for 
complete pepsin retrieval was increased in BAL compared to HEPES, likely due to 
other proteins coating the bead surface. Sodium chloride solution was effective 
in subsequently removing the majority of this non-specifically bound protein 
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from the beads through interferance with electrostatic and ionic interactions 
(Thermo Scientific, 2009). 
It was perhaps unsurprising that optimisation of a protocol for release of pepsin 
from pepstatin was challenging, considering that following binding, the physical 
conformation of pepsin alters to enclose the inhibitor tightly within it’s active 
site (Figure 6.1) (Fujinaga et al., 1995). Use of heat, a proprietary surfactant 
(to aid proteolysis) and reduction and alkylation (to break the disulphide bonds 
known to be present in pepsin) enabled subsequent complete trypsin proteolysis 
of pepsin from the beads. 
Porcine pepsin spike retrieval from BAL and subsequent detection using LC-MSMS 
MRM transition monitoring was demonstrated. However, human pepsin peptides 
were not detected in a strongly pepsin positive BAL sample (by WB analysis). 
There are various potential explanations for these incongruous results, which 
will require further investigation. The first explanation may be that the amount 
of human pepsin A retrieved was below the lower limit of detection for the new 
assay. The limit of detection will need to be established for both ‘identification’ 
peptides in BAL matrix, ideally using a labelled peptide solution, which has been 
accurately quantified.  
The effects of BAL sample matrix on bead function were considered however, 
direct effects of other substances found within the lung on pepsin structure are 
also possible. Various proteases are known to be present and active in the lung, 
which could potentially cause post-translational modification of pepsin 
(Juillerat-Jeanneret, Aubert, & Leuenberger, 1997; Kimura et al., 2005; Van Der 
et al., 1999). Carboxypeptidases, for example, could potentially cleave one or 
two amino acids from the pepsin A C terminus peptide ANNQVGLAPVA in vivo, 
thus altering the ‘identification’ peptide of interest (Nagae et al., 1993). 
Additionally, an example of a chemical modification that could affect the 
peptide QYFTVFDR in vitro (post digestion) is cyclisation of N-terminal glutamate 
to pyro-glutamate, resulting in a 17.03 Da loss in mass and alteration of 
chromatographic retention time (Reimer et al., 2011). All potential in vivo and 
in vitro modifications need to be considered and carefully interrogated. Such 
peptide modifications will pose additional complications to building a 
quantitative pepsin assay using labelled peptide standards. All modified peptide 
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formats which are identified would need to be individually quantified because of 
the potential for variability in the extent of protein or peptide modification 
between samples; for example, due to the variable presence of pulmonary 
proteases in vivo in health and disease (Dragović et al., 1995). 
The effect of freeze-thawing samples on subsequent retrieval of pepsin using 
pepstatin has also not been investigated. This could be tested by spiking BAL 
with purified human pepsin 3b and attempting to retrieve this pre- and post- 
freezing. It is possible that the use of pepstatin may be restricted to fresh 
sample analysis. Finally, we have assumed that human pepsin 3b will behave in 
the same way as porcine pepsin with regard to pepstatin agarose bead 
interactions. This seems likely, due to the high degree of homology between 
these two proteins, but will need to be tested following production of purified 
human pepsin 3b from gastric juice (A. T. Jones & Roberts, 1992).  
In further development of a quantitative LC-MRM-MS assay, the challenges of 
absolute quantification using MS technology will need to be considered. These 
include variable ionisation, chromatographic behaviour and sample preparation 
factors including protein mis-cleavage, which can be influenced by factors such 
as temperature and length of the sample preparation (Lubec & Afjehi-Sadat, 
2007). Some of these challenges can be overcome through use of matched stable 
isotope labelled peptides as internal standards for quantification. These 
peptides should behave identically to the biological peptide of interest during 
chromatographic processing and ionisation therefore, reducing the influence of 
‘run-to-run’ variability (Bantscheff, Schirle, Sweetman, Rick, & Kuster, 2007). 
Inconsistencies introduced during sample preparation need to be assessed via 
technical replicate testing and subsequent critical analysis of possible points of 
inconsistency in the sample preparation protocol. 
Despite these challenges, the work presented clearly demonstrates the validity 
of bead based affinity techniques to extract pepsin from BAL matrix. Pepstatin 
agarose offers a promising option for affinity extraction but other options such 
as antibody based techniques could be considered if insurmountable challenges 
arise in future work. LC-MRM-MS quantification assay development is challenging 
but potentially could provide a reliable, transparent gold standard with which to 
make quantitative measurements of pepsin in BAL. Should pepsin prove to be a 
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useful clinical biomarker, simple bedside test development would be the 
eventual aim. The likelihood of eventual successful return to BAL pepsin analysis 
using simpler immunological methods of analysis (such as ELISA) is increased by 
the addition of a ‘sample clean up’ step using bead-based methods for affinity 
enrichment, as outlined in this chapter. However, in view of the various 
limitations of immunological analysis, validation by quantitative LC-MRM-MS 
methods would be a valuable tool. 
6.10 Conclusions 
Based on the evidence presented within this chapter, the use of a bead based 
inhibitor affinity technique for the extraction of pepsin from paediatric BAL 
samples is valid. Subsequent development of a quantitative LC-MRM-MS assay 
would offer a gold standard for identification and quantification of pepsin in 
BAL. Based on Western blot and MS data generated in this thesis, I believe that 
an optimised inhibitor affinity enhanced LC-MRM-MS assay will have adequate 
sensitivity for measurement of pepsin in bronchial lavage samples. Large patient 
studies making accurate quantitative measurements of BAL pepsin in health and 
disease are essential to assess whether pepsin is a useful biomarker of reflux-
aspiration. 
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 Chapter 7 – Effects of mild pH alteration and 
pepsin exposure on airway epithelial cells 
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7.1 Introduction 
Chronic aspiration results in recurrent lower respiratory tract infections and 
ultimately leads to pulmonary fibrosis and bronchiectasis, the end stage 
pathology commonly observed in children with severe ND (Piccione et al., 2012; 
Seddon & Khan, 2003). However, the mechanism of aspiration related lung injury 
is poorly understood. Following aspiration, the airway epithelium is the first to 
encounter inhaled refluxate. Whilst having important barrier functions, the 
airway epithelium also plays a key role in coordinating the airway immune 
response to environmental insult, through the secretion of pro-inflammatory, 
anti-microbial and regulatory mediators and direct interaction with other airway 
cells involved in generating the immune response (Kato & Schleimer, 2007; 
Polito & Proud, 1998). Airway epithelial cells (AECs) also play direct roles in 
airway remodelling through release of specific mediators, such as TGF-1 (a key 
driver of fibrosis) and direct interaction with the mesenchymal unit, sometimes 
leading to structural changes within the airway wall, characterized by smooth 
muscle hypertrophy, basement membrane thickening, angiogenesis and sub-
mucosal fibrosis (Davies, 2009; Hackett et al., 2009). Direct investigation of the 
primary AEC response to elements of the refluxate is therefore central to 
increasing our understanding of the mechanisms of aspiration related lung injury 
and the resulting clinical outcomes, ultimately leading to development of new 
therapeutic targets. 
The majority of previous literature has focussed on the effects of unphysiological 
acid lung injury: this has been extensively studied in both animal and in vitro 
models (Amigoni et al., 2008; Beck-Schimmer et al., 2003; Bonnans, Fukunaga, 
Levy, & Levy, 2006; Bonnans et al., 2007; Nagase et al., 2000; Segal et al., 
2007). However, the acidity of gastric aspirate once it reaches the lower airway 
is probably much less extreme, particularly in the context of chronic micro-
aspiration, the commonest clinical scenario. Combined oesophageal and tracheal 
pH studies have been performed in children and adults with asthma, cystic 
fibrosis, post stroke and when ventilated on intensive care (Beck-Schimmer et 
al., 2003; Clayton et al., 2006; Donnelly, Berrisford, Jack, Tran, & Evans, 1993; 
Hue et al., 1996; Jack et al., 1995; Ledson, Wilson, Tran, & Walshaw, 1998). 
Moderate falls in tracheal pH associated with marked falls in oesophageal pH 
were reported in all these studies, lasting for prolonged periods in some subjects 
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and sometimes correlated with other parameters of respiratory morbidity. 
However, it is notable that falls in tracheal pH below pH 4 are rarely reported 
(most studies using pH 5.5 as their cut off to define tracheal aspiration) and 
therefore, the clinical relevance of studies involving direct instillation of acid 
into the lungs or onto AECs is debatable. However, study of the effects of mild 
pH alteration on AECs is important and relevant in children with ND, both in the 
context of exogenous acid inhalation (following aspiration of gastric contents) 
and also in the context of possible endogenous airway pH alteration, associated 
with chronic lower airway inflammation (as discussed in Section 7.2.2). 
The role of other non-acid elements of the gastric refluxate (such as pepsin and 
bile acids) in aspiration-related injury is unclear, and the question of whether 
reflux aspiration is equally or more damaging than direct aspiration of saliva is 
relevant to clinical practice. Various groups have investigated the effects of bile 
acids on the airway and have shown induction of AEC production of TGF β1, IL-8, 
and connective tissue growth factor (CCN2) and also increases in cell membrane 
permeability and decreasing cell viability in type II pneumocytes (Oelberg, 
Downey, & Flynn, 1990; Perng et al., 2007; Perng et al., 2008). The effect of 
pepsin on AECs has been studied less extensively. A recent study showed that 
exposure of AECs to unphysiological levels of pepsin resulted in inflammation 
and cell death, and that these effects increased at lower pH (Bathoorn et al., 
2011). However, it is essential to consider the physiological norm in order to 
generate meaningful results. We know that airway pH decreases moderately in 
inflammatory and infective disease states (as discussed in Section 7.2.2) and 
possibly following reflux-aspiration (Fischer & Widdicombe, 2006) (Carpagnano 
et al., 2004). It is thus possible that pepsin, as an acidic protease, has potential 
to cause greater injurious effects in the airways of individuals with chronic 
airway diseases, whether they have acid reflux-aspiration or not. However, the 
pH of the lining fluid may also be less relevant in the context of pepsin activity. 
Johnston et al. recently found that pepsin causes laryngeal epithelial damage, 
even at pH 7 (Samuels & Johnston, 2009). The authors speculated that this was 
because it is reactivated in low pH intracellular compartments such as late 
endosomes and the Golgi apparatus. 
In this chapter, AEC response is studied following exposure to physiologically 
relevant concentrations of pepsin (according to available literature) at both a 
 218 
neutral and mildly acidic pH, using a submerged AEC culture model. AEC 
expression (mRNA and protein) of IL-8, IL-6 and TGF-1 is assessed and 
cytotoxicity and cell viability are monitored by measurement of lactate 
dehydrogenase (LDH) activity and trypan blue staining.  
7.1.1 Pepsin concentration of the epithelial lining fluid 
In vivo, direct contact of inhaled substances with AECs occurs via the AEC lining 
fluid (ELF). Therefore, in vitro experiments should aim to mimic physiologically 
relevant ELF pepsin concentrations in cell culture media. Gastric juice is 
estimated to contain 20-260μg/ml pepsin, variable according to meal times and 
gastric pathology (Pearson & Roberts, 2001). Aspiration of large amounts of 
gastric juice is uncommon, the usual scenario being chronic small volume 
aspiration. In this situation, small amounts of gastric juice travel to the top of 
the oesophagus where it is diluted in saliva before travelling down the trachea 
into the lungs, where it becomes further diluted in ELF. The process of bronchial 
lavage collection produces a sample with a further diluted (up to one hundred 
times) representation of the ELF (Rennard et al., 1986). Measurements of pepsin 
in BAL samples have ranged from sub 10ng/ml levels to over 1000ng/ml (Abd El-
Fattah, Maksoud, Ramadan, Abdalla, & Aziz, 2007; McNally et al., 2011; N. A. 
Metheny et al., 2006; Stovold et al., 2007). These quantifications may be 
inaccurate (as discussed in Chapter 5), however they provide the best available 
estimation of ELF pepsin levels post aspiration. Therefore, taking account of BAL 
dilution, cell growth media pepsin concentrations of 1 and 10μg/ml were used in 
this study. 
7.1.2  Airway pH 
Consideration of airway pH is essential when studying the effects of pepsin on 
AECs, as pepsin enzymatic activity is pH dependent (Nikki Johnston et al., 2007). 
The normal ELF pH remains difficult to measure, due to the susceptibility of 
sampling techniques to cause irritation and trigger sub-mucosal gland secretion. 
However, review of the available evidence suggests it may be mildly acidic 
(Fischer & Widdicombe, 2006; J.W., 2005). A tightly regulated ELF pH is 
important for airway health (Fischer & Widdicombe, 2006). Airway acidification 
can occur through exogenous acid inhalation, gastro-oesophageal 
reflux/aspiration or through altered endogenous pH homeostasis. It is 
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hypothesised that ELF pH self-regulation may be part of an innate host defence 
strategy in chronic inflammatory/infective disease states (Fischer & 
Widdicombe, 2006). Paediatric and adult exhaled breath condensate studies 
have demonstrated abnormal airway acidity, particularly at times of 
exacerbation, in asthma and cystic fibrosis which improves with treatment (J. F. 
Hunt et al., 2000; Tate, MacGregor, Davis, Innes, & Greening, 2002). 
Both exogenous and endogenous airway acidification may be relevant in children 
with severe ND, who have a high incidence of GORD plus chronic lower airway 
inflammation (as documented in Chapter 4). Known detrimental effects of 
acidification include impaired ciliary function and increased mucous viscosity 
(Clary-Meinesz, Mouroux, Cosson, Huitorel, & Blaive, 1998; Holma & Hegg, 1989; 
Holma, Lindegren, & Andersen, 1977). However, studies investigating the 
potential direct inflammatory effects of mild acidification on human AECs have 
been limited. 
 
7.1.3 Outcome measures 
AEC expression of three important chemokines/cytokines (IL-8, IL-6 and TGF-1) 
was chosen as the outcome measure for cell culture experiments in this chapter. 
The relevance of IL-8 and TGF-1 in the investigation of aspiration lung disease 
was discussed in Sections 4.1.1 and 4.1.2. In Chapter 4, both of these proteins 
were found to be raised in BAL collected from children with severe ND, 
compared to healthy controls.  
Interleukin-6 (IL-6) is a multifunctional cytokine with a range of both pro and 
anti-inflammatory actions within the lung (M. Yu, Zheng, Witschi, & Pinkerton, 
2002). Produced by a variety of respiratory cells (monocytes, macrophages, T 
cells, B cells, fibroblasts and AECs), IL-6 has direct actions on T and B cells, as 
well as inducing production of acute phase proteins (Chung, 2001). Anti-
inflammatory actions include inhibition of cellular apoptosis, inhibition of other 
pro-inflammatory cytokines, stimulation of metalloproteinase inhibitor 
production and anti-oxidant actions (M. Yu et al., 2002). More specifically, IL-6 
levels have been shown to be raised in the sputum of adults and children with 
non-cystic fibrosis bronchiectasis and Bathoorn et al demonstrated direct 
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induction of AEC IL-6 expression following stimulation with unphysiological levels 
of pepsin at a low pH (Osika et al., 1999) (Bathoorn et al., 2011). 
7.1.4 Cytotoxicity and cell viability 
Cell supernatant lactate dehydrogenase (LDH) was used for monitoring 
cytotoxicity. LDH is a cytoplasmic enzyme which is present in most cell types 
and catalyses the conversion between pyruvate to lactate and the inter-
conversion of NADH to NAD+ through hydrogen ion transfer (Drent, Cobben, 
Henderson, Wouters, & Van Dieijen-Visser, 1996). This cytoplasmic enzyme is 
only released on breakdown of the cell membrane and therefore, it can be used 
as a measure of cell death. Cell viability was also assessed by trypan blue 
staining, another measure of cell wall integrity. Cells differentially take up this 
stain if the cell wall barrier is compromised. The percentage of viable cells can 
be assessed by light microscopy (K. H. Jones & Senft, 1985). 
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7.2 Aims 
In order to assess the effects of pepsin and mild pH alteration on AECs, the 
chapter aims were to expose BEAS-2B cells (in a submerged culture model) to 
media of neutral and mildly acid pH, with and without pepsin, for a range of 
time-points and subsequently assess: 
1) Cell morphology by light microscopy 
2) Cell viability and cytotoxicity by trypan blue staining and measurement of LDH 
activity in cell culture supernatants 
3) AEC mRNA expression of IL-8, IL-6 and TGF-1 by real time quantitative PCR 
(Taqman assays) and subsequent protein secretion through measurement of IL-8, 
IL-6 and TGF-1 protein by ELISA assay in cell culture supernatants  
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7.3 Specific methods 
BEAS-2B cells were grown to 70% confluence in 96 well plates, as described in 
Section 2.7. Bronchial epithelial cell growth media (BEGM) pH was adjusted to 
pH 6.5 or pH 6 using a 1 molar solution of hydrochloric acid. Porcine pepsin A 
(Sigma Aldrich, UK) was also added to aliquots of BEGM media at pH 7.4, pH 6.5 
and pH 6 to a final concentration of 1 or 10μg/ml. Cell media was replaced with 
BEGM at pH7.4, pH6.5 or pH6 with either no pepsin, 1μg/ml pepsin or 10μg/ml 
pepsin for up to 24 hours. A protein control (1μg/ml BSA in BEGM, pH7.4) was 
used as a negative control for the pepsin media conditions, to assess any non-
specific AEC response to alteration of the media protein concentration.  
Cells were harvested at 2, 6 and 12 hours and IL-8, IL-6 and TGF-1 mRNA 
expression was assessed using quantitative RT-PCR (Taqman gene expression 
assays), as described in Section 2.6.3. Positive and negative controls were used, 
as described in the methods. Cell supernatants were collected at 2, 12 and 24 
hours and IL-8, IL-6 and TGF-1 protein secretion was measured by ELISA (R&D 
Systems), as detailed in Section 2.4. Cytotoxicity was assessed using an LDH 
activity assay, as described in Section 2.4.6. Cell viability was assessed using 
trypan blue staining and visualisation by light microscopy. All experiments were 
run in triplicate and at least three experimental repeats were performed for 
each condition. 
The potential effect of acidic pH on protein degradation and ELISA function was 
assessed by spiking equal amounts of the protein of interest (IL-8, IL-6, TGF-B1) 
into media of varying pH (pH7.4, pH6.5 or pH6) and incubating at 370C for 12 
hours. The samples were subsequently assayed and spike retrieval was compared 
between pH conditions. 
7.3.1 BEAS-2B cell culture model 
Cell culture is a process where cells are grown outside of their natural 
environment. The conditions for cell growth are tightly controlled in terms of 
temperature, CO2 concentration and hormonally supplemented growth media. 
Cultures can either be established from primary cells (taken directly from the 
host) or using cell lines. Cell lines originate from primary cells and have become 
immortalised through mutation or modification using foreign genes, commonly 
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introduced using a virus or plasmid. This process inhibits the cell’s ability to 
initiate senescence, meaning it will proliferate indefinitely under suitable 
conditions (Shay, Wright, & Werbin, 1991). The cell line chosen for this study 
was the BEAS-2B cell line (available from the European Cell Culture Collection). 
This cell line originated from bronchial epithelial cells isolated from patients 
with non-malignant conditions. The cells were infected with a replication-
defective SV40/adenovirus 12 hybrid and cloned. 
The two major variations in cell culture are 2D (monolayer) or 3D (air-liquid 
interface culture) models. The normal, differentiated bronchial epithelium is a 
columnar, pseudo-stratified layer which contains ciliated, goblet, and basal cells 
(Parker et al., 2010). In monolayer culture, cells grow on a plastic surface in 2D 
and remain undifferentiated. Therefore, the mucociliary functions of the in vivo 
airway epithelium are not expressed. However, if cells are grown at air liquid 
interface (on inserts), differentiation occurs leading to expression of all the cell 
types in the functional bronchial epithelium, thus giving a closer representation 
of in vivo conditions (Dvorak, Tilley, Shaykhiev, Wang, & Crystal, 2011). The 3D 
model also enables the cells to interact, form gap junctions, signal and migrate 
as they would in vivo (Abbott, 2003). However, monolayer cultures provide a 
good starting point to study early cellular responses to novel mechanisms of 
injury and therefore, submerged monolayer cultures were used in this study. 
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7.4  Results 
7.4.1 Morphological changes 
Morphological changes in cell appearance were noted on visualisation by phase 
contrast light microscopy. An elongated cell shape was often, but not 
universally, noted following exposure of cells to pH 6 from the 6 hour time-point 
onwards (Figure 7.1). 
7.4.2 Cell viability 
Cell viability was monitored by adding a small volume (30μl) of 1:5 diluted 
trypan blue stock solution to each experimental well at 2, 6, 12 and 24 hours. 
Cells were visualised by light microscopy, using a phase contrast lens. No 
consistent fall in cell viability was noted in any experimental condition up to the 
12 hour time-point (Figure 7.2). However, by 24 hours cell viability was variable 
(Figure 7.3). Formal viability cell counts were not recorded. 
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Figure 7.1 Images of (a) control BEAS-2B cells and (b) BEAS-2B cells exposed to pH 6 for 12 
hours. 
BEAS-2B cells were grown to 70% confluence in 96 well plates and exposed to conditions of 
variable pH (pH 7.4, pH 6.5 or pH 6) +/- 1-10μg/ml pepsin. Cells were visualised at 2-24 hours 
using a light microscope with a phase contrast lens. An elongated cell shape was often (but not 
universally) noted in cells exposed to pH 6 from the 6 hour time-point onwards. 
 
Figure 7.2 Images of (a) control BEAS-2B cells, (b) BEAS-2B cells exposed to 10μg/ml 
pepsin, (c) BEAS-2B cells exposed to pH6, (d) BEAS-2B cells exposed to pH6 +10μg/ml 
pepsin. Images shown were recorded at the 12 hour time-point, post trypan blue staining. 
BEAS-2B cells were grown to 70% confluence in 96 well plates and exposed to various conditions 
of altered pH (pH 7.4, pH 6.5 or pH 6) +/- 1-10μg/ml pepsin. Cell media was removed at 2-24 hours 
and replaced with a dilute solution of trypan blue stain. Cells were visualised using a light 
microscope with a phase contrast lens. Images shown demonstrate no obvious change in cell 
viability up to the 12 hour time point in any condition. 
 
Figure 7.3 Images of (a) control BEAS-2B cells, (b) (c) and (d) BEAS-2B cells exposed to pH6 
+10μg/ml pepsin 24 hours (post trypan blue staining) in three separate experiments. 
BEAS-2B cells were grown to 70% confluence in 96 well plates and exposed to control media or 
pH6 + 10μg/ml pepsin for 24 hours. Cell media was removed at 24 hours and replaced with a dilute 
solution of trypan blue stain. Cells were visualised using a light microscope with a phase contrast 
lens. Images shown demonstrate a high degree of inter-experiment variation in cell viability by 24 
hours in the cells exposed to pH 6 conditions. 
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7.4.3 Interleukin-8 gene and protein expression 
IL-8 mRNA expression was significantly up-regulated (compared to control cells) 
following 2 hours of exposure to pH 6.5 (mean 2.8x, p=0.002), pH 6.5 + 1μg/ml 
pepsin (mean 3.24x, p=0.013) and pH 6.5 + 10μg pepsin (mean 4.2x, p=0.002), 
with a trend towards an additional effect of pepsin. Up-regulation of IL-8 mRNA 
was also seen at pH 6 (2.4x, p=0.001), pH 6 + 1μg pepsin (2.5x, p=0.047) and pH 
6 + 10μg pepsin (3.35x, p=0.121). IL-8 mRNA expression had returned to control 
levels in all pH 6.5 conditions by 12 hours, whereas those cells exposed to pH 6 
further up-regulated IL-8 mRNA expression (pH 6, 6.5x, p=0.005; pH 6 + 1μg 
pepsin, 6.5x, p=0.005; pH 6 + 10μg, 9.5x, p=0.081). No statistically significant 
effects of pepsin exposure at a neutral pH were seen (Figure 7.4). 
A trend towards down regulation of IL-8 protein secretion in those cells exposed 
to pH 6 conditions was observed at the 2 hour time-point, reaching statistical 
significance in the pH 6 + 1μg/ml pepsin condition (60.1% of control levels, 
p=0.043). However, IL-8 protein secretion then increased (relative to control) in 
cells exposed to pH 6 conditions and this reached statistical significance for pH 6 
+ 1μg pepsin (139.0% of control levels, p=0.040) and pH 6 + 10μg pepsin (172.4% 
of control levels, p=0.011) at 12 hours. No corresponding increased IL-8 protein 
secretion was observed in conditions exposed to pH 6.5, despite up-regulation of 
IL-8 mRNA at 2 hours (Figure 7.4).  
7.4.4 Interleukin-6 gene and protein expression 
IL-6 mRNA expression was significantly increased compared to control cells 
following two hours exposure to pH 6.5 (2.5x, p=0.019), and a similar trend was 
observed in those cells exposed to pH 6.5 with pepsin. No additive effect of 
pepsin was observed. Interestingly, following continued exposure, the same cells 
had down-regulated IL-6 mRNA expression (compared to control cells) by 12 
hours (pH 6.5 + 1μg/ml pepsin, 0.62x, p=0.044; pH 6.5 + 10μg/ml pepsin, 0.64x, 
p=0.005). There was a trend towards up-regulation of IL-6 mRNA expression in 
all cells exposed to pH 6 conditions. There did not appear to be any additional 
effect of pepsin exposure. There was also a trend towards a dose-wise increase 
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in IL-6 mRNA expression at two hours post exposure to pepsin at a neutral pH 
(Figure 7.5). 
IL-6 protein secretion (expressed as % control) was significantly down regulated 
by two hours in conditions of altered media pH (pH 6.5, 70.29%, p=0.013; pH 6.5 
+ 10μg/ml pepsin, 77.97%, p=0.004; pH 6, 31.68%, p=0.014; pH 6 + 1μg/ml 
pepsin, 32.34%; pH 6 + 10μg/ml pepsin, 31.47%, p=0.009). IL-6 protein secretion 
continued to be significantly down regulated in all cells exposed to pH6 at 12 
hours (pH 6, 50.9%, p=0.001; pH 6 + 1μg/ml , 49.9%, p=0.006; pH 6 + 10μg/ml, 
51.9%, p=0.007) and at 24 hours (pH 6, 31.6%, p<0.001; pH 6 + 1μg/ml pepsin, 
31.8%, p=0.005; pH 6 + 10μg/ml pepsin, 35.8%, p=0.001). A dose wise trend 
towards increased IL-6 protein secretion was observed on exposure to pepsin at 
a neutral pH at the 2 hour time-point, although this did not reach statistical 
significance (Figure 7.5).  
7.4.5 TGF-B1 gene and protein expression 
No differences in TGF-1 mRNA expression were observed at two hours, 
compared to controls cells. However, by twelve hours, TGF-1 mRNA was up-
regulated in all conditions at pH 6.5 and pH 6, reaching statistical significance in 
two conditions (pH 6.5 + 10μg/ml pepsin, 1.69x, p=0.043; pH6, 3.08x, p=0.043). 
There was no additional up-regulation in mRNA with the addition of pepsin 
(Figure 7.6). 
TGF-1 protein secretion was not detectable in any condition until twelve hours 
post media change. At this time-point, TGF-1 protein secretion was 
significantly down regulated (relative to control cells) in all cells exposed to an 
altered pH (pH 6.5, 50.2%, p=0.039; pH 6.5 + 1μg/ml pepsin, 30.6%, p=0.029; pH 
6.5 + 10μg/ml pepsin, 42.2%, p=0.022; pH 6, 41.4%, p=0.001; pH 6 + 1μg/ml 
pepsin, 37.5%, p<0.001; pH 6 + 10μg/ml pepsin, 33.3%, p=0.016). This pattern 
continued at 24 hours exposure (pH 6.5, 66.4%, p=0.003; pH 6.5 + 1μg/ml, 64%, 
p=0.008; pH 6.5 + 10μg/ml, 65.24%, p=0.010; pH 6, 39.21%, p=0.001; pH6 + 
1μg/ml, 44.8%, p=0.010; pH6 + 10μg/ml, 41.8%, p=0.006) (Figure 7.6). 
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Figure 7.4 Bar charts to show BEAS-2B cell IL-8 mRNA expression (relative to L32) following 
2 and 12 hours exposure to pH 6.5 or pH 6 +/- pepsin and the corresponding IL-8 protein 
secretion at 2, 12 and 24 hours. 
BEAS-2B cells were grown to 70% confluence in 96 well plates and exposed to conditions of mildly 
altered pH (pH 6.5 or pH 6) +/- 1-10μg/ml pepsin for up to 24 hours. At 2 and 12 hours, cells were 
harvested for mRNA analysis. mRNA analysis was performed using Taqman gene expression 
assays (Applied Biosystems, UK) and all IL-8 mRNA expression was normalised to the ribosomal 
L32 housekeeping gene, using the comparative CT method for analysis. IL-8 protein secretion was 
measured in supernatants at 2, 12 and 24 hours using commercially available ELISA kits (R&D 
systems, UK). Mean (SEM) is displayed. * = p<0.05, ** = p<0.01.  
 229 
 
Figure 7.5 Bar charts to show BEAS-2B cell IL-6 mRNA expression (relative to L32) following 
2 and 12 hours exposure to pH 6.5 or pH 6 +/- pepsin and the corresponding IL-6 protein 
secretion at 2, 12 and 24 hours. 
BEAS-2B cells were grown to 70% confluence in 96 well plates and exposed to conditions of mildly 
altered pH (pH 6.5 or pH 6) +/- 1-10μg/ml pepsin for up to 24 hours. At 2 and 12 hours, cells were 
harvested for mRNA analysis. mRNA analysis was performed using Taqman gene expression 
assays (Applied Biosystems, UK) and all IL-6 mRNA expression was normalised to the ribosomal 
L32 housekeeping gene, using the comparative CT method for analysis. IL-6 protein secretion was 
measured in supernatants at 2, 12 and 24 hours using commercially available ELISA kits (R&D 
systems, UK). Mean (SEM) is displayed. * = p<0.05, ** = p<0.01.  
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Figure 7.6 Bar charts to show BEAS-2B cell TGF-1 mRNA expression (relative to L32) 
following 2 and 12 hours exposure to pH 6.5 or pH 6 +/- pepsin and the corresponding  
TGF-1 protein secretion at 2, 12 and 24 hours. 
BEAS-2B cells were grown to 70% confluence in 96 well plates and exposed to conditions of mildly 
altered pH (pH 6.5 or pH 6) +/- 1-10μg/ml pepsin for up to 24 hours. At 2 and 12 hours, cells were 
harvested for mRNA analysis. mRNA analysis was performed using Taqman gene expression 
assays (Applied Biosystems, UK) and all TGF-1 mRNA expression was normalised to the 
ribosomal L32 housekeeping gene, using the comparative CT method for analysis. TGF-1 protein 
secretion as measured in supernatants at 2, 12 and 24 hours using commercially available ELISA 
kits (R&D systems, UK). Mean (SEM) are displayed. * = p<0.05, ** = p<0.01.  
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7.4.6 Cytotoxicity 
No significant differences in cell supernatant LDH activity were observed for any 
experimental condition at 2, 6 or 12 hours exposure (Figure 7.7 (a)). 
7.4.7 Effects of pH alteration on ELISA function 
Experiments were conducted to investigate whether the down-regulation of 
cytokine protein secretion observed was due to ELISA dysfunction or protein 
degradation, secondary to pH alteration. A known amount (250pg) of each 
cytokine protein measured (IL-8, IL6 and TGF-B1) was spiked into BEGM at both 
pH 7.4 and pH 6. This was incubated at 370C, 5% C02 for 12 hours. It was then 
assayed as normal and spike retrieval was compared between unadjusted and pH 
adjusted BEGM media. No significant differences in spike retrieval were 
observed (Figure 7.4 (b)).The experiment was repeated twice and all samples 
were assayed in duplicate. 
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Figure 7.7 Bar charts to show (a) LDH activity (U/ml) in cell culture supernatants following 
exposure of BEAS-2B cells to pH 6.5, pH 6 or pH 6 + 10μg/ml pepsin. (b) % spike retrieval 
following incubation of equal amounts of cytokine protein (IL-8, IL-6 and TGF-1) at normal 
media pH (pH 7.4) and pH 6 for 12 hours. 
(a) BEAS-2B cells were grown to 70% confluence in 96 well plates and exposed to conditions of 
mildly altered pH (pH 6.5 or pH 6) +/- 1-10μg/ml pepsin for up to 24 hours. At 2, 6 and 12 hours, 
cell culture supernatants were collected for LDH activity analysis (Roche, UK). No difference in 
LDH activity was observed following exposure of cells to any experimental condition. Selected 
results are presented. Mean (SEM) is displayed. 
(b) Equal amounts (250pg) of each cytokine protein (IL-8, IL-6 and TGF-1) were incubated in 
BEGM media at normal pH (pH 7.4) and pH 6 for 12 hours, at 37
0
C and 5% CO2. Samples were 
then assayed by ELISA and spike retrieval was compared between conditions. No differences were 
observed and therefore, it was concluded that no protein degradation or ELISA dysfunction had 
occurred due to alteration in media pH. 
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7.5 Discussion 
In this chapter, the BEAS-2B cell response to pepsin exposure, with or without 
mild alteration in cell media pH was examined. Pepsin exposure (1-10μg/ml) at 
normal growth media pH (7.4) did not induce statistically significant effects on 
IL-8, IL-6 or TGF-1 mRNA or protein expression. However, BEAS-2B cells were 
sensitive to mild acidification, significantly up-regulating TGF-1, IL-8 and IL-6 
gene expression. Corresponding increase in cytokine protein secretion was not 
observed and in some cases, was down regulated. It was difficult to assess the 
effects of pepsin exposure at a mildly acidic pH due to the marked pH driven 
effect on protein expression however, a trend towards a dose dependent 
increase in IL-8 mRNA and protein expression was observed. No significant 
cytotoxicity (as assessed by cell supernatant LDH activity) or decrease in cell 
viability (as assessed by trypan blue staining) was observed in any experimental 
condition for a period of up to 12 hours, in keeping with previous literature (D. 
S. Cohen, Palmer, Welch, & Sheppard, 1991) (Ichimonji et al., 2010). Continued 
up-regulation of gene expression between 2 and 12 hour time-points also adds 
supportive evidence of continuing cell viability. No pH induced protein instability 
was observed and therefore, this did not provide an explanation for the 
seemingly down-regulated cytokine protein results. 
The most striking responses were those triggered by mild alteration in media pH. 
Gene expression of all three cytokines was up-regulated, with various peaks in 
differential cytokine mRNA expression observed at different time-points and pH 
levels. It is unclear from our experiments whether the observed increase in 
cytokine mRNA expression is due to increased transcription or decreased 
degradation of mRNA. However, it does appear that the effects of extra-cellular 
acidification are not cytokine specific, although differential signalling is 
observed at different time-points and pH levels. Patterns of cytokine expression 
are likely to be variable between cell types, as observed by previous researchers 
studying TNF-alpha expression following acid stimulation (Heming et al., 2001). 
It may be of interest to conduct multiplex array mRNA analysis in future 
experiments to further characterise the AEC response. This was the approach 
taken by Johnston et al when studying the effects of pepsin exposure on 
laryngeal epithelial cells (N. Johnston, Wells, Samuels, & Blumin, 2009). 
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Interestingly, corresponding up-regulation of cytokine protein secretion was not 
necessarily observed and indeed TGF-1, IL-6 and IL-8.were all significantly 
down-regulated from as early as two hours post stimulation at pH 6. However, 
this down-regulation was selectively transient for IL-8 protein secretion, which 
subsequently increased over control levels at later time-points, reaching 
statistical significance in selected conditions at 12 hours. 
Various potential explanations for cytokine protein down regulation can be found 
within the literature. A previous study of LPS induced TNF-alpha protein 
expression in alveolar macrophages demonstrated increased mRNA expression at 
pH 5.5 compared to pH 7.4, but decreased extracellular TNF-alpha protein 
expression. The authors investigated potential effects of pH on protein stability 
and cell viability. However, as in this study, they concluded that protein 
instability or reduced cell viability did not explain their findings. However, on 
measuring intra-cellular TNF-alpha protein, they found significantly increased 
levels of retained synthesised cytokine at pH 5.5 (Heming et al., 2001). They 
proposed a mechanism of pH stress, causing inhibition of protein transfer from 
the Golgi network to the plasma membrane and interference with membrane 
exocytic and endocytic transport pathways. Cosson et al elegantly demonstrated 
this pH sensitive mechanism in fibroblasts (on reduction of fibroblast cytosol pH 
to pH 6.8) in the 1980s (Cosson, De Curtis, Pouyssegur, Griffiths, & Davoust, 
1989). The observed reversibility of this mechanism implies that stimulation and 
recovery experiments would be interesting in any future extension of our study, 
particularly if intra-cellular cytokine levels were found to be raised compared to 
extra-cellular levels on further investigation. 
In contrast, other researchers found increased IL-6 and connective tissue growth 
factor mRNA which was accompanied by increased protein secretion in human 
airway smooth muscle cells exposed to pH 6.3 for 16 hours (Ichimonji et al., 
2010; Matsuzaki et al., 2011). This highlights potential differences in response to 
acidity between cell types. The authors acknowledged previous findings of down-
regulated cytokine protein secretion on exposure of cultured cells to acidic 
conditions, and proposed that these differences may be due to differential 
cellular expression of proton sensing G-protein coupled receptors. They 
demonstrated that knockdown of the proton-sensing ovarian cancer G-protein-
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coupled receptor (OGR 1) in airway smooth muscle cells attenuated the cellular 
inflammatory response to acidic conditions (Matsuzaki et al., 2011) Ichimonji, 
2010). The potential for differential response of different respiratory cell types 
to extracellular acidification suggests that once the primary bronchial epithelial 
cell response has been characterised, co-culture models may be useful in 
studying terminal remodelling effects on the airway epithelium. 
An alternative explanation for the observed response could be post-
transcriptional regulation of cytokine protein production. This could potentially 
occur through regulation of mRNA processing, mRNA export and localization, 
mRNA decay or mRNA translation (Paul Anderson & Kedersha, 2009). Noxious 
environmental triggers (including alteration in extracellular pH) could trigger a 
cellular ‘stress response’ in which selective mRNA protein translation is halted in 
order to conserve energy for cellular repair. This response is known to be under 
the control of various eIF2α kinases (Paul Anderson & Kedersha, 2008; Johno et 
al., 2012). One example of an eIF2α kinase is PERK (PKR-like endoplasmic 
reticulum kinase). This is a resident endoplasmic reticulum (ER) protein, 
activated following accumulation of unfolded or mis-folded proteins in the 
endoplasmic reticulum (ER) lumen (responsible for the production and folding of 
secretory proteins) (Schroder & Kaufman, 2005). In an attempt to restore 
homeostasis, the stressed ER triggers the ‘unfolded protein response’ in which 
protein transcription and translation is halted, production of molecular 
chaperones involved in the process of protein folding are up-regulated (such as 
heat shock proteins and foldases) and ER associated degradation of unfolded 
proteins is increased. If resolution is not achieved, apoptotic pathways are 
ultimately triggered (Schroder & Kaufman, 2005). It has been suggested that 
post transcriptional control of cytokine production, via mechanisms such as 
these, may play a role in the control of inflammation (P. Anderson, 2008; 
Kitamura, 2011). Interestingly, Cohen et al documented depressed overall 
protein synthesis with specific up-regulation of stress proteins, following 
transient mild acidification of guinea pig AECs. Further investigation of cellular 
stress markers at early experimental time-points may be helpful in 
understanding the mechanisms involved in the human bronchial epithelial cell 
response to mild alterations in pH. Also, further detailed study of the pathways 
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leading to cell death (with continued insult) at later time-points would be 
informative.  
Once mechanisms of pH injury have been fully investigated, therapeutic targets 
can be explored. Hunt et al explored one such target, investigating intrinsic 
buffering mechanisms within AECs. They demonstrated increased glutaminase 
activity after exposure of human AECs to pH 5.6, leading to increased pH 
buffering through the production of ammonia. Interestingly, this self-protective 
cellular response to acidic stress was found to be inhibited by inflammatory 
cytokines (JOHN F. HUNT et al., 2002). This work demonstrated one of many 
potential mechanisms of cellular defence against acid stress. However, overall 
the investigation of therapeutic targets in this field has been limited to date.  
Correlation between pepsin and lower airway inflammatory markers has been 
found in clinical studies, providing justification for study of the direct effects of 
pepsin exposure on the airway epithelium. Bathoorn et al documented 
inflammatory effects of pepsin at low pH on AECs. However, the concentrations 
of pepsin and levels of acidity used in their stimulation studies were not 
physiologically relevant. Mertens et al conducted limited studies of AEC response 
to pepsin exposure at a neutral pH and found no effect on IL-8 protein secretion. 
However, Johnston et al found increased inflammatory cytokine mRNA 
expression on multiplex analysis post exposure of laryngeal epithelial cells to 
pepsin at a neutral pH (Samuels & Johnston, 2009). They subsequently 
documented cytotoxicity (by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay) and up regulation of genes involved in 
stress and toxicity (N. Johnston et al., 2009). The pepsin levels used in these 
experiments were appropriately higher than those used in our study, as it is 
likely that the contents of gastric refluxate are further diluted by the point of 
contact with the airway epithelium. We found no statistically significant effect 
of pepsin at neutral or mildly acidic pH on TGF-1 or IL-6 gene or protein 
expression. However, a consistent dose wise trend was observed at neutral and 
mildly acidic pH on IL-8 mRNA and protein expression, although this did not 
reach statistical significance. It would be interesting to perform a wider array 
analysis, as performed by Johnston et al, to fully investigate the effects of 
pepsin on the AECs. It would also be useful to examine intracellular cytokine 
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protein content, in view of the marked pH related effects on cytokine protein 
secretion and the discussion presented above. Therefore, although no significant 
effects were observed in this study, further study of the response of AECs to 
pepsin exposure at a neutral and mildly acidic pH is justified. 
Ideally, this experimental series should be repeated on primary AECs of 
paediatric origin and in an air-liquid interface culture model. Marked differences 
in immunological response between BEAS-2B cells and primary epithelial cells 
have been noted by our group in the context of viral infection, however, this has 
not been explored in the field of pH injury (Fonceca, Flanagan, Trinick, Smyth, 
& McNamara, 2012). There are always limitations to translating in vitro findings 
into an in vivo context. However, multilayer air-liquid interface culture models 
provide a closer representation of the in vivo airway epithelium than monolayer 
cultures, as discussed in Section 7.3.1. A key limitation of this study is the lack 
of mucus secreting cells in the 2D culture model. Mucus plays an important role 
in buffering changes in airway pH and studies have shown increased mucus 
viscosity in response to pH alteration: potentially another self-protective 
strategy of AECs (Holma & Hegg, 1989). Also, although monolayer cultures can 
be used in studying early cellular responses, multi-layer ALI culture models are 
more appropriate for the study of airway remodelling and repair (Hackett et al., 
2009). There are various reasons for this, including the limited lifespan of 
monolayer cultures: squamous terminal differentiation and consequent falls in 
viability occur when monolayer cultures reach confluence. Also, epithelial cell 
death and sloughing may form an important part of the injury and repair process 
and this cannot be examined in a monolayer model. Finally, differences in cell 
viability observed at 24 hours may have been due to slight variations in cellular 
confluence at the beginning of the experiment. Cell-cell interaction and 
adhesion is important for epithelial cell defence and this variable would have 
increased uniformity in an ALI culture model (Heijink et al., 2010). If different 
cell culture models are to be used in future experiments, intracellular pH will 
need to be considered. Multiple studies have established that extracellular pH 
does not directly reflect intracellular pH (Furukawa, Nakamura, & Okabe, 1997) 
and it is possible that intra-cellular buffering capacity may vary between cell 
types and cell culture models. This would therefore require further 
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characterisation in order to understand the thresholds at which acid stress injury 
occurs in AECs, and also to comment on differences in results between models. 
Effects of pH alteration on the constituents of the growth media need to be 
considered. Again, a solution to this potential confounder lies in using an air-
liquid interface culture model, where normal growth media would be used on 
the basal side of the epithelium, whilst the apical side would be exposed to a 
solution of appropriate ELF osmolarity and altered pH. Finally, addition of 
hydrochloric acid to growth media may have altered both the media osmolarity 
and chloride concentration. Previous researchers have explored potential effects 
of adjusting the pH of DMEM media using hydrochloric acid. Significant alteration 
in osmolarity was only identified at pH 2 and below (Ishizuka et al., 2001). 
Therefore, this is unlikely to have been a confounder in our study. However, 
chloride concentration may have affected the results and this could be further 
explored by using glacial acetic acid to adjust media pH and comparing to results 
to those obtained when using hydrochloric acid. 
7.6 Conclusions 
Beas-2B cells are sensitive to mild acidification, up-regulating IL-8 and IL-6 gene 
expression by two hours and TGF-1 mRNA expression by 12 hours. However, 
corresponding cytokine protein release is generally not observed and in some 
cases, is down regulated. This did not appear to be due to protein degradation 
or reduction in cell viability. There are various potential mechanistic 
explanations which require further investigation. Exposure of AECs to pepsin did 
not induce statistically significant effects in terms of IL-8, IL-6 or TGF-1 
expression. However, extended investigation of the potential effects of AEC 
pepsin exposure at a neutral or mildly acidic pH is justified. 
This preliminary evidence suggests that mild alterations of airway pH may 
directly contribute to the patho-physiology of inflammatory airway diseases and 
may also be relevant in reflux-aspiration related lung disease. This area requires 
further detailed scientific and clinical study as a potential novel therapeutic 
target
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 Chapter 8 - Concluding Remarks and Future 
Work 
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8.1 Background 
Respiratory disease is a major cause of morbidity and mortality in children with 
severe ND (Seddon & Khan, 2003). The evidence base in this area is limited, but 
these children have a shortened life expectancy and respiratory pathology is the 
leading cause of death (J. L. Hutton, 2006; Jane L. Hutton, 2008; Reid et al., 
2012; Strauss et al., 1997; Thomas & Barnes, 2010). The daily burden of 
respiratory symptoms is poorly documented, however, children with severe ND 
are at high risk of prolonged, complicated hospital admissions and high re-
admission rates, impacting on quality of life (Mahon & Kibirige, 2004; Young et 
al., 2011). This has considerable healthcare cost implications: in 2006, 29% of US 
children’s hospital expenditure was on inpatient care of children with ND and at 
least 10% of these admissions were for respiratory problems (Berry et al., 2012).  
Clinical management of this patient group is challenging, due to the complex 
background aetiology of the respiratory disease and the lack of high quality 
evidence on which to base clinical interventions (Seddon & Khan, 2003; Waespi 
et al., 2000). This contributes to the ‘reactionary’ approach to care discussed by 
Berry et al (Berry Jg & et al., 2011; Berry et al., 2012). Aetiological factors 
include poor cough, muscle weakness, scoliosis, poor nutrition and sleep apnoea. 
Gastro-oesophageal reflux and direct or indirect (reflux) aspiration are likely to 
be major contributory factors, but diagnosis is difficult due to the challenges of 
clinical assessment and limitations of diagnostic testing. Consequently, clinical 
decision-making is challenging both for clinicians and parents, particularly when 
symptomatic management of two potentially indistinguishable conditions (for 
example, reflux or direct aspiration) is distinct and furthermore, potentially 
invasive.  
Novel biomarkers of reflux and direct aspiration, such as BAL pepsin and alpha 
amylase, have been proposed, but some of the available evidence is conflicting, 
particularly with regard to BAL pepsin (Trinick, Johnston, et al., 2012). 
Interestingly, these biomarkers have not previously been studied in this 
particularly high-risk patient group.  
The clinical outcomes and underlying patho-physiology of aspiration lung disease 
remain ill-defined, primarily due to limitations in diagnostic testing. Clinical 
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associations have been shown between aspiration and bronchiectasis and a cycle 
of recurrent aspiration leading to repeated respiratory tract infection, resulting 
in chronic inflammatory changes and ultimately bronchiectasis or lung 
parenchymal damage has been proposed (Piccione et al., 2012; Seddon & Khan, 
2003). Elements of the refluxate (such as pepsin or altered pH) may be directly 
damaging to the airway epithelium (the first pulmonary barrier to encounter 
inhaled substances) and therefore, study of the direct immunological response of 
AECs to elements of the refluxate is directly relevant to furthering our 
understanding of the patho-physiology of aspiration lung disease and developing 
new therapeutic targets. 
8.2 Daily respiratory symptomatology and levels of lower 
airway inflammation are high in children with severe 
ND, even at times of stability 
Data presented within this thesis documents (for the first time) details of the 
type and character of daily respiratory symptoms, lower airway inflammation 
and microbiology in individuals with severe ND. Even at a time of stability, 
children with severe ND often have significant respiratory symptoms, particularly 
at night, the consequences of which affect them and their families. Respiratory 
symptoms appeared to relate to airway neutrophilia in Elective-ND patients. 
There was also a trend for greater airway neutrophilia and respiratory symptoms 
in those with lower airway microbial rDNA positivity, suggesting that lower 
airway infection may play a significant role. This requires further study in a 
much larger population in order to draw firm conclusions, as discussed in 
Chapter Four.  
The co-morbid complexity of this patient group was highlighted in Chapter 
Three. Prospective, interventional studies are needed to fully assess the detailed 
interactions of co-morbidities and respiratory symptoms in these children. 
Marked variation was observed in the use of respiratory interventions (such as 
prophylactic antibiotics and anti-cholinergic medications). Interestingly, in this 
study the majority of ND patients were not under the care of a respiratory 
paediatrician, despite high levels of chronic respiratory symptoms. Those who 
were under specialist care often required home oxygen or non-invasive 
ventilation, suggesting that referral for a respiratory paediatric opinion occurs 
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late in the disease process, again highlighting a reactionary rather than 
prophylactic approach to care. Future studies should focus on the outcomes of 
early respiratory intervention, specifically in terms of child and family quality of 
life.  
The use of a standardised respiratory symptom score to document respiratory 
symptoms has been shown to be useful in other paediatric groups (Powell et al., 
2002; Trinick, Southern, et al., 2012). However, this is the first time it has been 
studied in children with ND. The LRSQ-Neuro has the potential to be used both 
to screen for patients who may benefit from specialist respiratory assessment or 
as a possible outcome measure in future prospective clinical trials. However, 
further psychometric evaluation will be required, particularly with regard to 
sensitivity to change and relevance of scores to longer-term respiratory 
outcomes (Cella et al., 2007; Turner et al., 2007). Early, tailored respiratory 
assessment of children with severe ND and chronic respiratory symptoms may be 
useful and well-designed clinical trials are needed to determine the risks and 
benefits of various prophylactic therapies in this group. Useful, patient/family 
relevant outcome measures will be central to the success of such studies.   
8.3 BAL tests (current and novel) for reflux aspiration are 
limited: an affinity enhanced mass spectrometry BAL 
pepsin assay may provide a new gold standard 
The finding of no BAL LLM positivity was surprising in this high-risk patient 
group. However, the lack of test specificity dictates a high cut off for positive 
reporting by cytopathologists which, amongst other limitations (as discussed in 
Chapter Five), restricts the use of LLMs as a diagnostic test (Reid-Nicholson et 
al., 2010).  
The lack of consensus within the literature regarding the utility of pepsin as a 
biomarker of reflux aspiration is perhaps partially explained in Chapter Five. 
There are various potential explanations for the finding of conflicting results 
between two published pepsin ELISAs and WB techniques. Certainly, no firm 
conclusions can be drawn about pepsin as a biomarker of reflux aspiration until 
an accurate method of BAL pepsin detection and equally importantly, 
quantification is validated due to occasional detection of pepsin in 
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asymptomatic controls. The crucial questions are:  i) whether there are 
significant differences in BAL pepsin load in those who are symptomatic and 
have other evidence of pathological reflux aspiration; ii) if pathological reflux 
aspiration is definable using BAL pepsin levels, what are the longer term clinical 
outcomes of this and how do clinical interventions influence these (studied 
longitudinally)? 
The data presented in Chapter Six confirms the feasibility of using a bead based 
inhibitor affinity enrichment followed by LC-MRM-MS analysis to create a ‘gold 
standard’ assay for pepsin identification and quantification. Further work is 
needed to validate this approach in more detail and there is potential for use of 
a similar assay to study GORD in salivary samples. This could allow accurate 
quantitative measurement of salivary or BAL pepsin in health and disease, 
something that is essential to assess whether pepsin is a useful biomarker of 
reflux or reflux aspiration, respectively. Should pepsin prove to be a useful 
biomarker, future development of a simpler bedside assay is conceivable, using 
MS as a ‘gold standard’ for validation.  
8.4 BAL alpha-amylase activity is a promising biomarker 
of direct aspiration 
Data presented within Chapter Five suggests that BAL alpha-amylase activity 
may be a promising biomarker of direct aspiration. Significantly increased alpha 
amylase activity levels were found in Elective-ND patients compared to healthy 
controls, suggesting this may be a useful biomarker of chronic direct aspiration. 
Importantly, the correlation between BAL alpha amylase activity and lower 
airway inflammatory markers in Elective-ND patients suggests that the degree of 
chronic aspiration may be directly linked to lower airway pathology in these 
patients.  
BAL alpha-amylase activity does not differentiate direct and reflux aspiration. 
However, it may potentially be interpreted alongside specific biomarkers of 
reflux aspiration in determining the relative contributions of direct and reflux 
aspiration in this group. The question of whether alpha-amylase is directly 
damaging to AECs is interesting and it may be that other elements of the 
aspirate are also relevant, including gastric and bacterial contents. Future 
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studies should focus initially on establishing normative BAL alpha amylase 
activity levels in health and disease, both in the paediatric and adult age groups. 
Further studies defining longitudinal clinical outcomes related to BAL alpha 
amylase activity and accompanying microbiology would be of great interest, as 
supported by the relationship of BAL alpha-amylase activity and microbial rDNA 
positivity observed in this study. Interventional studies of, for example, surgical 
salivary management options, with measurement of BAL alpha-amylase pre-
operatively and careful study of respiratory outcomes post-operatively, would 
also be very informative in assessing interventional treatment outcomes.  
8.5 Mild pH alteration is damaging to the airway 
epithelium and may provide a promising therapeutic 
target 
Data presented in Chapter Seven documents BEAS-2B cell sensitivity to mild 
acidification, up-regulating IL-8 and IL-6 gene expression following 2 hours 
exposure and TGF Beta 1 mRNA expression by 12 hours. Interestingly, 
corresponding cytokine protein release was generally not observed and in some 
cases was significantly down-regulated. There are many potential underlying 
mechanisms to explain this response, including interference with membrane 
exocytic and endocytic pathways, differential cellular expression of proton 
sensing G-coupled receptors and post transcriptional regulation of cytokine 
protein production as part of a cellular ‘stress response’.  
Mild airway pH alteration may theoretically occur in children with severe ND: i) 
as a result of chronic inflammation caused by recurrent aspiration as well as 
other contributory factors to lower airway disease; or ii) as a direct result of 
reflux aspiration. It would be useful to investigate this, taking direct 
measurements of airway epithelial lining pH in this group compared to healthy 
controls once appropriate technology allows (current limitations are discussed in 
Chapter Seven). 
Further investigation of the cellular mechanisms of injury following mild pH 
alteration (as well as the effects of exposure to other elements of the aspirate) 
is important in the exploration of novel therapeutic targets for aspiration lung 
disease.  This approach may be critical in children with ND, given that it may be 
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impossible to completely control aspiration in this group. Targeted management 
of lower airway damage secondary to aspiration is therefore paramount and will 
only be possible with further exploration of the specific mechanisms behind AEC 
aspirate induced injury. An alternative approach to investigating the effects of 
chronic aspiration on the lower airway may be to perform proteomic analyses on 
BAL samples from children with and without high risk of aspiration (based on 
clinical evidence and BAL biomarkers), documenting broader differences in 
pro/anti-inflammatory and pro-resolution proteins. This data may help to inform 
and direct further research both in vitro and vivo.  
8.6 Study Limitations  
Various limitations of this study are discussed in greater detail within the 
individual chapters. However, it is important to further consider ways in which 
the study could be improved, should it be repeated. As discussed in Chapter 
Three, achievement of study recruitment targets is essential to ensure the study 
is adequately powered to detect differences between study groups. If the study 
were to be repeated, it would be useful to have a recruitment team or 
potentially consider multi-centre recruitment in order to achieve recruitment 
targets. It would also be essential to try and include a non-respiratory PICU 
cohort in order to further investigate aspiration risk pre/post PICU admission. 
Ideally, all samples should be processed fresh by pre-optimised assays. This 
would be particularly important for any microbiology work, where ideally 
conventional culture as well as 16S PCR techniques (+/- human DNA degradation) 
would be used. Any further cell culture work should be conducted in an air-liquid 
interface model which would allow isolated apical exposure to elements of the 
aspirate (as in vivo) and also allow key cellular defences, such as tight junction 
integrity and mucus production, to play their role.  
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Proforma – Group 1 (PICU-ND) 
 
 
Study Number    …………………………………………………………………………. 
 
AH Number        …………………………………………………………………………. 
 
Initials                .…………………………………………………………………………. 
 
Date of birth       ……………………………………………………………………......... 
 
Weight               ....................................................................................................... 
 
Gender               Male           Female  
 
Contact number ..………………………………………………………………………… 
 
Consultant          .……………………………………………………………………....... 
 
Cerebral Palsy GMFC group    4                   5          
 
Medical Diagnoses 
………………………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
History of atopic symptoms  
……………………………………………………………………………………………… 
 
Medication  
………………………………………………………………………..…………………….
………………………………………………………………………................................ 
 
Gastrostomy      Yes         No    
 
Any oral feeds?              Yes       No    
 
Details……………………………………………………………………………………... 
 
Anti reflux surgery previously?     Yes        No    
 
Details……………………………………………………………………………………... 
 
Previous videofluoroscopy  Yes     No    
 
Details…………………………………………………………………………………….. 
 
Previous oesophageal biopsy   Yes    No 
 
Results…………………………………………………………………………………….. 
 
Date/time of BAL/brushings/blood samples ……………………………………… 
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Sample numbers     ……………………………………… 
 
Hours since onset of illness   ……………………………………… 
 
Hours ventilated     ……………………………………… 
 
History of Current Illness 
………………………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
Current FiO2    ……………………………………...……………… 
 
Oxygenation Index   ……………………………………………………… 
 
Ventilatory support   ……………………………………………………… 
 
CXR changes   ……………………………………………………...  
 
ETT                                               Cuffed      Uncuffed     
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Proforma – Group 2 (Elective-ND) 
 
 
Study Number    …………………………………………………………………………. 
 
AH Number        …………………………………………………………………………. 
 
Initials                 …………………………………………………………………………. 
 
Date of Birth       ……………………………………………………………................... 
 
Weight                …………………………………………………………………………. 
 
Gender               Male           Female  
 
Contact number   ………………………………………………………………………… 
 
Consultant           ……………………………………………………………………....... 
 
Cerebral Palsy GMFC group    4                   5          
 
Medical Diagnoses 
………………………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
History of atopic symptoms  
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
Medication  
………………………………………………………………………..…………………….
………………………………………………………………………................................ 
 
Date/time of BAL/brushings/blood samples ……………………………………… 
Sample numbers     ……………………………………… 
 
Had videofluoroscopy?  Yes        No 
Results 
………………………………………………………………………………………………
…………………………………………………………………………………………..…. 
Had oesophageal biopsy?   Yes        No 
Results 
………………………………………………………………………………………………
…………………………………………………………………………. …………………. 
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Pepsin as a biomarker of pulmonary aspiration in children with CP 
Proforma – Group 3 (Healthy Controls) 
 
 
Study Number    …………………………………………………………………………. 
 
AH Number        …………………………………………………………………………. 
 
Initials                 …………………………………………………………………………. 
 
Date of Birth       ……………………………………………………………………........ 
 
Gender               Male           Female  
Weight                …………………………………………………………………………. 
 
Contact number   ………………………………………………………………………… 
 
Consultant           ……………………………………………………………………....... 
 
Medical Diagnoses 
………………………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
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Comparison of SepsiTest
TM
 results for paired samples stored in recommended UMD tubes 
versus BAL supernatant fractions stored in Eppendorf tubes 
SepsiTest results for BAL samples which were divided into two and stored either as ‘whole’ 
(unprocessed) BAL in the recommended UMD tubes or as supernatant fractions in Eppendorf 
tubes (S/N).  
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